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Summary 
In spite of extensive research there is little infonnation about apoptosis or programmed 
cell death in the genesis and progression of cancers of the lung. In our project we have 
investigated the role of apoptosis and two of the genes controlling apoptosis (bcl2 and 
C040) in squamous cell carcinoma of the lung. Also we have tried to formulate an 
accurate way of measuring apoptotic rate in tumour specimens. 
We counted apoptotic cells in Haematoxylin and Eosin stained histological sections of 
squamous cell carcinoma of the lung. The apoptotic indices we obtained were very 
reliable showing remarkable reproducibility and strong correlation with apoptosis 
measured by monoclonal antibody to apoptosis specific protein (ASP). In our series 
apoptotic index did not correlate with survival, disease stage, differentiation, AgNOR or 
ONAploidy. 
Histological sections were stained with monoclonal antibodies to Bc12 and CD40. In 
all, 32% of squamous cell carcinoma of lung were Bc12 positive (i.e. more than 50% of 
the tumour cells contained Bc12 protein) and 22% were positive for C040. The 
expression of Bc12 correlated positively with the apoptotic indices. Patients with Bel2 
positive squamous cell lung cancers survived significantly longer although Bcl2 
expression did not correlate with any marker of disease severity e.g. stage, grade, 
AgNOR or DNA ploidy. 
C040 expression in squamous cell lung cancer had no effect on apoptosis, survival or 
any of the other previously mentioned markers of disease severity. The expression of 
C040 in our series showed a tendency to correlate inversely with the expression ofBcl2. 
We devised a way to measure apoptotie rate in prinwy cultures of tumour cells by 
serial estimation of sub-diploid fractions in cell suspensions double stained with PI and 
BerEP4-FITC. We believe that the apoptotic rate measured in this fashion is biologically 
more relevant, and therefore could be more useful in predicting prognosis, than 
apoptosis measured from histological sections. 
CHAPTER! 
INTRODUCTION 
2 
Preface 
Inspite of rapid advances in medical technology cancer still remains a scourge of 
humanity, inspiring awe and fear both in the lay person and among medical professionals. 
An incomplete understanding of the biology of cancer is felt to be one of the main 
impediments to devising successful ways of combating it. Being a chest physician my 
interest is in the area of lung cancer and I have chosen to look at one particular aspect of 
its biology - namely the role of apoptosis and the genes controlling it in the development 
and progression of lung cancer. 
This introductory chapter will provide the background for our experimental work and 
has been laid out in four sections. The first section is on lung cancer where we shall briefly 
describe the common types of pulmonary neoplasms followed by a discussion of the 
various aetiological factors involved. Next we shall describe the steps involved in the 
transformation of normal bronchial epithelium to malignancy with particular reference to 
the role of apoptosis and apoptosis controlling genes in this multi-step process. 
Section two is on apoptosis. The morphological features and biochemical mechanisms of 
this newly discovered physiological process are described here in some detail. Following 
this, the importance of this process in various pathological conditions and in particular its 
role in cancer is discussed in depth. 
The final two sections deal with two protein molecules which regulate apoptosis in cells -
namely Bcl2 and CD40. In each of these sections a description of the structure and the 
distribution of the protein is followed by a discussion of its normal role in various 
physiological processes and altered role in cancer. 
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1.1 Lung Cancer 
1.1.1 Introduction 
At the beginning of the twentieth century lung cancer was a rare, essentially reportable 
condition but it has now become the commonest fatal neoplastic disease in the world. In 
the United States alone around 150,000 new cases appear annually. In the United 
Kingdom it is estimated that every year there are 300 deaths due to lung cancer per 100,00 
male population (Office of Population Censuses and Surveys, 1987). It is the most 
common cancer in British men and in women takes second place only to cancer of the 
breast. 
The predominant cause of this epidemic is well known. For more than four decades, 
scientists and physicians have recognised the inextricable link between cigarette smoking 
and lung cancer. In spite of this well recognised relationship, only in recent years have men 
and women in parts of the Western world started to curtail their use of tobacco. Sadly, a 
similar trend has not been noticed in many other parts of the world. Worse yet, increased 
tobacco use is the norm for most underdeveloped countries and even some industrialised 
nations. Thus, lung cancer is and will remain a significant health problem throughout the 
world for many years to come. 
There are no effective ways of treating this disease and it carries a very poor prognosis. 
The median survival is 12 months and only 13% of patients are still alive at 5 years after 
diagnosis. Introduction of new modalities of treatment (e.g. adjuvant chemotherapy 
following surgery in NSCLC) has not appreciably dented these dismal figures. It is widely 
felt that a deeper understanding of the biology of this dreadful disease might lead to new 
avenues of managing it more effectively. Understanding the pathogenesis of lung cancer 
should help in devising new prevention strategies, strategies for early diagnosis (maybe 
even at a pre-malignant stage) and strategies for new innovative means of treating this 
cancer. 
4 
Recently much attention has been focused on one particular aspect of lung cancer 
biology namely the role of apoptosis and apoptosis controlling genes in the genesis and 
development of pulmonary neoplasms. Although extensive research has been carried out, a 
lot still remains to be known about this fundamental physiological process and its relative 
importance amongst myriad other pathological changes seen in lung cancer. 
1.1.2 Clinical Pathology 
Lung cancer is not a single entity but a generic term applied to a heterogeneous group of 
malignancies (Appendix A). Most cancers of the lung are epithelial tumours, or 
carcinomas. In contrast to other common cancers, such as cancers of the colon, breast and 
prostate, which are mostly adenocarcinomas, there are four main histological types of lung 
cancer, each with distinct biological characteristics. They are squamous cen carcinoma 
(50%), adenocarcinoma (1 S%), large cell carcinoma (1 ()o1o) and small cell carcinoma 
(25%). Clinically and therapeutically, lung cancer is divided into small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC) which includes all the other carcinomas. 
Below is a brief account of the four common types of lung cancer followed by a short 
discussion on malignant pleural effusions which is a common clinical manifestation of 
cancers of the lung and which formed part of our investigations. 
1.1.2.1 Squamous cell carcinoma 
This is the most common type of lung cancer. It usually affects males and is closely 
correlated with a smoking history. Squamous cell carcinomas usually arise in the large 
central bronchi. The epithelium in the nonnal tracheobronchial tree does not contain 
squamous cells but over the years an area of altered bronchial mucosa undergoes 
progressive changes which include hyperplasia, squamous metaplasia, dysplasia and 
carcinoma in situ eventually leading to frank carcinoma. The histological features of 
squamous cell carcinoma are distinctive (see Fig. 1.1). Tumour cells which are arranged in 
nests or pseudoductal pattern, are stratified and show intercellular bridge formation and 
5 
visible keratinization. Extensive accumulation of keratin may lead to formation of keratin 
pearls. While squamous cell carcinoma may grow very rapidly, they often remain confined 
within the thoracic cavity and the incidence of extra-thoracic metastases (haematogeneous 
and lymphatic) is somewhat less than in the other histologic types (Seaton et at. , 1989). 
Fig. 1.1 Histological section of squamous cell carcinoma oflung (x2S0) 
stained with H&E showing tumour cells arranged in nests. 
The patient is usually a middle aged male smoker who presents with any or all of the 
following symptoms-breathlessness, cough, haemoptysis and chest pain, or a symptom 
referable to a site of distant metastasis. Occasionally the disease is asymptomatic and first 
comes to light on a 'routine' chest X-ray. The diagnosis is established by chest X-ray, CT 
scan and bronchoscopic biopsy or percutaneous aspiration cytology. All NSCLCs 
(including squamous cell carcinoma) are treated along identical lines although the response 
varies (see below) (Minna, 1991). 
Surgery is the major curative modality for patients without demonstrable metastatic 
disease. Of the surgically treated patients the majority will relapse with local recurrence, 
extra-thoracic metastases or a second primary tumour. To delay or prevent this from 
happening, adjuvant chemotherapy following operation has been recommended, but the 
6 
results have not been uniformly favourable (Tonato, 1996). Unfortunately more than two 
thirds of NSCLC patients are unresectable at presentation. These patients are treated with 
a combination of chemotherapy and radiotherapy. 
Patients vary in their response to treatment. In general squamous cell carcinomas fare 
much better than adenocarcinomas or large cell carcinomas, but even among the same 
histological type and the same clinical stage there is often variation in response. Several 
factors have been shown to influence outcome after surgical treatment: immunological 
markers such as PCNA, Ki-67, ras and p53, tumour DNA content (ploidy), peri operative 
blood transfusion, and presence of certain blood group antigens (reviewed by Mountain, 
1995). Response to chemotherapy is influenced by a different set offactors one of which is 
the presence of neuroendocrine (NE) features (see SCLC below). Almost all SCLCs and 
only about 10-15% of NSCLCs demonstrate features of NE differentiation. The subgroup 
of NSCLCs which have NE features respond more readily to chemotherapy than do 
tumours without these features (Linnoila et al., 1989). It is important to investigate other 
biological features of tumours which may influence response to surgery. chemotherapy or 
radiotherapy. The results of such efforts could help select the ideal treatment for a 
particular patient and thus dramatically alter how NSCLC is managed. 
1.1.2.2 Adenocarcinoma 
Adenocarcinoma is the commonest type of lung cancer in women and non-smokers, even 
though most adenocarcinoma patients do smoke. The incidence of this cancer has 
increased over the last decade and in the United States it has now become the most 
common form of lung cancer (Devesa et 01., 1991). Adenocarcinomas usually arise at the 
periphery of the lung often at the vicinity of old scars e.g. old TB, pulmonary infarcts (see 
Section 1.1.3.5). These tumours originate from cells normally found distal to the terminal 
bronchioles i.e. mucin secreting bronchiolar cells, Clara ceJls or Type II (granular) 
pneumocytes. They are unrelated to the bronchi other than by spread, except in a few 
cases where the tumours are truly bronchogenic, arising from mucous glands in the 
proximal bronchi. Microscopically the tumour consists of gland-like structures which often 
produce mucin. Adenocarcinomas grow more slowly than squamous cell carcinomas but 
7 
they tend to penetrate pleural lymphatics and metastasise to distant sites even before they 
produce any symptoms in the chest. 
Bronchiolo-a1veolar carcinomas are an important subgroup of adenocarcinomas which 
arise from terminal bronchioles and alveolar walls. They comprise about 5% of lung 
cancers. The tumour almost always occurs in the peripheral portions of the lung either as a 
single nodule or, more often, as multiple diffuse nodules that sometimes coalesce to 
produce a pneumonia-like consolidation. Microscopically the tumour is characterised by 
distinctive tall columnar epithelial cells that spread along the walls of alveoli and 
bronchioles using these structures as supporting stroma (Edwards, 1984). 
1.1.2.3 Large ceO carcinoma 
This is a heterogeneous group that has been fonned in a negative way to accommodate 
those 'left over' tumours that do not show the distinguishing features of squamous cell, 
small cell or adenocarcinoma (patton et aI., 1951). They tend to be anaplastic showing no 
signs of maturation on light microscopy and having large, less well differentiated 
polygonal, spindle-shaped or oval cells with abundant cytoplasm. Many of these tumours 
represent undifferentiated forms of adenocarcinoma or squamous cell carcinoma. These 
tumours arise towards the lung periphery and are large and bulky and often cavitate. 
Surgical treatment offers a significant chance of cure in large cell carcinoma as in the other 
NSCLCs such as squamous cell carcinoma and adenocarcinoma. 
1.1.2.4 Small ceO carcinoma 
This highly malignant tumour has a distinctive cell type. The epithelial cells are generally 
small, have little cytoplasm (high nuclear:cytoplasmic ratio) and are round and oval, and, 
occasionally lymphocyte-like (although they are about twice the size of a lymphocyte). In 
1926 WG Barnard gave the first detailed histologic description of this tumour and likened 
these small oval tumour cells to that of oat grains (Barnard, 1926). The cells grow in 
clusters that exhibit neither glandular nor squamous organisation. These cells are thought 
to arise from the neuroendocrine (NE) cells that are normally present in bronchial 
epithelium. Like the NE cells oat cells have been shown to contain neurosecretory 
granules and some of the tumours are able to secrete polypeptide hormones. Such 
"ectopic" hormone production is a characteristic feature of oat cell carcinomas. 
Small cell carcinomas have a strong relationship to cigarette smoking, and only about 1 % 
occurs in non-smokers. The tumours usually develop proximally in the large bronchi, grow 
rapidly and metastasise early and widely. At presentation over two thirds of patients have 
evidence of metastatic disease in the liver, central nervous system and bone(Cohen and 
Matthews, 1978). Surgery is therefore not an option. In contrast to all other forms of lung 
cancer small cell carcinoma is very sensitive to both chemotherapy and radiotherapy. 
1.1.2.5 Malignant pleural effusions 
An abnormal accumulation of fluid in the pleura (a closed serosal space separating the 
lungs from the chest wall) is a common manifestation of malignancy in the lungs but it 
occurs in other non-malignant conditions as well. 
The patient usually presents with shortness of breath, dry cough and a dull ache over the 
chest-although if the fluid accumulates slowly over months even a large effusion may 
produce few symptoms. The classical signs on examination are diminished breath sounds, 
dullness on percussion and mediastinal shift to the opposite side. On chest X-ray there is 
usually an opacity in the lower zone with an upward concave level. The disease causing 
the effusion is determined by aspirating a portion of the fluid for biochemical, cytological 
and bacteriological tests. Often, histological examination of a pleural biopsy is needed as 
well. 
Pleural effusions mayor may not be associated with disease of the pleura. In general, 
effusions due to pleural disease more nearly resemble plasma (exudates), while those 
occurring with a normal pleura are ultrafiltrates of the plasma (transudates). Of the latter 
the commonest cause is congestive cardiac failure which often leads to bilateral pleural 
effusions due to alterations in hydrostatic pressure across a normal pleura. 
Hypoalbuminaemia, as occurs in nephrotic syndrome and cirrhosis, also leads to increased 
formation and decreased reabsorption of pleural liquid on the basis of decreased 
intravascular oncotic pressures. 
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Various non-malignant diseases can cause pleural effusions. Bacterial pneumonia is 
associated with pleural effusion in about 40% of cases. (Light et aI., 1980) Tuberculosis is 
the commonest cause in certain parts of the world. Other uncommon causes include 
connective tissue disorders like rheumatoid disease, pulmonary infarction, pancreatitis, 
uraemia and sarcoidosis. 
Malignant involvement of the pleura may be primary or secondary to tumours elsewhere. 
Primary pleural tumour is almost always mesothelioma which is strongly associated with 
exposure to asbestos and carries a poor prognosis. It is often difficult to distinguish this 
tumour cytologically and histologically from secondary adenocarcinomas in the pleura. 
The BerEP4 monoclonal antibody has been found to be useful in making this distinction 
(Sheibani et al.,1991; Dejmek and Hjerpe, 1994; Hartmann and Schutze, 1994. Also see 
Section 3.1.5 a). 
Bronchogenic carcinoma is the commonest malignancy causing pleural effusion and may 
do so by direct extension to the pleural surface, obstruction to lymphatic drainage 
(secondary to mediastinal spread), or by pleural inflammation secondary to pneumonia 
behind an obstructed bronchus. Almost any other malignant neoplasm may occasionally 
metastasise to the pleura, common sources being breast, stomach and ovary (Chernow and 
Sahn, 1977). Lymphoma may directly involve the pleura or obstruct lymphatic drainage 
leading to a pleural effusion. 
Malignant effusions are characteristically heavily blood-stained and protein rich and tend 
to reaccumulate quickly within days of aspiration. Although the presence of effusion 
indicates a poor prognosis, only those patients with demonstration of tumour cells in the 
pleural fluid or on closed pleural biopsy samples are considered unresectable (Mountain, 
1985). Other patients with effusion are considered to have resectable lesions, despite their 
poor prognosis. 
That the malignant cells in effusions survive and even thrive in an environment where 
they are deprived of some of the usual survival signals (mediated by cell-cell and cell-ECM 
contact; see Section 1.2.3.2) indicate that they may represent a specially selected group of 
cells. One aspect that may differentiate them from the cells in the mother tumour might be 
an extra resistance to apoptosis. 
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1.1.3 Aetiological factors in lung cancer 
A number of extraneous factors contribute to the development of lung cancer. The 
foremost amongst these is cigarette smoking which is responsible for the majority of lung 
cancers. In comparison the other factors play a relatively negligible role but are 
nevertheless important in that many of them can cooperate with cigarettes and increase 
many fold the effectiveness of the carcinogens within cigarette smoke. 
1.1.3.1 Cigarette smoking 
King James I of England expressed his dislike of tobacco smoking forcibly in 1604, 
describing it as 'loathsome to the eye, hateful to the nose, harmful to the brain, dangerous 
to the lungs, and in the black stinking fume thereof nearest resembling the horrible Stygian 
smoke of the pit that is bottomless' (Stuart, 1604). These early Royal misgivings have 
been amply justified and extensive research has shown that cigarette tobacco smoking is 
by far the world's most common cause of lung cancer. It is estimated that world wide over 
90% of lung cancer deaths are attributable to tobacco smoking. The overwhelming 
evidence against tobacco can be arrayed under the following headings:-
a) epidemiological evidence, b) pathological evidence, c) biochemical evidence, d) 
molecular genetic evidence and e) animal experiments. 
a) Epidemiological evidence 
Three hospital-based case control studies published in the early 1950s provided evidence 
that is now regarded as conclusive in establishing the causal link between cigarette 
smoking and lung cancer. Two English investigators compared the smoking habits of more 
than 1300 lung cancer patients in London hospitals to that of a matched group of controls 
(Doll and Hill, 1952). Two American groups carried out similar studies - all three 
demonstrated that a significantly greater proportion of the lung cancer patients were 
smokers (Levin et al., 1950; Wynder and Graham, 1950). Convincing support was 
provided by further prospective trials. Doll and Peto correlated the smoking habits of over 
34,000 British physicians with mortality from lung cancer over a period of 20 years and 
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found a significant decline both in cigarette smoking and mortality in this group in contrast 
with the general population in whom neither mortality rates from this disease nor tobacco 
consumption fell (Doll and Peto, 1976). 
It is estimated that cigarette smokers are 8-20 times more likely to develop lung cancer 
than life-long non-smokers. The extent of the risk correlates with the duration of smoking, 
the number of cigarettes smoked, the depth of inhalation, the tar content of cigarettes and 
the presence of filter tips. Pipe and cigar smokers are at a lower risk because less smoke is 
inhaled. There is no lower limit of exposure below which there is no risk and even 'passive 
smokers' (those who involuntarily inhale side stream smoke that is emitted into the 
environment while an active smoker pursues his habit) have an approximately 300/0 
increment in risk. About a quarter of the cases of lung cancer in non-smokers can be 
attributed to passive smoking (Wald et 01., 1986). Cessation of smoking progressively 
lowers the risk of lung cancer with time, to about two and a half times that of non-
smokers by 10-20 years. 
It is likely that the incidence of all principal histological types of lung cancer is increased 
by tobacco smoking but those cell types with the clearest association are squamous cell 
and small cell carcinoma. There is also epidemiologic evidence to show an association 
between cigarette smoking and the following cancers in decreasing order of frequency:-
lip, tongue, floor of mouth, pharynx, larynx, oesophagus, urinary bladder and pancreas. 
b) Pathological evidence 
The genesis of lung cancer is a multi-step process and is preceded by a continuum of 
pathological changes that include hyperplasia, metaplasia, dysplasia and carcinoma in situ 
(See Section 1.1.4.1) Auerbach and colleagues noted a similar spectrum of histological 
changes in the tracheo-bronchial tree of the majority of smokers while very few non-
smokers showed such pre-cancerous changes. The changes were reversible when the 
subjects stopped smoking. Also, such pre-cancerous changes are often found in the 
'normal' epithelium surrounding a tumour (Auerbach et 01., 1961; Auerbach et 01., 1962). 
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c) Biochemical evidence 
Tobacco smoke contains over 3800 constituents many of which are carcinogens. They 
include both initiators (polycyclic aromatic hydrocarbons such as benzo[ a ]pyrene) and 
promoters such as phenol derivatives. Radioactive elements may also be found (polonium-
210, carbon-14, potassium-40) as well as other contaminants such as arsenic, nickel, 
moulds and additives. Of these the polycyclic aromatic hydrocarbons (P AH) are some of 
the most potent carcinogens known. They require metabolic activation and can induce 
tumours in a wide variety of tissues and species. The primary target of such chemical 
carcinogens is cellular DNA where they induce mutations (Harris, 1983). 
d) Molecular genetic evidence 
Mutations in oncogenes and tumour suppressor genes play a crucial role in the 
pathogenesis of lung cancer as discussed in Section 1.1.4. Many of these mutations are 
brought on by exposure to chemical carcinogens. Each carcinogen causes a characteristic 
mutation in DNA. For instance benzo(a) pyrene found in cigarette smoke characteristically 
causes GC to T A transversions which is the most prevalent type of mutation seen in lung 
cancer in p53 and K-ras genes (Slebos et al., 1991). This last bit of evidence could be 
considered the proverbial smoking gun irrevocably proving tobacco's guilt. 
e) Animal experiments 
Repeated application of a condensate of cigarette smoke to the skin of animals produces 
cutaneous tumours. Notwithstanding the numerous difficulties of simulating human 
smoking conditions in animal experiments lung carcinomas have been produced in rats in 
response to tobacco smoke inhalation and in hamsters following the intra-tracheal 
instillation of respiratory carcinogens (Dalbey et al., 1980). 
1.1.3.2 Radon gas 
This indoor pollutant has recently attracted a lot of attention as a potential cause of lung 
cancer. 
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Radon is an inert gas formed from radium during. the natural decay of uranium. The 
predominant source of radon in indoor air is the soil beneath structures. Radon diffuses 
through the soil and enters basements and from there spreads throughout the air in the 
home. Radon and its decay products are invariably present in indoor air, and a wide range 
of concentrations has been observed in homes. Some homes have levels comparable with 
those measured in uranium mines. But the majority are much lower (Harley, 1984). 
Radon decomposes into short-lived particulate decay products which can attach 
themselves to environmental aerosols and be deposited in the bronchi. Two of these 
products emit alpha particles, which are highly effective in damaging cells because of their 
high energy and high mass. The effects of such radiation damage are cumulative and can 
eventually lead to lung cancer. Prolonged exposure to radon in Uranium miners has been 
shown to cause a characteristic codon 249 mutation in p53 gene which is quite distinct 
from the usual GC to T A transversions caused by tobacco smoke. In America extensive 
epidemiologic data from studies of miners has established a causal association between 
exposure to radon and lung cancer. There is synergism between the effects of cigarette 
smoke and radon particles implying that smokers are more susceptible to the cancer 
inducing effects of radon (Samet, 1993). 
World wide radon is considered to be the second most important cause of lung cancer 
although its overall contribution is still negligible compared to cigarettes. 
1.1.3.3 Atmospheric pollution 
Many potential cancer-causing agents are released into the atmosphere from natural 
sources and from the industrial and non-industrial activities of humans. Polycyclic 
hydrocarbons are generated by fossil fuel combustion and industrial activities and can be 
identified in the air of urban locations. Other respiratory carcinogens include metals, 
radionuclides, diesel exhaust, and asbestos fibres. Unquestionably we all swim in a sea of 
carcinogens and it is conceivable that atmospheric pollutants may play some role in the 
increased incidence of bronchogenic carcinoma today. However the epidemiologic 
evidence for this is limited and the role of atmospheric pollutants, if any, is greatly 
subservient to that played by the personal pollution of tobacco smoke (Vena, 1982). 
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It may be that environmental agents act as co-carcinogens by augmenting the effects of 
other carcinogens. Thus animal experiments investigating the effects of two common 
gaseous pollutants (sulphur and nitrogen dioxides) and one common particulate pollutant 
(ferric oxide) have found that none of these agents is carcinogenic alone but they are 
capable of producing a carcinogenic effect from known carcinogens at doses that would 
otherwise be ineffective (Nettesheim et al., 1975). 
1.1.3.4 Occupational factors 
Certain occupations are associated with a higher than expected incidence of lung cancer. 
Often the causative agent is known but the additive or multiplicative effect of cigarette 
smoking makes the apportionment of blame difficult in individual cases. Asbestos is 
particularly notable for its association with lung cancer in addition to causing diffuse 
pulmonary fibrosis. Non-smoking asbestos workers have a S-fold increased risk of death 
from lung cancer as compared with other non-smoking workers. Asbestos workers who 
smoke one pack of cigarettes per day experience a 90-fold increased risk as compared to 
unexposed non-smokers. In this respect the effects of smoking and asbestos are 
multiplicative (Selikoff et al., 1968; Berry et al., 1972). 
Increased risks of lung cancer have been described in workers extracting metal ores from 
deep mines. The causative agent in these cases is radioactivity from radon gas rather than 
injury by the metal being sought (Harley, 1984). Other occupational exposures associated 
with lung cancer include nickel refining, the extraction and production of chromium salts, 
the use of arsenicals in the metal refining and chemical industries, the use of chloro-ethers 
in various organic industrial processes and coke oven working in the steel industry. It is 
suspected that printing ink used in the newspaper industry may have been associated with 
lung cancer. 
1.1.3.5 Otber diseases of tbe lung 
Localised scarring of the lung and diffuse pulmonary fibrosis tend to predispose to lung 
cancer. Scarring, the consequence of inflammation, may promote carcinogenesis by 
providing a local environment rich in factors that stimulate cell proliferation and 
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angiogenesis (see Section 1.1.4.4 a). Histologically such scar associated lung tumours are 
usually adenocarcinomas. Microscopically areas of epithelial hyperplasia are often seen in 
the near vicinity of lung scar tissue. These may in time undergo neoplastic change. 
However the mere presence of a scar is not enough to explain the development of these 
tumours and the patient's smoking history is also highly relevant in these cases. This is 
illustrated by the relationship between asbestos and smoking discussed above (Section 
1.1.3.4). Fibrosing alveolitis whether cryptogenic or occurring with a connective tissue 
disorder such as systemic sclerosis or rheumatoid disease is also associated with an 
increased incidence of adenocarcinoma (Turner-Warwick et al., 1980). The association of 
adenocarcinoma and old TB scars has already been mentioned in Section 1.1.2.2. 
Chronic bronchitis and emphysema (both smoking related diseases) may represent 
independent risk factors for the development of lung cancer, even when age, gender and 
smoking history have been considered (Skillrud et al., 1986). 
1.1.3.6 Diet 
Diet has recently been considered a potential influence on lung cancer risk in smokers. 
Nutrients of particular interest include Vitamin A, Vitamin C, Vitamin E and selenium. 
Data is sparse and inconclusive on all except Vitamin A (Colditz et al., 1987). 
Vitamin A is a fat soluble vitamin found mainly in animal derived foods e.g. eggs, milk, 
meat and fish. Vitamin A precursors called carotenoids (e.g. beta-carotene) are found 
abundantly in leafy green and yellow vegetables e.g. spinach and carrots. Vitamin A is 
thought to play a role in cell differentiation and proliferation by binding to nuclear 
receptors that regulate gene transcription. Deficiency of Vitamin A causes deregulated cell 
growth which leads to squamous metaplasia of specialised epithelium in the upper 
respiratory tract and the gastro-intestinal tract. It is speculated that advanced metaplasia 
can, in time, lead to cancer at these sites. In addition to this direct role in cell proliferation, 
Vitamin A (along with some other Vitamins) may be able to prevent cancers by acting as 
an anti-oxidant within the cell. Epidemiologic data show a protective effect of dietary 
Vitamin A intake from vegetable sources, but not of pre-formed Vitamin A which is 
derived from meat and dairy sources. 
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High dose Vitamin A has been used to successfully prevent the development of second 
primary tumours in patients with 'cured' head and neck cancers which is similar to lung 
cancer in many aspects. Similar trials are underway to prevent lung cancer in high risk 
groups with chronic administration of high dose Vitamin A (Hong et al., 1990). 
1.1.4 Lung Carcinogenesis 
1.1.4.1 General Remarks 
It is now widely accepted that carcinogenesis is a multistep process characterised by the 
stepwise acquisition of various heritable genetic defects. These genetic changes cause the 
cell to undergo a series of morphological, biochemical and physiological alterations until it 
finally becomes frankly malignant. This process can take years and during this intervening 
period the tissue becomes increasingly abnormal in appearance and behaviour. Epithelial 
tissues, for instance, go through the stages of hyperplasia, dysplasia, metaplasia, adenoma 
and carcinoma in situ before the appearance of invasive carcinoma. 
The transition from pre-malignancy to malignancy has been most closely studied in the 
colon where a large percentage of patients with benign adenomas eventually go on to 
develop colorectal cancer. The existence of this clinically recognisable pre-malignant stage 
has enabled the molecular events of colorectal carcinogenesis to be delineated in a way 
that is not possible for most other malignancies. Mutations in at least five to six growth 
controlling genes is necessary for the development of colonic cancer. There seems to be a 
preferred temporal order for these mutations and the appearance of each new mutation 
coincides with progression to the next higher stage of pre-malignancy (Vogelstein et al., 
1988). 
Although a similar series of events can be presumed to take place in lung cancer as well, 
it has been almost impossible to prove because of the practical difficulties implicit in 
subjecting an 'at risk' group to the hazards and discomfort of repeated bronchoscopic 
examinations. Also, most patients of lung cancer have invasive if not metastatic disease at 
presentation precluding any analysis of disease progression. Thus, most of our knowledge 
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in this field is obtained from circumstantial evidence (clinical studies correlating oncogene 
expression and disease outcome) and from extrapolation of molecular events seen in cell 
lines and in animal models of lung cancer. 
Such drawbacks notwithstanding, it has been possible to piece together a composite 
picture of the events that most likely precede the onset oflung cancer. 
1.1.4.2 Introduction 
The process of conversion of normal cells to malignancy takes place in three stages. This 
was demonstrated by experiments on skin carcinogenesis in mice. Treatment of an area of 
the skin with low doses of methyl cholanthrene-a genotoxic agent-"initiates" the disease 
but does not immediately result in the development of tumours. Subsequent chronic 
irritation with croton oil (itself not carcinogenic) leads to the formation of mostly benign 
papillomas. It seems that the initiated cells are "promoted" to a higher state of 
proliferation by this co-carcinogen. Further treatment with genotoxins results in malignant 
transformation of some papillomas-"tumour progression" (Berenblum, 1941). 
A similar step-wise progression of events is seen in lung cancer. Individual cells within 
the tracheobronchial tree are "initiated" when they develop mutations after exposure to 
carcinogens in cigarette smoke. After a long latent period, when eventually the right set of 
conditions emerge, some of the initiated cells proliferate into small islands of pre-
malignant clones-"tumour promotion". Finally the cells become frankly malignant by 
acquiring new genetic defects. The stage of "tumour progression" is characterised by 
expansion of the tumour and acquisition of a more aggressive phenotype e.g. the ability to 
invade blood vessels and lymphatics and metastasise to distant organs. 
1.1.4.3 Lung Tumour Initiation 
Nine out of ten cases of lung cancer are caused by cigarette smoke which contains 
genotoxic carcinogens and is irritant (Harris, 1983). Other carcinogens like radon gas, 
atmospheric and industrial pollutants are rarely involved (see Section 1.1.3). The chief 
carcinogen in cigarette smoke is benzo(a)pyrene (BP) a polycyclic aromatic hydrocarbon. 
The mutations observed in several genes which are frequently altered in lung cancer are 
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those that would be expected from the chemistry of BP thus directly proving its 
pathogenicity. But before BP can induce mutations in genes it needs to be transformed to 
its active form within the cell. Individuals differ in their ability to metabolise and activate 
carcinogens which would explain the observed differences in susceptibility to cigarette 
smoke amongst individuals and families. Subjects who have a high level of aryl 
hydrocarbon hydroxylase (AJllI) - one of the enzymes concerned with activating 
respirable hydrocarbon - show a greater propensity to lung cancer (Kellermann et al., 
1973). Similarly, the ability to metabolise Debrisoquin an anti-hypertensive agent may be 
an indirect indicator of the ability to activate carcinogens within cigarette smoke (Ayesh et 
al., 1984). 
The active fonn of the carcinogen forms adducts with DNA and induces mutations in 
particular genes. The cell has in-built defence mechanisms to detect and repair these 
genetic defects. If the defect is very severe and cannot be repaired the cell dies by 
apoptosis, a physiological process of cell death which is discussed in detail in the next 
section (Section 1.2). If, for any reason , these defences are breached, and cell division 
occurs before repair can take place, then any changes in one DNA strand will be replicated 
and no longer recognisable as an error. Thus the DNA mutation will be perpetuated and 
passed on to all future progeny. 
It is not surprising therefore that one of the earliest genes to be inactivated in lung cancer 
is p53 a gene involved in modulating apoptotic cell death in response to DNA damage 
(see Section 1.2.3.5 b). Unlike colonic cancer where p53 mutations occur late in the 
process, in lung cancer such mutations are found even in pre-neoplastic lesions like 
dysplasia and metaplasia (Bennett et al., 1993). In a retrospective analysis of sputum 
specimens stored over a 10-year period, evidence was found for mutations in pS3 in eight 
of the ten patients who subsequently developed lung cancer. This has potential uses in the 
surveillance and screening of high risk patients e.g. heavy smokers (Sidransky, 1994). 
Mutations of the p53 gene are a relatively common event in lung cancer being found in 
almost all SCLCs and in about 700Al of NSCLCs. In the latter group, the highest incidence 
is amongst squamous cell carcinomas whereas only 300Al of adenocarcinomas show p53 
mutations (Takahashi et al., 1989; Greenblatt et aI., 1994). Although it is an early event 
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the loss of p53 seems to have a bearing on the biological behaviour of the cancer in its 
later stages as well. Tumours with inactivated p53 show a higher rate of metastases to 
hilar nodes and distant sites (Fontanini et al., 1994). 
Another early event in 100% of SCLCs and 75% of NSCLCs is deletion in the 3p 
chromosome. Such a deletion, coupled with a mutation within a putative tumour 
suppressor gene located on chromosome 3p, could be another important step in the 
development of lung cancer. It is almost certain that the short arm of chromosome 3 
contains a tumour suppressor gene crucial for the development of lung cancer. Multiple 
candidate tumour suppressor genes that map to the consistently deleted segment of 
chromosome 3p include retinoic acid receptor, protein tyrosine phosphatase gamma and 
the von Hippel-Lindau disease tumour suppressor gene. None of these have yet been 
proven to be the culprit (Brauch et al., 1990). 
Initiating mutations take place in large number of cells but only a small fraction survive 
and the final tumour probably results from the clonal expansion of only one of the initiated 
cells. The other surviving initiated cells remain dormant for years or undergo 
transformation at a much slower pace and may emerge as a second tumour years later. 
The high incidence of "recurrent" lung tumours includes a fair proportion of what should 
rightly be called second primary tumours which display genetic defects quite different from 
the initial tumour. This has given rise to the Field Cancerization theory which describes 
the diffuse fieldwise mucosal carcinogenic effects of tobacco. In fact this field is now 
thought to extend beyond the tracheobronchial tree and include the upper digestive tract 
and the head and neck as well. There is a high incidence of second primary tumours in the 
lung following successful treatment of cancers in these areas and it is likely that both 
tumours were initiated by the same inciting agent (Foulds, 1969; Chung et al., 1993). 
1.1.4.4 Lung Tumour Promotion 
Once a cell has been initiated the next step is to expand the clone by accumulating faster 
than its neighbouring normal cells. This stage of tumour promotion can last for years and 
is clinically silent. During this phase the epithelium passes through a continuum of 
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histological changes that include hyperplasia, dysplasia and carcinoma in situ. It is unlikely 
that every initiated cell is promoted into a pre-neoplastic clone. To be successfully 
promoted a clone of cells must display a combination of the following properties:- (a) 
rapid proliferation rate (b) slow apoptotic rate (c) biochemical changes that favour 
proliferation. 
(a) Rapid proliferation 
_Initiated cells can multiply rapidly in response to growth factors Chronic inflammation is 
known to promote tumours at several sites in the body by maintaining a steady supply of 
growth factors and cytokines (Grasso, 1987). There is a high incidence of cancer in 
association with ulcerative colitis, chronic pancreatitis, chronic viral hepatitis and 
oesophagitis. In the lungs the chronic bronchial inflammation engendered by the constant 
inhalation of cigarette smoke is likely to create the right milieu for tumour promotion. 
Healing wounds, as in scars from old tuberculosis, have been shown to predispose to lung 
adenocarcinomas (1.1.2.2). 
Although an excess of prevailing growth factors would help, it would still not place the 
initiated cells at any position of special advantage as the neighbouring normal cells too 
would be exposed to the same factors. There are two ways in which the initiated cells can 
get round this problem. They can either increase their sensitivity to these factors by 
expressing more growth factor receptors on their cell surface or they can manufacture 
their own growth stimulants. There is evidence to show that both these events happen 
during the stage of lung tumour promotion. 
Non small cell lung cancers in general and squamous cell lung cancers in particular have 
been shown to over-express a spectrum growth factor receptors (Berger et aI., 1987). 
These include the epidermal growth factor receptor (EGFR)-encoded by the gene c-
erbBl, transforming growth factor a (TGFa) receptor and a EGFR-related receptor for 
an unknown ligand coded by the Her-2/neu gene. It is interesting that none of these 
receptors are found on SCLC cells which are more adept at synthesising their own growth 
factors. 
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SCLC cells are known to produce peptide hormones with growth stimulating 
properties. They also express the corresponding receptors to complete the 'autocrine 
loop'. Examples include gastrin releasing peptide (GRP), bombesin, neuromedin Band 
insulin like growth factor I (IGF-I). Of these GRP is thought to be an important tumour 
promoter in early lung cancer (Johnson, 1995). During this stage of promotion, cells may 
be susceptible to negative influences as well -for example to retinoic acid - a fact which is 
utilised in the design of chemoprevention programmes (see Section 1.1.3.6). 
It is likely, that as the cells become increasingly dysplastic they outgrow their dependence 
on these extrinsic growth stimulants. 
(b) Slow apoptosis 
Reduced loss of cells from preneoplastic populations might also be expected to influence 
their growth. There is evidence from animal models of possible interplay between 
proliferation and apoptotic cell death in early carcinogenesis (Section 1.2.5). 
Two of the main genes involved in the control of apoptotic cell death i.e. p53 and bcl2 
have been found to be deranged in lung cancer from a very early stage. Loss of p53 
protein would make a cell less prone to apoptosis . As mentioned before this is seen to 
happen in a large fraction of both SCLCs and NSCLCs. 
The product of the bell gene inhibits apoptosis (see Section 1.3). Several studies have 
shown that about 30010 of NSCLCs overexpress Bc12 and the observations of Pezzella et 
al. indicate that such overexpression may start from a very early stage (pezzella et al., 
1993). The role ofbel2 in lung cancer is quite complex and extends beyond its role as an 
anti-apoptotic agent. This is discussed more fully elsewhere (see Section 6.8). 
During tumour promotion cells which are less prone to apoptosis because of 
derangement of either or both of these genes are theoretically more likely to survive and 
acquire more harmful genetic mutations. 
(ct) Biochemical changes 
A whole host of subtle biochemical changes have been reported in pre-malignant cells in 
the bronchus and elsewhere. These include shifts in the pentose phosphate and glycolytic 
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pathways. Such changes might be expected to endow pre-neoplastic cells with the ability 
to channel more of their energy production into processes like cell proliferation (Ito et al .• 
1995). 
1.1.4.5 Lung Tumour Progression 
The stage of tumour progression is characterised by accumulation of yet more mutations 
in oncogenes and anti-oncogenes. There is controversy about the minimum number of 
such mutations that is necessary with estimates ranging from six to twenty. There is 
controversy also about the need for these mutations to occur in any particular order. While 
the Vogelstein model of colorectal cancer seems to imply that an orderly progression is 
necessary most other commentators agree that the 'bulk' of the mutations is more 
important than the order in which they are acquired. Yet certain genes tend to be mutated 
more often at certain stages of the disease. There is controversy about whether these later 
genetic events occur 'endogenously' i.e. as a result of the inherent genetic instability 
within the cell or whether further carcinogen exposure is needed. Most lung cancer 
patients continue to be exposed to cigarette smoke carcinogens till a late stage of their 
disease and even the later genetic mutations in such patients show characteristic GC to T A 
transversions. 
As a result of the genetic alterations during the stage of progression, the tumour becomes 
more aggressive and acquires the potential to invade local tissues and spread to distant 
organs. Metastasis is the result of a multistep process including basement membrane 
disruption, stromal invasion, neoangiogenesis, intravasation and extravasation of tumour 
cells and invasion of a secondary site. Thus several aspects of normal cell behaviour must 
be disrupted before a cancer cell is able to metastasise successfully. 
Resistance to apoptosis should be an advantage to a metastasising cancer cell. A lung 
cancer cell in the alien environment of a lymph node or liver parenchyma is deprived of 
many survival signals and the normal reaction is to undergo apoptosis. Cells which are 
inherently resistant to apoptosis (because of the appropriate genetic mutations) should find 
it easier to survive and colonise a distant organ (see Section 1.2.5.3). 
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An example is the resistance to apoptosis which is conferred by the loss of expression of 
the DAP (death associated protein) kinase gene. DAP kinase is a calcium/calmodulin 
dependent enzyme that was first identified as a positive modulator of apoptosis induced by 
IFN-y in HeLa cells (Deiss et al., 1995). Inactivation of the DAP kinase gene may be an 
important event in the later stages of lung cancer progression. Highly aggressive and 
metastatic murine lung cancer clones were found not to express DAP kinase in contrast to 
their low metastatic counterparts. Restoration of DAP kinase to physiological levels in 
high metastatic Lewis carcinoma cells suppressed their ability to form lung metastases 
after intravenous injection into syngeneic mice and delayed local tumour growth in a 
foreign micro-environment (Inbal et al., 1997). 
Alteration in the matrix metalloproteinases (MMPs) is observed late in the life history of 
many tumours and seems to correlate with enhanced metastatic potential. The MMPs are a 
family of proteases capable of degrading the components of basement membrane and 
extracellular matrix. It is obvious that such enzymes will have enormous practical value to 
metastasising cells. Normal tissues also produce inhibitors of MMPs called TIMPs (tissue 
inhibitors of metalloproteinases). In a study involving 88 resected lung tumours where 
cancerous areas as well as adjacent nonnallungs were examined for expression of MMPs 
and TIMPs, it was observed that progression of bronchopulmonary cancers involves a 
progressive disruption of the MMP/TIMP balance in favour of MMPs. High MMP 
expression correlated with poorer histological differentiation and higher clinical stage. 
These enzymes may represent an attractive target for anti-invasive and anti-metastatic 
therapy for lung tumours (Nawrocki et al., 1997). 
Acquisition of metastatic capacity has also been associated with reduced expression of 
the nm23 gene. This gene codes for a nucleoside diphosphate kinase which is active in 
microtubule assembly. Mitotic spindle fonnation and cell locomotion both require 
microtubule function and are both deranged in malignant cells. In NSCLC the 
immunohistochemical expression of nm23 has been found to correlate inversely with the 
frequency of distant metastases. This antibody may be useful in selecting patients for post-
operative adjuvant chemotherapy (Lai et al., 1996). 
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CD44 is an integral membrane glycoprotein that functions as a receptor for the 
extracellular matrix glycan, hyaluronan. Expression of CD44 isoforms by tumour cells is 
thought to play a role in tumour growth and metastasis by altering the anchorage 
properties of malignant cells to other cells and to basement membrane (Hom et ai., 1996). 
A number of other genes also participate in lung tumour progression (reviewed by 
Gazdar, 1994). Ras is involved primarily in pulmonary adenocarcinomas. Activation of 
myc is associated with a greater incidence of lymph node and distant metastases in 
squamous cell carcinoma. The retinoblastoma gene is absent or abnormal in 20% of 
NSCLCs and influences disease progression. 
In the late stages a range of karyotypic abnormalities can be observed in lung cancer 
including loss of 9p and 11 p (Testa and Siegfried, 1992). Some of these regions might 
host genes of importance (such as the interferon gene on 9p) but it is still not clear 
whether these deletions have any pathological significance or whether they are merely a 
reflection of the state of genetic anarchy that prevails in cells at this late stage. 
From the foregoing discussion it can be seen that the failure of apoptosis is an important 
event in the early stages of the natural history of lung cancer and it is likely to play a 
crucial role in the late stages as well for instance during metastasis. The role of apoptosis 
in cancer (and in other pathological processes) is being investigated enthusiastically in 
laboratories around the world. In the next section we shall describe this newly discovered 
biological phenomenon and explain why its discovery has engendered so much enthusiasm 
and optimism amongst biologists and physicians alike. 
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1.2 Apoptosis 
1.2.1 Introduction 
Evidence for the existence of two morphologically distinct types of cell death was first 
obtained by Kerr in 1965 from histochemical studies of ischaemic injury to rat liver (Kerr, 
1965). Some cell death occurred with the typical changes seen in tissue necrosis: clumping 
of chromatin into ill defined masses, swelling of organelles, membrane disintegration and 
infiltration of inflammatory cells. Cells in other areas of the damaged liver, however, died 
a different death. They contained chromatin compacted into sharply delineated masses, the 
cytoplasm was condensed, and there were outcropping of cytoplasmic "blebs" or 
protuberances that became pinched off and released to be devoured by tissue phagocytic 
cells. No inflammatory reaction was noted around cells dying by this second mechanism. 
Kerr's further studies with Currie and Wyllie showed that this second mechanism of cell 
death occurred as tissues underwent remodelling during development and in that sense 
was a "physiologic cell death" (Kerr et al., 1972). The original term for this phenomenon, 
"shrinkage necrosis", did not seem an appropriate one for this process, so they searched 
for another. A colleague of theirs at the University of Aberdeen, professor James Carmack 
of the Department of Greek, suggested the term apoptosis meaning "falling off' of petals 
from a flower or leaves from a tree. The term has stuck ever since. 
The concept of apoptosis was largely ignored till the mid to late 1980s when the 
discovery of the ced genes in the roundworm Caenorhabditis elegans and of the bc12 gene 
in B lymphocytes put the field on a solid genetic basis. In spite of extensive research the 
molecular processes controlling and executing cell death through apoptosis are still poorly 
understood. Apoptosis has been shown to be involved in diverse biological processes both 
physiological and pathological. In particular the role of apoptosis in cancer has been 
investigated with great zeal and fervour. 
Recognition of the widespread importance of apoptosis has been one of the most 
significant changes in the biomedical sciences in the past decade. 
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1.2.2 Morphological features 
The morphological changes of apoptosis are quite distinctive and can be said to occur in 
three phases (Wyllie et a/., 1980). 
Phasel. 
The earliest ultrastructural changes of apoptosis include the loss of cell junctions and 
other specialised plasma membrane structures such as microvilli. This causes the cells to 
detach themselves from their neighbours and adopt a smooth contour. 
The most characteristic change occurs next and consists of condensation of chromatin 
into crescentic caps at the nuclear periphery. This change is associated with cleavage of 
nuclear DNA. 
Along with these nuclear changes the cytoplasm gradually condenses, the organelles 
become compacted and the cell generally shrinks in size (Fig. 1.2). The contraction of 
cytoplasamic volume is associated with loss of intracellular fluid and ions. This is the result 
of the endoplasmic reticulum dilating and fonning vesicles that fuse with the plasma 
membrane and void their contents extracellularly. Cytoskeletal elements aggregate in side-
to-side arrays often parallel to the cell surface and ribosomal particles clump in semi-
crystalline formations but otherwise the organelles remain intact. In contrast to necrosis 
mitochondria do not show high amplitude swelling, the cell membrane does not become 
permeable to vital dyes at this stage and apoptotic cells within tissues do not elicit an acute 
inflammatory reaction. These alterations in cell volume and shape have been ascribed in 
part to the induction in apoptotic cells of the enzyme transglutaminase (Section 1.2.3.4 c). 
In phase 2 (which may overlap with the first) there is blebbing at the cell surface and 
crenation of the nuclear outline. Both nucleus and cytoplasm may split into fragments of 
various sizes. Typically the cell becomes a cluster of round smooth membrane bound 
apoptotic bodies some containing nuclear fragments and others without. Apoptotic bodies 
provide a potent stimulus for phagocytosis and are engulfed by neighbouring cells. These 
engulfing cells are often members of the mononuclear-phagocyte system but also can be 
normal epithelial cells, vascular endothelium and tumour cells. 
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In phase 3, there is progressive degeneration of residual nuclear and cytoplasmic 
structures. In tissues these changes (sometimes called secondary necrosis) usually occurs 
in the phagosomes of the ingesting cell . Eventually membranes disappear, organelles 
become unrecognizable and the appearance is that of a lysosomal residual body. 
Fig. 1.2 Section of squamous cell lung cancer (x630) stained with H&E 
showing an apoptotic cell characterised by dark pyknotic 
nucleus and condensed cytoplasm. 
A brief word about the speed of apoptosis. Time lapse cinematographic studies have 
shown (Evan et ai., 1992) that the initial changes of apoptosis (Phases 1 & 2 ) are 
achieved in the course of a few minutes and results in the formation of small dense 
apoptotic cells. Ifnot phagocytosed immediately, these cellular particles undergo a gradual 
loss of cell density but remain recognisable within tissues for 3-6 hours before they are 
completely lysed by secondary necrosis. This rapidity of clearance of apoptotic bodies ill 
vivo means that the identification of only a few apoptotic bodies in a tissue section can 
represent a considerable degree of cumulative cell loss. Numerically small differences in 
'apoptotic indices' (i .e. the percentage of cells that are apoptotic) can therefore be of great 
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biological import. For example, an intravenous bolus of anti-CD4 antibody increases the 
apoptotic index in murine lymph nodes from 0.06% to 1.33%, and this is sufficient to 
halve the total cell count of the lymph nodes within 48 hours (Howie et ai., 1994). 
1.2.3 Biochemical mechanisms and genetic control of apoptosis 
1.2.3.1 Introduction 
A close inspection of the phenomenon of apoptotic cell death reveals that there are four 
components to it. First of all there must be a signal, arising either from within the cell or 
outside it, which asks the cell to commit suicide. This message is conveyed via second 
messengen or signal transducers to the death etTecton-a group of chemicals which 
when activated kills the cell producing the typical morphological features of apoptosis. 
Finally there are modulaton which can (positively or negatively) influence the activity of 
the effectors and transducers. 
1.2.3.2 Signals 
Apoptosis can occur in response to an external or internal trigger (Bellamy et ai., 1995). 
Apoptosis is commonly seen during an organism's development and is best exemplified by 
the co-ordinated death of web space cells that sculpts digits from the coarsely shaped limb 
bud and by the chronologically and spatially invariant death of 13 1 cells that occurs during 
development of the nematode Caenorhabditis eiegans (Ellis et ai., 1991). These examples 
of developmental apoptosis were previously thOUght to be 'autonomous' in that no trigger 
was apparent and cell death was presumed to be initiated by some internal clock or by an 
in-built 'programme' within the genome which caused specific cells to die at specific 
times. However, it has now been found that signals like retinoic acid trigger apoptosis in 
many of these situations for instance in the limb bud (Jiang and Kochhar, 1992) and in the 
developing brain (Maden et a/., 1997). 
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In other situations there are clearly identifiable triggers arising from within the cell. 
Examples include DNA damaged by radiation or chemotherapy or foreign (viral) nucleic 
acids within the cytoplasm. 
External stimuli can be (a) appearance or withdrawal of soluble signalling molecules like 
growth factors, cytokines or hormones (b) cell bound ligands e.g. Fas ligand or (c) matrix 
associated molecules that act on surface integrin receptors. The latter is now recognised as 
an important survival signal for differentiated endothelial and epithelial cells. Without 
integrin-matrix binding these cells undergo apoptosis, a phenomenon that has been termed 
anoikis ('homelessness'). Such cells therefore cannot survive out of position if the 
appropriate matrix requirements are not fulfilled. Thus matrix composition localises seed 
to soil in a strict manner, a concept of critical importance to understanding mechanisms of 
neoplastic progression (see Sections 1.1.4.5 and 1.2.S.3c). In contrast fibroblasts do not 
show integrin dependence, in keeping with the need to rove across tissue boundaries 
during repair of injury (Meredith et al., 1993; Frisch and Francis, 1994). 
A cell is constantly being showered by such external chemical information which it must 
interpret in the context of its own lineage, developmental stage. cell cycle stage and 
metabolic state. After integrating all this information there are basically four ways in which 
a cell can respond. It can maintain the status quo of quiescence. it can divide, it can 
differentiate (if it is an immature cell) or, if it senses that its presence is redundant or 
harmful to the organism, it can decide to die by apoptosis (Williams and Smith, 1993). The 
same stimulus can evoke different responses in different cells at different times. For 
example, all the cells in the body of a metamorphosing tadpole are exposed to increased 
levels of thyroid hormone. In response to this the developing limb differentiates to 
produce legs, while muscle cells in the tail die by apoptosis. 
Thus there probably are no specific "apoptotic signals" as such. The context in which a 
signal arrives (or is withdrawn) largely determines its effect on the cell. 
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1.2.3.3 Signal Transduction 
Signals generated within or outside the cell must be transmitted to downstream effector 
molecules that often lie in different subcellular compartments. Of the various signal 
transduction systems two are known to be heavily involved in apoptosis. 
(I) Calcium-phosphoinositol-PKC 
Following the binding ofa wide range of hormones and growth factors to their receptors 
there is activation of phospholipase-Oy (PLCy) which enzymatically cleaves membrane 
phosphatidylinositol biphosphate (PIP2) to produce diacyl glycerol (DAG) and inositol 
trisphosphate (IP3). DAG operates within the cell membrane to activate protein kinase C 
(PKC) and IP3 mobilises calcium from cellular stores like the endoplasmic reticulum (ER) 
to raise the intra-cellular free calcium level. Some of this free calcium after complexing 
with a protein called calmodulin activates several enzymes of the PKC family. The 
substrates of PKC include cytoskeletal proteins, cell surface receptors and other proteins 
and enzymes which may form part of the apoptotic machinery. In addition calcium may 
directly activate enzymes such as endonuclease and transglutaminase which have a more 
obvious role in apoptosis (Hale el al., 1996) . 
Sustained increases in intracellular free calcium precede apoptosis induced by a number 
of agents or conditions, and apoptosis is delayed or inhibited when calcium is depleted 
from the cellular growth medium. Calcium ionophores such as A23187, which allows 
calcium to enter the cell, induces apoptosis in some cell types. However, calcium influx 
does not accompany apoptosis in all cell types and thus may not be an essential 
requirement but rather an after-effect of cell membrane perturbation. 
Increased levels of the mRNA encoding the calcium-binding protein calmodulin have 
been observed in apoptotic cells, and calmodulin antagonists inhibit apoptosis in some cell 
types (Zheng et al., 1991). Evidence for the effects of protein kinase C activators and 
inhibitors is equivocal. Phorbol esters, which stimulates PKC, inhibit apoptosis in some 
cell types, but inhibition of PKC inhibits apoptosis in others (Schwartzman and Cidlowski, 
1993). 
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Thus it is likely that this pathway of apoptotic signal transduction is used only in some 
cells in response to specific signals. 
(b) Ceramide 
Ceramide is used as an apoptotic signal transducer by Fas (also known as Apol or 
CD9S) a member of the tumour necrosis factor receptor (TNFR) superfamily (see Section 
1.4.1). When Fas is bound by its ligand, Fas-L, the cell dies by apoptosis. It has been 
shown that Fas binding leads to the enzymatic cleavage of membrane sphingomyelin to 
form ceramide. Ceramide triggers the subsequent stages of the apoptotic pathway perhaps 
by activating the ICE/ced-3 cysteine proteases discussed in Section 1.2.3.4 a. Inhibition of 
ICElced-3 by the cowpox virus protein CrmA can prevent Fas and ceramide mediated 
apoptosis. 
Ceramide has also been found to be involved in several other apoptotic pathways e.g. 
that following dexamethasone, cross-linking of surface receptors by antibodies and serum 
withdrawal (Pushkareva et al., 1995). 
The internal signal of DNA damage (induced by radiation or chemicals) is transmitted to 
the death effector machinery by the pS3 gene product. In that sense it too is a signal 
transducer (see Section 1.2.3.5 b). Several other such signal transduction pathways exist 
e.g. cAMP and its analogues or agents that increase intracellular cAMP level, and the 
cytoplasmic glucocorticoid receptor which transduces dexamethasone induced apoptosis. 
Often these paths cross each other so that one signal can modulate the effects of another. 
1.2.3.4 CeU Death etTectors 
There are two ways in which signal transducers may set into motion the death effector 
machinery within a cell. They may activate the transcription of genes which code for these 
effectors. Alternatively, they may activate pre-formed death effectors within the 
cytoplasm. It seems that the second alternative is more commonly practised. While in 
some instances inhibitors of RNA and protein synthesis have been found to inhibit 
apoptosis in most other cases their presence has no effect on the process and may even 
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enhance apoptosis (Raff et 01., 1993). Also cells from which nuclei have been removed are 
capable of dying apoptotically indicating that new protein synthesis is not essential for this 
process (Jacobson et al., 1994). 
Although the full range of such molecules is unknown it seems that the same final set of 
molecules is universally used by all cells because the morphological changes of apoptosis 
are the same irrespective of species, cell type or trigger. Because these morphological 
changes can be prevented almost universally by a single protein - Bcl2 - it is probable that 
only a few effectors are involved in the final common pathway of apoptosis. Several 
candidates have been proposed. 
(a) The ICE! Ced-3 proteases or Caspases 
These proteolytic enzymes are a core component of the cell death effector machinery. 
Evidence for their involvement has arisen from studies on the nematode Caenorhabditis 
elegans . During the maturation of this wonn apoptosis takes place in some cells in an 
orderly and predictable fashion making it an ideal candidate to study this phenomenon in 
great depth. So far 14 genes controlling apoptosis in C. elegans have been identified. Two 
of these Ced-3 and Ced-4 are involved in the actual implementation of cell death as 
mutations in these genes prevents apoptosis altogether. A third gene Ced-9 (to which bcl2 
shows close structural and functional similarity) is a negative regulator of the activity of 
Ced-3 and Ced-4 (Hengartner et al., 1992). 
Cloning of the C. elegans Ced-3 gene showed that the protein is homologous to the 
mammalian cysteine protease ICE (Interleukin I-B Converting Enzyme). The only known 
function of ICE is the proteolytic maturation of pro-interleukin I-B to the biologically 
active inflammatory cytokine. Although this initially implicated ICE itself in mammalian 
apoptosis it now seems clear that other ICE homologues are more likely candidates as 
functional counterparts of Ced-3 in higher organisms. This has been supported, for 
example, by ICE deficient knockout mice where no defects in apoptosis appear. 
Molecular cloning has identified several human homologues of ICE and Ced-3 including 
ICE..cI-II (TX, ICH-2), ICE..cI-III, ICH-I (equivalent to murine Nedd2), CPP32 (apopain, 
Yarna), Mch2 and Mch3 (ICE-LAP3). These enzymes are now collectively known as 
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caspases. Unlike other mammalian cysteine prot eases, caspases cleave their substrates 
following aspartate residues. Furthermore proteases belonging to this family exist as 
zymogens that in tum require cleavage at internal aspartate residues to generate the two 
subunit active enzyme. As such, family members are capable of activating each other. 
It has been shown for several of the caspases that over-expression can cause apoptosis 
and that death can be inhibited by interfering with protease function The cowpox virus 
protein CrmA which is a specific inhibitor of ICE like cysteine proteases, can inhibit 
apoptosis in a wide range of situations indicating that caspases are recruited as effectors 
by a wide range of apoptotic stimuli. This recruitment does not require gene transcription 
or new protein synthesis as it has been shown to occur even in cells from which nuclei 
have been removed. This would imply that the caspases are always present in the 
cytoplasm awaiting activation. 
Once activated these proteases act on a variety of substrates both in the nucleus and in 
the cytoplasm not all of which are needed for apoptosis. For instance, CPP321apopain, 
which appears to play a key role and may be a human counterpart of nematode Ced3, 
cleaves the protein poly (ADP-ribose) polymerase (PARP). Although this is a convenient 
marker for apoptosis, cleavage of P ARP is not actually related to ceO death. Of more 
relevance is cleavage of nuclear lamins which is an early event in apoptosis. Lamins are 
intermediate filament proteins residing at the nuclear envelope that serve to organise 
chromatin within the nucleus. Inhibition of lamin cleavage can prevent many of the nuclear 
events ofapoptotic ceO death (Vaux and Strasser, 1996; Nicholson, 1996). 
It is likely that apoptosis results from the downstream effects of several such cysteine 
protease cleaved substrates. Bcl2 is able to prevent apoptosis by blocking, in some 
unknown way, the various actions of the caspases (see Section 1.3.5). 
(b) Endonuclease 
The formation of DNA fragments of oligonucleosomal size (180-200 base pairs) is a 
biochemical hallmark of apoptosis in many cells and leads to the characteristic ladder 
pattern on gel electrophoresis (see Section 3.1.3). DNA cleavage is the result of an 
endogenous neutral Ca2+ and Mg2+ dependent endonuclease capable of inducing double 
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strand breaks at internucleosomal sites. Recent observations also suggest that large DNA 
fragments (30-50 and 200-300 kb) occur during cell death. Such large fragments may not 
be precursors of the oligonucleosomal fragments and both types of fragments can be 
produced, apparently idependently, under some circumstances (Hale et ai., 1996). 
Several candidate endonucleases of different cellular origins have been reported e.g. 
DNAse I, DNAse II and Nuc 18. These endonucleases are present constitutively in some 
cells (e. g. thymocytes) where they are activated by a rise of free cytosolic calcium, 
whereas in others the enzyme is induced transcriptionally before the onset of apoptosis. 
(c) Transglutaminase 
The characteristic alterations in cell volume and shape seen in apoptosis have been 
ascribed in part to the induction of transglutaminase, a calcium dependent enzyme which 
causes extensive cross-linking of cytoplasmic proteins forming a shell under the plasma 
membrane. This stabilizes the cytoplasm of dying cells, preventing the leakage of harmful 
intracellular elements into the extracellular environment which could lead to an 
inflammatory reaction. Five transglutaminases have been identified in humans. 
Neither endonuclease or transglutaminase is absolutely indispensable and apoptosis has 
been shown to proceed even in their absence. These enzymes are activated after the 
cysteine proteases and it seems that they are not the actual killers but are merely involved 
in the post-mortem packaging of dead cells. 
1.2.3.5 Modulators 
Whilst the triggers and the effectors of apoptosis are being defined, it is clear that there 
are other factors which may modulate the process. 
The modulation of apoptosis is complex and the details are still being unravelled with 
new bit players coming to light every day. The main genes controlling apoptosis are bcI2, 
p53 and c-myc. While the latter two are called into play only in certain cell types and in 
response to certain special situations, bcI2 or one of its homologues is part of the hard 
wired pathway of cellular apoptosis in most cells in all species from worms to humans. 
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(a) Bel2 
Bcl2 is the prime controller of apoptosis (see Section ] .3). Most other modulators 
(including p53 and c-myc) are able to control to control apoptosis mainly by regulating the 
bcl2 homologues within a cell. 
Over-expression of bcl2 inhibits apoptosis in most cells induced by most stimuli. How 
bcl2 achieves this is still not absolutely certain but all indications are that its ability to 
oppose the effects of the cysteine prot eases is crucial. The mechanism by which Bcl2 
opposes the caspases is far from clear. No direct chemical interaction between these two 
groups of molecules has been demonstrated or even proposed. But Bcl2 over-expression 
in a cell can prevent ICE induced apoptosis. That it can do so even in enucleated cells is 
proof that it does not act by down-regulating the genetic expression of ICEIced-3 
proteases but rather by opposing their effects in the cytoplasm. Thus two possibilities 
remain: bcl2 could either prevent the activation of the cysteine proteases from their 
precursors or block their actions after activation (White, 1996). 
It has been known for some time that Bcl2 is but one member of a family of proteins 
which have different effects on apoptosis. Thus while Bcl2 and Bel-XL inhibit apoptosis 
Bax, Bcl-xs and Bad promote it. These family members try to neutralise each others 
effects by forming heterodimers. Thus, Bax combines with Bcl2 to negate its anti-
apoptotic effect. If Bax is in excess the cell undergoes apoptosis. If Bcl2 is in excess it 
lives. Similar interactions occur between other family members. Therefore it is the ratio of 
these various Bcl2 proteins within a cell that largely determines its response to an 
apoptotic stimulus. Several modulators like p53 and c-myc are capable of altering this 
ratio by altering the rate of synthesis of individual family members. 
Yet another way of controlling Bcl2' s action is by phosphorylating the proteins after they 
have been synthesised. This can inactivate them or alter their binding capacity to other 
Bcl2 homologues. Ras, which has been found to co-precipitate with Bcl2 within cells 
probably inactivates it by phosphorylation (Haldar et 01., 1995). 
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(b) p53 
The pro-apoptotic p53 gene product prevents the proliferation of cells with damaged 
DNA. When U.V. rays or X-rays cause strand breaks in DNA the cellular concentration of 
P53 protein increases and this results in the cell cycle being blocked at G 1. The cell is thus 
given time to repair the damage before the cell cycle is initiated again. If the damage is 
irreparable the cell is eliminated by apoptosis. 
All these functions of p53 are sub served indirectly through other proteins. P53 is a 
transcriptional regulator of genes. It can increase or decrease the synthesis of several 
proteins by binding to the regulatory regions of their genes. For instance, p53 brings about 
cell cycle arrest by increasing the synthesis of the protein p21IWAF-IICIP-I and it aids 
DNA repair by increasing the synthesis ofGADD 45 (Velculescu and EI-Deiry, 1996). 
Apoptosis is promoted by p53 mainly by altering the Bax:Bcl2 ratio within a cell. When 
activated p53 increases the synthesis of the pro-apoptotic Bax and decreases the synthesis 
of Bcl2. This explains why over-expression of Bcl2 can prevent p53 mediated apoptosis 
(Hoffinan and Liebennann, 1994). p53 also upregulates the expression of the surface 
receptor Fas. Of course this will lead to apoptosis only if there is enough Fas-L around to 
bind to it. 
The role of p53 in apoptosis is confined to special situations. It is needed for radiation 
induced but not dexamethasone induced apoptosis of lymphocytes. It is not needed for the 
programmed cell death that takes place during embryogenesis and therefore p53-1- mice 
develop nonnally and are indistinguishable from other mice, except that from a young age 
these mice are prone to developing tumours at various locations. Thus the only 
physiological role ofp53 seems to be tumour prevention. 
(c) C-myc 
C-myc too is a nuclear transcription factor that controls cellular functions by regulating 
target genes. 
C-myc promotes cell proliferation. Following mitogenic stimulation there is increased 
synthesis of c-myc which leads to the transactivation of a set of genes thought to be 
essential for progression through G 1. C-myc concentration within cells decline rapidly 
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following withdrawal of serum or specific growth factors and the cells accumulate in the 
GO/G 1 phase. 
Paradoxically c-myc can also lead to cell death by apoptosis. Enforced over-expression 
of c-myc in the absence of serum or growth factors has been shown to cause apoptosis in 
myeloid progenitor cells and fibroblasts among other cell types. How does c-myc cause 
these diametrically opposite effects? There are two possible answers to this riddle (Ryan 
and Birnie, 1996). 
The so called "conflict model" proposes that apoptosis results from conflicting 
proliferative messages. While the lack of growth factors sends a negative growth signal, 
simultaneous over-expression of c-myc sends a positive growth signal. In the ensuing 
confusion the cell dies. 
By contrast, in the "dual signal" model apoptosis is considered a normal outcome of c-
myc expression which is evident only when there is a deficiency of growth factors. This 
system might have evolved as a fail-safe measure to eliminate cells with inappropriately 
activated c-myc. 
How c-myc promotes apoptosis is not known. One proposal is that it upregulates p53 
which in tum alters the Bax:Bcl2 ratio to cause apoptosis. This would explain why the 
pro-apoptotic effects of c-myc can be blocked by over-expression of Bc12. However, c-
myc can accelerate apoptosis in Ml leukaemic cells which lack p53 indicating that this 
might not be the only mechanism. Other mechanisms which have been proposed include 
over-expression of ornithine decarboxylase (ODC) which can kill cells by generating 
excess reactive oxygen species (ROS) (peckham and Cleveland, 1995). 
C-myc probably plays a part in the apoptosis which is seen during embryogenesis. 
Deletion of c-myc in mice is lethal in utero probably due to a physiologic deficit in the myc 
dependent deletion of cells. Many fonns of apoptosis are independent of c-myc function. 
(d) Other genes 
A number of other gene products are implicated in the control of apoptosis e.g. ras, raf, 
fos, jun and reI. In most instances it remains to sort out primary regulators from secondary 
perturbations. 
38 
1.2.4 Apoptosis in health and disease 
It is now widely accepted that apoptosis is of central importance for the development and 
homeostasis of metazoan animals. Aberrant apoptosis has been implicated in various 
pathological conditions. 
1.2.4.1 Physiological role of apoptosis 
Apoptosis is important in several physiological processes (Ueda and Shah, 1994). 
Apoptosis serves as a prominent force in sculpting the developing organism. It is 
responsible for the regression of the tadpole tail that takes place during its metamorphosis 
into a frog and for removal of interdigital webs during limb development in mammalian 
embryos. 
Apoptosis is a major mechanism for the precise regulation of cell numben. In adult 
mammals, apoptosis occurs continually in slowly proliferating cell populations, such as 
epithelium of liver, prostate and adrenal cortex, and in rapidly proliferating populations, 
such as the epithelium lining intestinal crypts and differentiating spermatogonia. Although 
much of the cell loss in populations of the later type clearly is the result of shedding of 
cells from the tissue, in the former, mitosis and apoptosis balance each other under steady-
state conditions. There is growing evidence that apoptosis is regulated in a reciprocal 
fashion to mitosis by growth factors and trophic hormones, and Raff et al. have suggested 
that most cells in higher animals may require continuous trophic stimulation to survive. 
They postulate that an increase in cell numbers in a particular location might lead to 
greater cellular competition for the trophic factors that stimulate mitosis and inhibit 
apoptosis and that this, in tum, might temporarily tip the balance between the two 
processes, leading to restoration of the cell population to its former level (RafT et al .• 
1993). 
A number of involutional processes occurring in normal adult mammals have been 
shown to be associated with marked enhancement of apoptosis. Well documented 
examples include reversion of the lactating breast to its resting state after weaning, ovarian 
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follicular atresia, and catagen involution of hair follicles. The trigger for breast involution 
is likely to be hormonal. but in the other instances. the nature of the initiating stimulus is 
uncertain. 
In the immune system. apoptosis subserves special physiologic roles. It is responsible 
for the deletion of autoreactive T -cells in thymus that is responsible for self-tolerance and 
for selection of B-cells in lymphoid germinal centres during humoral immune responses. 
Another specialised function is the deletion of effete cells such as ageing neutrophil 
leukocytes. 
Apoptosis is involved in antiviral defence mechanisms. There is good evidence that cells 
infected by viruses die through apoptosis before the virus can replicate. Interestingly. 
many viruses have evolved mechanisms for blocking apoptosis-including some viruses 
involved in cancer. 
1.2.4.2 Apoptosis in pathological conditions 
Both lack of apoptosis and excessive apoptosis have been implicated in various 
pathological conditions. 
Diseases associated with inhibition ofapoptosis are:-
l)Cancer 
2)Autoirnmune disorders 
3)Viral infections 
Diseases associated with increased apoptosis are:-
l)AIOS 
2)Neurodegenerative disorders 
3 )Myelodysplastic syndromes 
4)Ischaemic injury 
Cells from a wide variety of human cancen have a decreased ability to undergo 
apoptosis in response to at least some physiologic stimuli. The role of apoptosis in cancer 
is discussed in detail in Section 1.2.5. 
40 
Failure to remove autoimmune cells that arise during development or that develop as'a 
result of somatic mutation during an immune response can result in autoimmune disease. 
Recent work in animal model systems has clearly demonstrated the importance of 
dysregulated apoptosis in the aetiology of autoimmune disease. Fas is a cell surface 
receptor on activated lymphocytes stimulation of which leads to apoptosis. In mice, two 
forms of hereditary autoimmune disease have been attributed to alterations in Fas 
mediated apoptosis. MRL-Ipr mice, which develop fatal systemic lupus erythematosus 
(SLE) by 6 months of age, have mutation in the Fas receptor. In contrast, the OLD 
mouse, which develops a similar illness, has a mutation in the Fas ligand. In humans a 
secreted form ofFas has been identified. Patients with SLE have elevated levels of soluble 
Fas, which may competitively inhibit Fas ligand-Fas interactions. The resultant decrease 
in Fas mediated apoptosis may contribute to the accumulation of autoimmune cells in this 
disorder. Alterations in the susceptibility of lymphocytes to die by apoptosis in vitro have 
been reported in several other diseases e.g. rheumatoid arthritis, psoriasis, inflammatory 
bowel disease and autoimmune diabetes mellitus (Thompson, 1995). 
The disruption of cell physiology as a result of viral infection can cause an infected cell 
to undergo apoptosis. This suicide may be viewed as a cellular defence mechanism to 
prevent viral propagation. Cytotoxic T -cells can prevent viral spread by recognising and 
killing infected cells by activating the target cell's endogenous cell death programme. T-
cells induce apoptosis either by activating the Fas receptor on the surface of the target cell, 
or by introduction of proteases, such as Granzyme B, which activate the cell death 
programme from within the cytoplasm. To circumvent these host defences, a number of 
viruses have developed mechanisms to disrupt the normal regulation of apoptosis within 
the infected cell. For example adenoviruses produce the EIB 19-kD protein which can 
block apoptosis directly. EIB has been found to be homologous to Bc12. Poxviruses can 
prevent apoptosis by producing an inhibitor for the death effector molecule interleukin-l P 
converting enzyme (ICE). The crmA gene of poxviruses code for a specific inhibitor for 
ICE. Epstein-Barr viruses up-regulate the expression of Bcl2 through the viral gene LMP-
1 which is produced during latency. This provides a survival advantage to the latently 
infected cells. 
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In contrast to the above, certain viral infections, instead of preventing apoptosis, can 
promote apoptosis as part of their pathogenesis. The acquired immunodeficiency 
syndrome (AIDS) caused by the human immunodeficiency virus (HIY) is the most 
dramatic example. In this condition progressive depletion of CD4 T lymphocytes leads to 
lymphopenia and immunodeficiency. Recent evidence suggests that stimulation of the CD4 
receptor on T -cells, by its binding to the soluble viral product gp 120, results in the 
enhanced susceptibility of these cells to undergo apoptosis (Carson and Ribeiro, 1993). 
A wide variety of neurodegenerative disorders are characterised by the gradual loss of 
specific sets of neurons. Such disorders include Alzheimer's disease, Parkinson's disease, 
amyotrophic lateral sclerosis (ALS), spinal muscular atrophy and retinitis pigmentosa. In 
these diseases cell death results in specific disorders of movement and central nervous 
system function. In all these conditions apoptosis appears to be the main cause of neuronal 
cell death. The stimulus for such neuronal apoptosis has been identified in some cases. For 
instance, the (3-amyloid plaques that accumulate in Alzheimer's disease have been shown 
to induce apoptosis in neurones. Free radical injury is the trigger in ALS. 
Disorders of blood cell production such as myelodysplastic syndrome and some fonns 
of aplastic anaemia are associated with increased apoptotic cell death within the bone 
marrow. These disorders could result from the activation of genes that promote apoptosis, 
acquired deficiencies in stromal cells or haematopoietic survival factors, or the direct 
effects of toxins and mediators of immune responses. 
Two common diseases associated with ischaemic injury to cells are myocardial 
infarction and stroke. These diseases arise primarily as a result of an acute loss of blood 
flow (ischaemia). In both disorders, cells within the central area of ischaemia appear to die 
rapidly as a result of necrosis. However, outside the central ischaemic zone cells die over a 
more protracted period and morphologically appear to die by apoptosis. Agents known to 
be inhibitors of apoptosis in vitro have been shown to limit infarct size in these disorders 
(Salary et al.. 1996). 
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1.2.5 Apoptosis and cancer 
Apoptosis plays a significant role in various stages of the natural history of a tumour from 
its genesis to its response to treatment. 
1.2.5.1 Tumour initiation 
Cancer is a clonal disease arising from a single cell which has acquired a number of 
genetic mutations over time. The body's response to any DNA damage is to weed out the 
aftlicted cells by apoptotic cell death. This is achieved mainly by means ofpS3, a molecule 
that is capable of triggering apoptosis whenever it senses irreparable DNA damage 
(Section 1.2.3.5 b). It is because of such protective mechanisms that inspite of being 
constantly bombarded by carcinogens, cancer is still such a relatively rare event. If pS3 
function is lost, damaged cells are able to continue to divide and so any mutation arising 
will be fixed. That the inhibition of apoptosis through loss of pS3 function is a common 
early event in cancer is borne out by the following facts. Aberrant p53 is the commonest 
genetic abnormality among human tumours, being present in as much as 50010 of all 
cancers. In many of these tumours loss of p53 occurs early in the life history and is seen 
even in pre-cancerous cells. In lung cancer for instance, p53 is lost in the stage of 
hyperplasia and squamous metaplasia. In the Li Fraumeni syndrome, where there is 
inherited abnormality ofp53, patients are prone to develop cancer at an early age. In mice 
with the p53 gene deleted, development is normal but the incidence of cancer in young 
animals is enormously increased (Harris, 1996). 
Thus deregulation of apoptosis is likely to be a vital element in the establishment of the 
cancerous phenotype. 
1.2.5.2 Tumour promotion 
The importance of apoptosis during the stage of tumour promotion has been underscored 
by several experiments on rat hepatocarcinogenesis (Schulte-Hermann et 01.,1981; 
Schulte-Hermann et 01., 1990). There are numerous phenotypic markers which can be 
used to identify foci of transformed cells in rodent livers. Cell kinetic studies on these foci 
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reveal that DNA synthesis and mitosis are much higher within the foci than in the 
surrounding unaltered liver but their overall growth rate is lower than that predicted by 
this proliferation rate. This apparent contradiction was resolved by the discovery of a high 
incidence of apoptosis in altered foci which largely counterbalanced the high proliferative 
activity. Apoptosis, thus, functions as a defence mechanism against the development of 
cancer. 
Tumour promoting agents such as phenobarbital were found to enhance the 
accumulation of preneoplastic cells in the liver foci by increasing their proliferative activity 
and at the same time inhibiting apoptosis. Cessation of promoter treatment resulted in 
massive apoptosis within the transformed foci. This may explain how tumour promotion 
can be reversible (Bursch et al., 1984). 
The tobacco alkaloids nicotine or cotinine have been shown to inhibit apoptosis in 
cultured cells from different origins. It has been claimed that these alkaloids might 
promote tumour development by inhibition of apoptosis (Wright et al., 1993). 
In a real life situation, the transformation of normal colorectal epithelium to carcinoma 
was found to be associated with a progressive inhibition of apoptosis (Bedi et al., 1995). 
Samples were collected from normal colonic mucosa, adenomas from familial 
adenomatous polyposis, sporadic adenomas and frank carcinomas. These samples were 
disaggregated to obtain a single cell suspension and apoptotic rate was measured by serial 
flow cytometric analysis (at 0, 8, 16 and 24 hours) of PI stained cells. The rate of increase 
of the subdiploid fraction progressively diminished from normal mucosa to adenomas to 
carcinoma. Thus inhibition of apoptosis may contribute to tumour growth, promote 
neoplastic progression and confer resistance to cytotoxic anticancer agents (see Section 
6.2). 
1.2.S.3 Tumour progreniOD 
Studies in tissue kinetics have shown that substantial cell loss can occur even in 
established tumours. While some of this cell loss is accidental and necrotic, much of it is 
apoptotic (Kerr and Searle, 1972). There can be several triggers for apoptosis in an 
established tumour. In addition to the internal signal of damaged DNA (which the cell will 
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have had to overcome at least partially to reach the stage of frank carcinoma) there are 
several external factors. TNF-a has been shown to induce apoptosis in tumour cells ill 
vitro. Some of the apoptosis seen in tumours in vivo may be attributable to the release of 
this cytokine by infiltrating macrophages. Apoptosis may also be the result of attack on the 
tumour by cytotoxic T -lymphocytes. Apoptosis is often prominent near foci of confluent 
necrosis where mild ischaemia is likely to be involved in its initiation. This is a known 
cause of apoptosis in non-neoplastic tissues. Finally, increased apoptosis in tumours may 
result from processes intrinsic to the tumour cells, with differing rates of apoptosis being 
found in otherwise similar tumours expressing different oncogenes (Kerr et al., 1994). 
For the tumour to expand the cells must have to be relatively refractory to such apoptotic 
signals so that the rate of proliferation is greater than the rate of cell loss. Such a 
favourable state of affairs can be achieved by alterations in one or more of the oncogenes 
controlling apoptosis. In most tumours the oncogenes regulating apoptosis (bcI2, myc or 
p53) are frequently altered indicating that deregulated apoptosis is indeed an important 
factor. 
Bcl2 is a protein which prevents apoptosis in various types of malignant cells. In some 
lymphomas the rate of cell proliferation has been found to be very low (lower than in 
normal cells) but yet the tumour expands with time because of reduced apoptosis due to 
overexpressed Bc12. The role ofBcl2 in cancer is discussed more fully in Section 1.3.6. 
The acquisition of an aggressive phenotype during tumour progression is partly 
influenced by deregulated apoptosis. Resistance to apoptosis may select out a group of 
cancer cells with metastatic potential (Thompson, 1995). To maintain their viability most 
cells depend on environment specific signals. These may be soluble paracrine growth 
factors or cell-extracellular matrix (ECM) and cell-cell interactions mediated by integrin 
receptors on the cell surface. Withdrawal of one or more of these survival signals can 
result in apoptosis. This dependence may serve to prevent normal cells from surviving in 
non-physiological sites. Metastatic tumour cells must circumvent this homeostatic 
mechanism to survive at sites distant from the tissue in which they arose. Cells 
metastasising to serous cavities (pleura or peritoneum) are at a double disadvantage. In 
malignant pleural effusions for instance, the freely floating tumour cells are not only 
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deprived of their usual growth factors, they are also deprived of contact mediated anti-
apoptotic signals. Thus cells resistant to apoptosis are more likely to survive in the 
circulation and colonise successfully. 
1.2.5.4 Apoptosis and response to anti-cancer therapy 
Both chemotherapy and radiation have had a significant impact on the treatment of many 
haematological and paediatric neoplasms. For adult solid tumours, like small cell lung 
cancer, a major impediment to successful therapy has been the failure of some tumour 
types to respond to either form of treatment and the appearance of resistant cell 
populations upon relapse of an originally responsive malignancy. The underlying basis of 
cellular resistance to anticancer agents has been the focus of much experimental study. 
(a) Chemothe~ Numerous mechanisms of drug resistance are well established for 
tumour cells in vitro, including enhanced drug metabolism, altered drug accumulation, 
drug target amplification, and repair of damaged targets. Resistance to multiple drugs is 
often associated with overexpression of a 170 kD protein, P-glycoprotein (P-gp), the 
product of the mdrl gene. There is extensive evidence that overexpression ofP-gp results 
in reduced accumulation of drug within the cell. 
Resistance to apoptosis is a newly recognised pathway to multiple drug resistance, one 
that likely explains a significant proportion of treatment failures. Chemotherapy was 
previously thought to kill cells by inducing irreversible metabolic damages that result in 
target cell necrosis. It now appears that the primary mechanism by which most 
chemotherapeutic agents induce cell death is through creating aberrations in cellular 
physiology that result in induction of apoptosis. A failure of a tumour cell to engage 
apoptosis would therefore confer drug resistance, irrespective of the pharmacokinetic 
mechanisms mentioned above. Consistent with this hypothesis, over-expression of Bcl2 in 
different cell lines has been shown to render cells resistant to cytotoxic drugs with varying 
mechanisms of action. Similarly, in mouse fibroblasts, absence of p53 confers resistance to 
adriamycin, S-tluorouracil and etoposide. In clinical tumours too, the presence of mutant 
p53 is usually associated with a poor response to chemotherapy. On the other hand, 
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tumours that rarely express mutant p53 at presentation e.g. testicular cancer, Wilm's 
tumour and childhood acute lymphoblastic leukaemia, show an extremely good response 
to chemotherapy (Lowe et 01., 1993; Harrison, 1995). 
Thus, the sensitivity of tumour cells to chemotherapeutic regimens may be influenced by 
the expression of the apoptosis controlling oncogenes. 
(b) Radiation Ionizing radiation when given in small to moderate doses greatly enhances 
apoptosis in tissues without producing necrosis. Rapidly proliferating cells such as stem 
cells and cancer ceUs are particularly susceptible to radiation. Among the cancer cells 
however, the response to radiation is variable and depends on the presence of oncogenes. 
The p53 gene product is directly involved in radiation induced apoptosis. When DNA is 
damaged by radiation p53 product accumulates within the cell and may trigger deletion of 
the cell by apoptosis if the damage is irreparable. Thymocytes lacking p53 are resistant to 
the lethal effects of radiation while retaining their normal propensity to undergo apoptosis 
after treatment with g1ucocorticoids. Tumours that are deficient in p53 are relatively 
radioresistant (Lowe et 01., 1993). 
(c) Hormone Therapy Apoptosis is involved in the atrophy of endocrine-dependent 
organs such as the prostate, breast and adrenal cortex that follows withdrawal of trophic 
hormonal stimulation. Even the malignant cells that arise from these hormone dependent 
organs generally retain this sensitivity and undergo apoptosis causing the tumour to shrink 
in size. Hormone ablation has been successfully used to treat some forms of cancer e.g. 
the anti oestrogen tamoxifen is an effective treatment for breast cancer and the 
antiandrogen cyproterone acetate is useful in metastatic prostatic carcinoma. 
It is of great interest that Bc12 expression may be involved in resistance to hormone 
therapy. Thus although Bcl2 expression was found to be virtually undetectable by 
immunohistochemistry in 13 of 19 cases of androgen dependent human prostate cancers, 
all of the androgen independent cancers studied displayed positive staining for Bcl2 
protein (McDonnell et 01., 1992). 
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(d) Potential future therapeutic strategies 
The selective induction of apoptosis in tumour cells offers some fascinating possibilities 
for treatment of cancer in the future. 
A potential therapeutic strategy would be to inhibit bcl2 expression by using antisense 
oligonucleotides. An interesting study was performed (Smetsers et al., 1994) in chronic 
myeloid leukaemia (CML) cells. Bcr-abl antisense oligonucleotides could specifically 
reduce colony formation of early haematopoietic progenitor cells from CML patients. 
It has been shown in vitro that the treatment of tumour cells expressing FaslApo-l 
antigen with monoclonal anti-Fasl Apo-l antibody results in rapid selective death of these 
cells. This antibody could potentially be used to treat cancer (Debatin et al., 1990). 
However, the FaslApo-l antigen is also expressed on many normal cell types including 
peripheral blood B and T cells, liver cells and cells in the heart, lungs, thymus and ovary. 
When anti-Fas antibodies are injected into mice they die of fulminant hepatic failure 
caused by widespread apoptotic death of liver cells (Ogasawara et al., 1993). To avoid 
complications of this nature it would be necessary to find a way to accurately target the 
reagents to the tumour cells. 
Recently, the substitution of pS3 in tumours deficient in this protein has been attempted 
(Roth et al., 1996). A retroviral vector containing the wild-type p53 gene under control of 
a J3-actin promoter was used to mediate transfer of wild-type p53 into human non small 
cell lung cancers by direct injection. Nme patients whose conventional treatments failed 
were entered into the study. In situ hybridization and DNA polymerase chain reaction 
showed vector-p53 sequences in post-treatment biopsies. Apoptosis was more frequent in 
post-treatment biopsies than pre-treatment biopsies. Tumour regression was noted in three 
patients, and tumour growth stabilised in three other patients. 
A deeper understanding of this important physiological phenomenon can lead to many 
other avenues for the treatment of several human malignancies which at present evoke a 
dismal prognosis. 
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In summary it can be seen that this apparently innocuous looking cellular process (which 
has managed to evade the attention of biologists for well over three centuries since the 
invention of the first microscope) plays a vital role in many physiological and pathological 
processes. The biochemistry and the genetics of apoptosis is intricate and the web has not 
been fully untangled yet. A detailed knowledge of the genes controlling apoptosis would 
certainly improve our understanding of the biology of cancer. It is not possible to consider 
all the genes involved in apoptosis in full detail here, but, in the next two sections we shall 
discuss two genes - bcl2 and CD40 - as these figure prominently in our experimental 
work. 
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1.3 Bcl2 
1.3.1 Introduction 
Bcl2 is the acronym for the B celllymphomalleukaemia-2 gene. This oncogene was first 
discovered in 1985 by studying the t(14: 18) translocation associated with human B cell 
malignancies like non-Hodgkin's lymphoma (Tsujimoto et al., 1985). Unlike other 
oncogenes which promote cell proliferation, bc12 was found to act in an unique fashion-
by preventing cell death. A large body of investigations carried out over the next few years 
demonstrated Bc12's ability to prevent apoptotic cell death in a wide range of tissues. In 
1993, a Bcl2 homologue called Bax was discovered which could bind with Bel2 and 
prevent its anti-apoptotic action (Oltvai et al., 1993). Since then several other such 
mutually interacting structural homologues have been identified. Some of them are death 
antagonists like Bc12 (Bel-xL, Bcl-w, Btl-I, Brag-I,Mcl-1 and AI) while others promote 
apoptosis (Bax, Bale, Bcl-xS, Bad, Bid, Bik and Hrk). This family of Bcl2 related proteins 
is now thought to constitute one of the biologically most relevant classes of apoptosis-
regulatory gene products which play an important role in regulating cell survival in 
response to a variety of apoptotic stimuli including genotoxic damage, growth factor 
withdrawal and signal transduction through death inducing receptors such as F as. 
Normal bc12 function is required for a variety of physiological processes. Overexpression 
of bc12, by preventing the death of abnormal mutated cells, can contribute to the 
development of cancer. Such overexpression is frequently obsetved in many malignancies 
including lung cancer. 
1.3.2 Structure 
The bc12 gene is located at chromosome ISq21 and encodes a 239 amino acid protein of 
25kDa. The amino acid sequence contains no motifs that might suggest a biochemical 
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function for the regulation of apoptosis (Reed, 1994). Other members of the family 
possess variable amounts ofBcl2 homology (8H) regions (BHl to BH4) which determine 
their capacity to interact with each other or with other unrelated proteins. Most members 
of the family including 8cl2 possess a 19 amino acid carboxy-tenninal transmembrane 
region, but others do not (for example Bid and Bad) thereby influencing their subcellular 
distribution. Bcl2 is mainly located on the outer mitochondrial membrane and is also seen 
on the endoplasmic reticulum (ER) and nuclear membrane. Other Bcl2 family members 
have also been found at these locations. Bcl2's full function depends on its subcellular 
localisation because lack of the membrane anchor sequence partially abrogates its 
protective role (Kroemer, 1997). 
1.3.3 Function 
Vaux and associates were the first to report that bcl2 can prolong cell survival (Vaux et 
01., 1988). Using immature Interleukin-3 (IL-3) dependent pre-B cells these investigators 
noticed that stable transfer of bcl2 expression vectors permitted prolonged cell survival in 
the absence ofIL-3, but without concomitant cell proliferation. This was proved to be due 
to bc12's ability to prevent apoptosis. On the other hand, antisense mediated reductions in 
bc12 gene expression were shown to accelerate the rate of cell death in settings of growth 
factor withdrawal (Reed et 01., 1990). 
Bc12 is now known to be capable of preventing apoptosis due to a wide range of stimuli 
in a wide range of cell types with a few exceptions, the most notable being apoptosis 
during cytotoxic T-cell mediated killing (Vaux et 01., 1992). This general inclusiveness of 
bc12's anti-apoptotic function indicates that it must act after the convergence of many 
signals in the apoptotic pathway. Indirectly, this has led to the expectation that a final 
common pathway operates in all fonns of apoptosis and furthennore, that elucidation of 
the molecular function ofbc12 is a key to understanding this mechanism. 
There are many similarities between the apoptotic mechanisms observed in humans and 
other lower forms of life Hke the nematode C. elegans (see Section 1.2.3.2). The C. 
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elegans gene ced-9 prevents apoptosis by inhibiting the action of two other genes ced-3 
and ced-4. Ced-9 is structurally and functionally similar to Bc12; so much so that human 
bel2 can inhibit cell death in nematodes and can even partially substitute for the loss of 
ced-9 function. Bcl2 homologues have been found in many other species and in rodents 
such homologues bear a 70-80010 structural similarity with the human protein. 
Thus from worms to lower mammals to humans, bcl2 seems to have been conserved in 
the genetic machinery of all multicellular organisms over hundreds of millions of years of 
evolution and must therefore serve some important purpose. Broadly, it appears that the 
death repressor activity of bc12 plays a crucial role in two important physiological 
situations. 
1) Embryonic development; 
2) Control of cell numbers in tissues. 
1.3.3.1 Embryonic development 
Normal embryonic development requires the selective apoptotic death of groups of cells. 
The Bcl2 group of proteins are widely involved in the regulation of such developmental 
apoptosis. Experiments on gene disruption animal models have shown that there are clear 
differences in the lineage specificity of the various family members. 
During embryogenesis, bc12 is initially widely expressed but later its distribution becomes 
confined to the developing kidney, lymphoid organs and skin, where its presence is 
essential for normal development. bc12 -1- knockout mice are normal at birth but then 
become ill and die of renal failure within a few weeks. They develop polycystic kidney 
disease due to greatly increased apoptosis within the developing kidney. The lymphoid 
organs undergo atrophy due to massive cell death. Decreased melanocyte survival results 
in hypopigmentation (Veis et al., 1993). 
While the absence of bel2 allows viable mice to be bom, the absence of bel-x results in 
embryonic lethality. In contrast to 0012 , OOI-x appears to be essential for brain 
development and in bcl-x -/ - embryos there is extensive cell death throughout the brain 
and spinal cord. Massive cell death is also seen in the liver.(Motoyama et al., 1995) 
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bax-I- mice are born healthy but later develop lymphoid hyperplasia and females show 
excess granulosa cells in atretic ovarian follicles consistent with excess cell survival. 
However, males are infertile and show massive apoptosis of germ cell precursors 
(Knudson et al., 1995). 
Thus not only is there lineage specificity in the bcl2 family members, but depending on 
the cell type the same molecule can have a positive or a negative effect on cell death. 
1.3.3.2 Control of ceO numbers in tissues 
bcl2 is less widespread in adult than in foetal tissues. It is seen in lymphoid, 
haematopoietic. epithelial and neural tissues where its expression is limited to distinct cell 
types or topological areas. By such differential expression bel2 helps to protect cells which 
are vitally important. For instance. in lymphoid organs differential bel2 expression helps to 
protect memory B cells and plasma cells. 
bel2 is normally expressed in a wide variety of epithelia including bronchial epithelium, 
gastro-intestinal epithelium, thyroid, breast, prostate and skin (Hockenberry et al., 1991). 
In normal bronchial epithelium, only cells in the basal layers express bcl2 but the vast 
majority of differentiated cells are negative (Walker et al., 1995). The basal areas of 
bronchial epithelium contains stem cells and other undifferentiated cells which must be 
kept alive for their regenerative powers. As the cells differentiate they move up into the 
superficial layers and eventually undergo apoptosis and are shed into the bronchial lumen 
to make way for new cells. In a sense apoptosis can be considered to be a fonn of terminal 
differentiation. If for any reason be12 persists in these differentiated cells they will 
accumulate in large numbers and may acquire new mutations which can lead to cancer. 
Hockenberry has suggested that in certain tissues, in addition to its well documented role 
in preventing apoptosis, bel2 might have some other biological functions as well 
(Hockenberry, 1995). In certain locations. such as the germinal centres of lymph nodes, the 
anti-apoptotic role of bel2 is self evident. In other situations, cells which express bel2 are 
not known to require enhanced survival functions e.g. the mesenchymal elements 
associated with respiratory epithelium It is speculated that at these sites bel2 could play 
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some role in cell differentiation and proliferation. BHRF 1, a viral homologue of Bel2 (see 
Section 1.3.4 below), when transfected into the human squamous cell carcinoma cell line 
sec 12F was found to delay the terminal differentiation of these cells (Dawson et al., 
1995). It is certainly not unknown for genes to be involved in more than one cellular 
process e.g. c-myc is involved in both cell proliferation and cell death. Additional support 
for this added role for bel2 has come from some observations in the kidneys of bcl2 -/-
mice. As mentioned above, they develop polycystic kidney disease, but the histological 
picture is heterogeneous. In addition to marked apoptosis in the mesenchymal cells but 
there is also hyperproliferation in interstitial and glomerular epithelial compartments. 
Whether the latter is a direct effect of lack of bcl2 is not known yet. New experimental 
evidence has emerged which indicates that bcl2 can retard the rate of cell proliferation in 
cultures (Bomer, 1996). 
1.3.4 The Bel2 family 
The functions of Bcl2 are modulated by interactions with other proteins which bind to it. 
Most of these proteins are structurally very similar to Bel2 but they have opposite effects 
on cell death. Some of them are death antagonists while others are agonists. In general, 
the numerical ratio of these agonists and antagonists within a cell determines its response 
to an apoptotic signal. This ratio probably depends on cell lineage and state of 
differentiation but it can be modulated by other genes. pS3, for instance, can upregulate 
the transcription of bax and downregulate bcl2, thus altering the ratio in favour of 
apoptosis. However, there are situations where mere numerical superiority is not enough. 
Ras, by phosphorylating Bcl2 can prevent it from binding to other proteins and thus 
reduce its effectiveness. Also, mutations in the BHl and BH2 regions ofBcl2 have been 
induced in the laboratory, which can alter its ability to bind to other proteins (Yin et al., 
1994). Whether such mutations take place spontaneously in tumours is not known yet. 
Sax, was the first protein identified by its eo-immunoprecipitation with Be12. It counters 
the survival enhancing effects of bel2 in co-transfection experiments, proportional to the 
54 
BaxIBcl2 ratio. Bcl2 and Bax interact as homo- and heterodimers. The opposite cellular 
functions demonstrated for Bcl2 and Bax have raised the question of whether one dimer 
partner acts as a dominant negative inhibitor of the other partner's function. bax is widely 
distributed in tissues including a number of sites in which cells die during maturation. 
The bcl-x gene was isolated through its sequence similarity to the bcl2 gene. Bel-xL 
(large), the larger protein product of the human bcl-x gene, resembles Bcl2 in its ability to 
inhibit apoptosis in growth factor deprived cell cultures but the two proteins are expressed 
in different types of cells and perhaps fulfil different physiological roles. Bcl-Xs (short) 
counters the protective effects of both Bcl2 and Bcl-XL. 
Bak (Bcl2 homologous antagonist killer) is functionally similar to Bax. It interacts with 
Bcl2 and Bel-xL and opposes their death repressor activity when co-expressed in cultured 
cells. Bak differs from Bax in its preference for heterodimerizing partners. Bak appears to 
prefer Bcl-XL over Bc12. Bak and Bax may also have different cell type specificities as has 
been shown for Bcl2 and Bcl-xL. 
Yeast two hybrid screening revealed a new heterodimerizing partner ofBel2 and Bcl-xL 
called Bad (Bcl2lBcl-xL associated death promoter) which is found only in murine tissue. 
Like Bax, Bak and BcI-xs, Bad promotes apoptosis in cell cultures. Bad lacks the 
membrane anchor region characteristic of other family members. 
In conclusion, it appears that members of the Bc12 family interact with each other to 
form a dynamic equilibrium between homo- and heterodimers. Current data do not e1arify 
which dimers are true regulators ofapoptosis. (For review ofbd2 family members:- Yang 
and Korsmeyer, 1996; Kroemer, 1997). 
Two other bcl2 like genes were initially found to be expressed in specific cell lines in 
response to specific stimuli. Mcl-J, which was cloned from a myeloid leukaemia line after 
induction by phorbol ester, is a negative regulator of apoptosis Its pattern of expression 
differs from those of Bd2 and Bel-XL. It is expressed in epithelial cells that are more 
differentiated than those expressing Bc12 and in various types of muscle and 
neuroendocrine cells (Kozopas el al., 1993), Al is induced in several murine 
haematopoietic cell lines by GM-CSF and lipopolysaccharide (LPS). Inspite of its 
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structural similarity with bcl2 the precise role of this gene in cell death is still not clear (Lin 
eta!., 1993). 
Some viruses display genes which have functional and/or structural similarities with bcl2. 
The apoptosis inhibiting adenovirus EIB 19-kDa protein shows only minimal amino acid 
sequence similarity to Bcl2 but functionally the two are very similar and Bcl2 can 
substitute for EIB in preventing apoptosis in adenoviruses. Other viral genes which 
encode Bcl2 related proteins include the Epstein-Barr virus BHRFI gene (pearson et al., 
1987); the African swine fever virus (AFSV) LMW5-HL gene; the herpesvirus saimiri 
ORF 16 gene. It is likely that these proteins prevent or delay the apoptosis of infected cells 
to prolong viral replication. 
1.3.5 Mechanisms of action 
Although much is known about the interaction between the various Bcl2 family 
members, the actual mechanism by which bc12 prevents apoptosis still remains shrouded in 
mystery. Several conflicting theories have been proposed but none has yet been proved to 
be true. 
(a) From the present evidence, the likeliest explanation ofBcl2's prowess lies in its ability 
to interact with the Ced-3IICE-like proteases. These enzymes when activated lead to 
downstream events in the nucleus and cytoplasm which culminate with the cell dying by 
apoptosis. Bcl2 is able to prevent the Ced-3IICE-like proteases from having this effect but 
there is no experimental evidence of direct chemical interaction between the two types of 
molecules which might suggest how this happens. Bcl2 certainly does not control the 
expression of the Ced-3IICE-like proteases for it is known to be effective even in 
enucleated cells (see Section 1.2.3.5 a). It now seems that Bcl2 modulates Ced-3IICE 
function indirectly through its effect on Ced-4. Recently a human homologue of the 
nematode Ced-4 has ben identified and named Apaf-l (apoptotic protease activating 
factor-I) (Zou et al., 1997). Apaf-l is an adaptor protein that can receive an apoptotic 
signal, bind to pro-Ced-3 and activate it. By binding to Apaf-I, Bcl2 somehow prevents it 
from activating pro-Ced-). 
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There is now evidence that the Ced-3/ICE enzymes might not be involved in every form 
of apoptosis and Bax and Bak overexpression have been found to induce death in the 
presence of Ced-3/ICE inhibitors (McCarthy et al., 1997). 
(b) Many of the changes of apoptosis are thought to be due to excess production of 
reactive oxygen species (ROS) like peroxide or superoxide O2-. Although Bel2 cannot 
prevent the production of ROS it can protect the cell from their ill effects by inhibiting 
lipid peroxidation, a downstream event in oxidation (Hockenberry et aI., 1993). However, 
Bcl2 does not lose its protective power even in hypoxic conditions, in which the 
generation of ROS is greatly reduced, indicating that its anti-oxidant effect may not be the 
sole explanation of its ability to prevent cell death. 
(c) Apoptosis is associated with an efflux ofCa2+ from the endoplasmic reticulum (ER) to 
the cytosol and Bc12 can block this flux across the ER membrane. It is not clear if these 
alterations in Ca2+ contribute functionally to the apoptotic process because some cases 
Bcl2 is able to block apoptosis despite a rise in cytosolic calcium concentration (Lam et 
al., 1994). 
(d) It has been suggested that Bcl2 modulates the transport of ions and proteins across 
biological membranes to which it is attached i.e. mitochondrial, ER and nuclear 
membranes. Both Bcl2 and Bel-XL contain an amino acid sequence motif which is present 
in some nuclear pore proteins and deletion of this motif reduces the anti-apoptotic activity 
of Bcl2. The three dimensional structure of Bcl-XL was also shown to contain an element 
similar to the pore forming domain of bacterial toxins. Like these bacterial toxins, Bcl-xL 
is able to insert ion conducting channels into biological membranes. It is possible that 
through these channels Bcl-XL controls the intracellular distribution of a molecule that is 
crucial in apoptosis. One likely candidate is cytochrome c which normally resides in 
mitochondria but once in the cytoplasm it along with Apaf-l is essential for the activation 
of ICFlCed-3 like proteases (Minn et al., 1997; Vaux, 1997). It has been hypothesised 
that the key function ofBcl2 is to somehow retain cytochrome c in the mitochondria. 
Thus Bcl2 seems to be a versatile protein with multiple independent functions rather like 
a Swiss army knife. It can function both as a channel protein and as an adaptor/docking 
protein to achieve the same end i.e inhibition ofICFlCed-3 (Reed, 1997). 
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1.3.6 Bcl2 and cancer 
Although it has subsequently been found to be involved in many other physiological and 
pathological conditions it was bc12's involvement in malignancy that first sparked interest 
in this gene. 
In 85% of follicular lymphomas bcl2 is translocated from its normal position in 18q21 to 
position 14q32. This t(14:18) translocation places the gene in juxtaposition to powerful 
elements in the immunoglobulin heavy chain locus (lgH) resulting in overproduction of 
Bel2 protein which is normal in every other respect (Brada, 1992). To assess the 
contribution of this translocation and overexpression of bcl2 to neoplasia a series of 
experiments were devised. 
In normal haemapoietic cell lines in vitro, overproduction of Bcl2 by transfection of the 
gene did not immortalise them or induce proliferation but prolonged cell survival by 
inhibiting apoptosis. In the same cell lines, when c-myc was activated in addition, it 
resulted in profuse cell proliferation which was growth factor independent (Fanidi et al., 
1992). There were similar findings from parallel experiments on transgenic mice with 
deregulated bcl2 gene. These mice initially developed follicular lymphoid hyperplasia 
involving the spleen, lymph nodes and bone marrow. After a latency period of about I 5 
months some of these mice progressed to malignant lymphoma and this transformation 
was usually associated with the activation of the c-myc oncogene. Thus bcl2 alone is 
incapable of causing malignancy and its main role seems to be to keep the cells alive for 
long enough to acquire a second oncogenic hit. Often the second hit results in a 
deleterious mutation which normally would have resulted in apoptotic cell death were it 
not for the presence of excess Bcll. Instead the abnormally mutated cells are allowed to 
thrive and cause cancer (Marin et al., 1995). These experimental findings are compatible 
with the clinical experience of the behaviour of low grade lymphoma. The disease is 
characterised by a long indolent phase [t{14:18) bcl2 deregulation] followed by a highly 
malignant phase (c-myc activation). 
Bcl2 overexpression has now been documented in a wide range of other malignancies of 
both lymphoid and epithelial origin. As in lymphomas, in many carcinomas too bel2 
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overexpression has been shown to take place from an early pre-malignant stage. In lung 
cancer for instance, bcl2 overexpression is evident even in dysplastic epithelium where one 
of the earliest changes is alteration of the spatial distribution of Bcl2. Instead of being 
confined to the basal layers, bcl2 positive cells are also seen in the more superficial layers 
of dysplastic bronchial epithelium. With increasing severity of dysplasia, the staining 
becomes more prominent with a greater proportion of bcl2 positive cells in the upper 
layers (Walker et 01., 1995). Similar changes have also been documented in pre-malignant 
lesions of the stomach and colon. It seems very likely that as in lymphomas in carcinomas 
too, bcl2 may help in tumour promotion by prolonging the life-cycle of the cells and 
making them more tolerant towards new mutations. 
Unlike lymphomas where the t( 14: 18) translocation is responsible, in cancers the 
molecular mechanism underlying bcl2 overexpression is not known yet. No evidence of 
translocation or amplification of the bcl2 gene has been found in any cancer and it is 
thought that post-translational mechanisms are involved. The finding that the protein is 
absent or weakly expressed in proliferating lymphocytes, although bcl2 messenger RNA 
increases in peripheral blood lymphocytes after in vitro stimulation, suggests post-
transcriptional regulation as a possible physiologic mechanism controlling the expression 
of bcl2 (Reed et 01., 1987). If this is so, alterations in the control of messenger RNA 
translation could lead to aberrant accumulation of bcl2 protein. 
Whatever the cause of the overexpression it certainly persists in a sizeable fraction of all 
cancers till a late stage and probably contributes to tumour progression. The biological 
role of bcl2 at these late stages has not been defined clearly and it seems to vary widely 
according to the site and type of tumour (see Section 6.7). 
The overexpression of bc12 can result in diametrically opposite clinical consequences in 
different tumours. In lymphoma, acute myeloid leukaemia and adenocarcinoma of prostate 
elevated bcl2 is associated with poor response to chemotherapy and radiation and with 
shorter survival. This is easy to understand from the known biological effects of bcl2. 
Chemotherapy, radiotherapy and hormone ablation all kill tumour cells by apoptosis. 
Therefore cells which have excessive bcl2 would naturally be resistant to these forms of 
treatment. By preventing apoptotic death, bcl2 would lead to rapid expansion of tumour 
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mass and poor prognosis. Far less intuitive is the effect that bel2 is seen to produce in 
some other tumours e.g. breast cancer and lung cancer. In both these tumours bcl2 seems 
to be able to prolong survival and in breast cancer, presence of bel2 is paradoxically 
associated with a better response to chemotherapy and hormone therapy. Why this should 
be is not elear. It seems that oncogenes may have distinct biological effects depending on 
the cellular context and the presence of other factors e.g. the co-expression of other 
oncogenes. 
In the next section we shall discuss another apoptosis controlling gene (CD40) whose 
existence has been known for almost as long as that of bcl2. But unlike bcl2 the role of 
this gene in apoptosis (particularly in epithelial cells) has not been fully defined yet. 
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1.4 CD40 
1.4.1 Introduction 
In 1984, while investigating Tumour Associated Antigens (T AAs), Hannu Koho and 
colleagues isolated a monoclonal antibody, S2C6, by immunizing mice with urinary 
bladder cancer cells. They showed that this antibody reacted with transitional cell 
carcinoma of bladder while sparing normal bladder epithelium. They also showed that cells 
of B-Iymphocyte origin expressed the S2C6 antigen (Koho et al., 1984). By 1989 it was 
clear that this antigen was an important B-cell surface molecule and it was renamed C040 
at the Fourth International Workshop on Leukocyte Antigens in Vienna. 
C040 belongs to a growing family of molecules including Low affinity Nerve Growth 
Factor-Receptor (LNGFR), Tumour Necrosis Factor-Receptor (TNFR) and Fas which are 
involved in the transmission of apoptoticlanti-apoptotic signals. Collectively they comprise 
the so called TNFR superfamily. CD40 is an activation molecule for B-cel1s since its cross 
linking by C040 ligand (C040-L) augments proliferation of resting B-cells, promotes 
immunoglobulin isotype switching and prevents apoptosis in germinal centre B-cells. 
C040-L is expressed on activated T -cells and the C040/C040-L interaction plays a key 
role in T -cell dependent B-cen activation. 
In addition to lymphocytes CD40 is also expressed on various epithelial cells and on 
carcinomas at various sites. It is speculated that C040 might have a role in the genesis of 
some of these neoplasms. 
1.4.2 Distribution 
CD40 is a pan B cen antigen. It is acquired early in B cell ontogeny, retained through the 
different stages of B cell development and finally lost during tenninal B cell differentiation. 
Thus, ptasmabtasts express CD40 but plasma cells do not. It is expressed on malignant B 
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lymphocytes as well. Cells from B lineage acute lymphoblastic leukaemias (B-ALL), B-
chronic lymphocytic leukaemias (B-CLL), Non Hodgkin's Lymphoma (NHL) and the 
great majority of multiple myeloma cells express CD40. Reed Sternberg cells, the 
malignant cells of Hodgkin's Disease which are purportedly of B cell origin, express 
CD40. (Banchereau et al., 1994) 
T lymphocytes, in contrast, do not express CD40 but some of them express the ligand 
CD40-L (see below). Within lymphoid organs CD40 is also expressed on antigen 
presenting cells (APCs) like interdigitating dendritic cells, follicular dendritic cells and 
monocytes. 
CD40 was initially identified as an antigen on urinary bladder cancer cells. It has now 
been found on epithelial cells at various other sites - both on normal and neoplastic 
epithelium. Concerning nonnal epithelium, CD40 is expressed on the basal (proliferating) 
epithelial layer of nasopharynx, tonsil, ectocervix and on gastrointestinal and bronchial 
mucosa (Young et al., 1989). This preference for the basal cells is highly reminiscent of 
the distribution of bel2 in normal epithelium (see Section 1.3.3.2). It is also found on 
thymic epithelial cells and on cultured proximal tubular epithelial cells (PTEC) in the 
kidney. CD40 antigen has been identified on carcinomas at various sites such as colon, 
prostate, breast and lung as well as on skin melanomas (Ledbetter et al., 1987; 
Stamenkovic et al., 1989). 
CD40-L is expressed on activated mature T -cells but not on resting T -cells. It is 
primarily restricted to CD4+ cells. On immunohistological analysis such CD40-L 
expressing cells are mainly found in the germinal centres of lymphoid follicles. This is the 
site where CD40 dependent apoptotic rescue ofB-cells takes place. (see Section 1.4.4.1) 
The expression of CD40-L on activated T -cells is transient and seems to be tightly 
regulated. On activation of cultured CD4+ T-cells in vitro, CD40-L is expressed after 1-2 
hours and reaches a maximum at 6-8 hours before gradually declining. In addition to this 
intrinsic transient expression, in vivo the close proximity of B-cells further limits 
prolonged C040-L expression and thus prevents protracted CD40/CD40-L interactions. 
Following receptor ligand binding there is (a) downregulation of CD40 mRNA and (b) 
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receptor mediated endocytosis of CD40-L followed by its lysosomal degradation. Also B-
cells are capable of releasing soluble CD40 (sCD40) which can bind to CD40-L and in 
effect inactivate it. (van Kooten et al., 1994; Graf et aJ., 1995) 
Lung and skin mast cells and blood basophils also expressCD40-L. 
1.4.3 Structure 
The CD40 antigen is a phosphorylated glycoprotein of 48kDa. It has 277 amino acids 
with a 193 amino acid extracellular domain, a 22 amino acid transmembrane domain and a 
62 amino acid intracellular tail. The extracellular segment is similar to other TNFR 
proteins in its organisation. It has four protein domains of 40 amino acids with six cysteine 
residues each, which is the hallmark of this family of cell surface receptors. The 
intracellular tail of CD40 is quite unique and bears no relationship to those of other family 
members suggesting that it has different signalling properties. It has a Threonine residue at 
position 234 which is critical for signal transduction (see Section 1.4.5.2). 
In addition to the membrane bound form, B cells are also capable of releasing a soluble 
form of CD40 - sCD40 - which might have important regulatory roles. The soluble 
receptor is created either by proteolytic cleavage of the transmembrane protein or by 
alternative splicing of CD40 mRNA. 
The gene coding CD40 antigen is located on human chromosome 20qll - 2Oq13-2. 
CD4O-L is a transmembrane protein of 261 amino acids with a 22 amino acid 
intracellular domain, a 24 amino acid transmembrane domain and a 215 amino acid 
extracellular domain with five cysteines. A major portion of the extracellular domain 
( ..... 200 amino acids) shows a strong similarity to other TNF-Iike molecules. This region 
comprises the bio-active, receptor binding, globular portion of CD4O-L which assumes a 
"p-jellyroll" topology characteristic of all TNF family members. 
The gene coding for CD40-L is located on human chromosome X-q24. 
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(For a detailed review of CD40 and CD40-L structure vis a vis other TNF Superfamily 
members:- van Kooten and Banchereau, 1996) 
1.4.4 Function 
The function of CD40 will be discussed in the context of the three main types of cells in 
which it is known to be expressed. 
1.4.4.1 B Lymphocytes 
CD40 is one of the key molecules involved in the survival, growth and differentiation of 
B lymphocytes. 
Within the B lymphocytes the elimination of cells reactive with cross linking self antigens 
occurs in the bone marrow (where it mayor may not involve apoptosis). Further censoring 
of the mature B cell repertoire for autoreactivity occurs within the germinal centres of the 
peripheral lymphoid organs following the induction of high rate somatic mutation in Ig V 
region genes. Here germinal centre B cells apparently enter an apoptosis prone stage in 
their differentiation. Non self-reactive B cells can be rescued from apoptosis by the 
activation ofCD40 which causes upregulation ofbcl-xL (see Section 1.4.5.3). The stimulus 
for activation is provided by the nearby CD4+ T cells which express CD40-L on their 
surface. Thus, CD40/CD40 .. L is at the very heart of this vital T -B cell interaction which 
shapes the immune response (vanKooten and Banchereau, 1996). 
B cells which have been thus protected from apoptosis by CD40 also show signs of 
activation as evidenced by increased size, tendency to form homotypic aggregates and 
increased adhesiveness to endothelial cells. If these cells are co-stimulated with cytokines 
like IL-4 and ll..-10 they will proliferate rapidly. Indeed B cells have been shown to 
produce various cytokines e.g. ll..-I p, IL-6, IL-IO, TNFa, L Ta and GMCSF in response 
to CD40 activation (Burdin et al., 1995). These may serve as autocrine growth and 
differentiation factors. 
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The engagement of CD40 on B cells seems to tum on the immunoglobulin isotype 
switching machinery, the specificity of which is subsequently provided by cytokines. For 
example, IL-4 and IL-13 lead to increased 19B whereas IL-IO and TGF-f3 induce IgA 
production. CD40/CD40-L interactions also appear to play an important role in the 
subsequent development of B cells. In vitro studies have shown that proliferating 
centrocytes will mature into memory B cells in response to prolonged CD40 triggering 
and into plasma blasts when CD40 signalling is limited and IL-lO is available (Arpin et al., 
1995). 
Although CD40 protects B cells from apoptosis induced by surface immunoglobulin 
crosslinking (which is the main apoptotic stimulus within germinal centres) its role in Fas-
induced apoptosis is exactly the opposite. CD40 activation has been shown to upregulate 
the expression of Fas antigen and increase the susceptibility to Fas mediated apoptosis in 
murine B cells (Koizumi et al., 1996) as well as normal and malignant human B cells 
(Schattner et al., 1995; Wang et al., 1997). 
The importance of the CD40 signalling system in immune regulation is underscored by 
the Hyper IgM (HIGM) syndrome. In this X-linked disorder, the gene encoding CD40-L 
is mutated or deleted (Callard et al., 1993). Males affected by the HIGM syndrome are 
susceptible to bacterial infections. They do not make antibodies to exogenous antigens but 
make a variety of auto-antibodies. Their serum has vastly elevated concentrations of IgM 
and IgO but no detectable IgA or IgE and very low levels ofigG. The secondary lymphoid 
organs of these patients display no germinal centres. 
1.4.4.2 Antigen presenting cells 
On antigen presenting cells the effect of CD40 activation is in general stimulatory leading 
to increased growth, cytokine secretion and other signs of activation. In contrast to B 
cells, in dendritic cells CD40 ligation induces resistance to Fas induced apoptosis by a 
mechanism which involves upregulation ofbel2 rather than bel-XL (Bjorck et al., 1997). 
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1.4.4.3 Epithelial cells 
The physiological role of CD40 may be broader than initially suggested by its pan B cell 
expression. As stated before (Section 4.2) CD40 is expressed on a wide range of normal 
and malignant epithelium. Although its exact biological role in these cells has not been 
defined fully yet, even the early studies had indicated that CD40 might be a functional 
molecule on epithelial cells. Thymic epithelial cells are induced to secrete GM-CSF 
following triggering with soluble anti-CD40 in conjunction with IL-l or IFN-y, the latter 
upregulating CD40 expression (Galy and Spits, 1992). This could have implications for 
the growth of both normal and transformed epithelial cells. 
There are conflicting reports about the effects of CD40 ligation on the growth of 
epithelial cells. Unlike its protective role in B cells CD40 ligation on many epithelial cells 
has been shown to induce apoptosis. In both normal primary epithelial cells as well as in 
carcinoma cell lines, CD40 ligation resulted in growth inhibition and enhanced 
susceptibility to apoptosis induced by antineoplastic drugs, TNF-a., Fas and ceramide. 
Interestingly, the expression of Bcl2 did not affect the growth inhibition induced by CD40 
ligation in these cells (Eliopoulos et al., 1996). Deglieposti et al. found CD40-L to cause 
apoptosis of bladder carcinoma cell lines T24 and RT4, while Hess and Engelmann found 
the same effect on many types of transformed cells of epithelial and mesenchymal origin 
(Deglieposti et al., 1995; Hess and Engelmann, 1996). 
In sharp contrast, in prostatic cancer cell lines, CD40 was found to protect the cells from 
Fas and TNF-a. mediated apoptosis (Rokhlin et al., 1997). Further detailed investigations 
are clearly necessary to clarify the situation. It may be that as in B cells, in epithelial cells 
too, CD40 may have pro and anti apoptotic roles in different situations in different cells. 
1.4.5 Signal transduction through CD40 
Studies indicate that CD40 ligation activates protein tyrosine kinases (PTKs) including 
Lyn and Syk and results in tyrosine phosphorylation of multiple substrates including 
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phosphatidyl inositol3-kinase and phospholipase C-y2. However the cytoplasmic segment 
of CD40 does not have any intrinsic enzymatic activity and signal transduction is likely to 
be mediated by associated molecules. There is evidence for at least three possible 
pathways of signal transduction:-
l)CRAF-l; 
2)NF-KB; 
3)BcI2IBcl-XL. 
1.4.5.1 CRAF-l 
TNF receptors in general have been found to require the help of a group of proteins 
called TRAF (TNF receptor associated factors) to transmit signals. Recently, using the 
two hybrid system, a similar protein has been found which specifically assists in CD40 
signal transduction. It has been named CRAP-l (CD40 receptor associated factor I). This 
567 amino acid protein has several important functional domains. 
CRAF-I has a string of Zn fingers that can bind to DNA. Close to the NH2 terminal it 
also has a Zn ring structure which, in other proteins, has been shown to have diverse DNA 
related functions including recombination, repair and transcription regulation. These 
structural data suggest that after activation CRAF-l could dissociate from the cytoplasmic 
tail of CD40 and directly transmit transcriptional signals to the nucleus. The CRAP -C 
domain at the carboxy terminal helps to bind CRAP-l to the cytoplasmic tail ofCD40. Its 
presence is also essential for CRAP-l to form homo- and/or hetero-oligomers with other 
members of the TRAF family which is thought to occur following ligand binding. CRAF-I 
mediates an anti-apoptotic signal while the other TRAP members transmit a pro-apoptotic 
signal. It is possible that apoptosis and cell survival may be determined by an equilibrium 
of dimerization between TRAP family members (Cheng et al., 1995). 
1.4.5.2 NF-1CB 
NF-lCB is a transcription factor that is utilised by several members of the TNFR family. 
Activation of CD40 induces the transcription factor NF-KB by a mechanism which seems 
to require the T234 residue. NF-lCB binds to teD sites within the A20 promoter gene. This 
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results in increased production of A20 within an hour of CD40 activation. A20 is a novel 
zinc finger protein that confers at least partial resistance against apoptosis. It seems 
probable that the heightened state of resistance to apoptosis conferred by CD40 activation 
is due to synergistic interaction between A20 and a Bcl2 like protein e.g. Bel-XL which is 
also CD40 inducible (Sarma et al., 1995). 
1.4.5.3 Bcl2lBd-XL 
The relation between CD40 and the Bcl2 family of proteins is controversial and has been 
the subject of considerable debate. Given the protective effects of Bc12 against apoptosis 
in several models, it was speculated that the anti-apoptotic effects of CD40 activation 
might be implemented through Bc12. In fact early evidence did seem to point to this fact. 
Kamesaki et al. demonstrated in 1994 that Bcl2 appears to confer partial protection 
against anti-IgM induced apoptosis in the immature B cell line CH31 (Kamesaki et al., 
1994). 
However, subsequently it has emerged that CD40 mediated apoptotic rescue ofB cells is 
probably independent of Bcl2 but needs the co-operation of Bcl-XL, which is a member of 
the Bel2 family (see Section 1.3.4). Most of this work has been done on WEHI-231 a 
murine B lymphoma cell line that resembles immature B cells. Wang et al. showed that 
BcI-xL is upregulated within three hours of CD40 engagement and protects WEID-231 
cells from sIg induced apoptosis. Antisense oligonucleotides to Bcl-XL can partially block 
this CD40 mediated apoptotic rescue. In contrast the expression of Bcl2 is not 
significantly affected by CD40 activation (Wang et al., 1995). Further, studies on Bel2 
deficient mice showed that CD40 ligation can prevent B cell apoptosis even in Bel2 
negative cells (Nakayama et al., 1995). Several other investigators have reported that bel-
XL plays an important role in CD40 mediated rescue of B cells (Ishida et al., 1995; 
Tuscano et al., 1996; Fang et al., 1997). 
In contrast, in their experiments on the B cell lines CH31 and WEHI-279, Koizumi et al. 
found no evidence of upregulation of bel-XL following CD40 ligation (Koizumi et al., 
1996). Again, in human dendritic cells, Bjorck et al. have shown that the ligation of CD40 
results in the upregulation ofBcl2 protein expression (Bjorck et al., 1997) .. 
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Thus it seems that CD40 recruits different bcl2 family members in different cell types. 
There is as yet no information about which. if any, bcl2 family member is involved in 
CD40 mediated signal transduction in epithelial cells. Further studies are necessary. 
1.4.6 CD40 and carcinogenesis 
Ever since CD40 (the erstwhile S2C6 antigen) was identified on urinary bladder cancer 
cells in 1984 there has been speculation that it might, in some way, be linked to the genesis 
of epithelial neoplasms. The initial observation (now proved wrong) that it was selectively 
expressed on cancer cells while sparing normal epithelium, added fuel to this view. If 
CD40's demonstrated proliferative and anti-apoptotic influence on B lymphocytes can be 
proved to be true in the context of epithelial cells as well, one could easily imagine a role 
for it as an oncogene in carcinomas. Meanwhile the discovery of CD40 on an ever 
increasing number of carcinomas at diverse sites continues to provoke research in this 
area. 
1.4.6.1 Lympboid tumoun 
There are good grounds to believe that CD40 is involved in the pathogenesis of some 
tumours of lymphoid origin e.g. Hodgkin's disease and multiple myeloma. 
The malignant cells in Hodgkin's disease (HD) are the Hodgkin and Reed Sternberg cells 
(HRS). Although the origin of these cells is still unclear (could be T cells, B cells or 
APCs) there is evidence that dysregulation of CD40 in these cells may playa role in the 
pathogenesis of HD. Overexpression of CD40 compared to normal B cells has been found 
on most HD cases studied immunohistologically (Ogrady et al., 1994) and on all HD 
derived cell lines examined flow cytometrically for surface expression and by Northern 
blot analysis for mRNA expression. In all lID derived cell lines, binding with CD40-L led 
the cells to produce cytokines like IL-6, IL-8, TNF and L T -a. and induced the expression 
of cell surface molecules like ICAM-I and B 7 -1. Despite this, CD40 crosslinking has not 
been demonstrated to have any mitogenic effect on these HD derived cell lines. This could 
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be due to in vitro loss of response to CD40-L or on the need for additional co-stimulatory 
compounds such as cytokines or cellular antigens. The model of HD caused by CD40 
dysregulation still remains attractive. One intriguing possibility is that the abundant non-
malignant T cell infiltration seen in lID may provide the proliferative stimulus through the 
CD40-L expressed on their surface (Gruss et al., 1994). T cell mediated CD40 signalling 
is also thought to be essential for the development and progression of low grade MALT-
type (MALT = mucosa associated lymphoid tissue) B cell lymphomas (Greiner et 
al., 1997). 
In contrast, in various aggressive histology B cell lymphomas and cell lines, both in vivo 
and in vitro, CD40 stimulation can inhibit growth (Funakoshi et al., 1995).This indicates 
that CD40 stimulation is selective in its effects among B cells. 
CD40 expression in multiple myeloma cells may play an important role in tumour cell 
expansion by inducing autocrine 1L-6 secretion. IL-6 serves as a primary growth factor for 
myeloma cells both in vivo and in culture in vitro. It has been shown that CD40 
stimulation leads to cell proliferation and to increased IL-6 mRNA levels in ANBL-6 cells 
derived from multiple myeloma (Tong et al., 1994). 
1.4.6.2 Epithelial tumoun 
Information about the role of CD40 in epithelial tumours is scarce and whatever little is 
available is often contradictory. 
In 1989 Stamenkovic et al. showed that IFN-y upregulated the expression of CD40 
mRNA in carcinoma cell lines HS294T (melanoma) and HepG2 (hepatocarcinoma). Since 
IFN-y is produced by activated T cells at sites of inflammation and since cancers often 
arise at sites of chronic infection and inflammation (e.g. hepatocellular carcinoma 
associated with chronic active hepatitis and cervical squamous cell carcinoma arising in the 
context of herpes virus infection) it was reasoned that CD40 activation by infiltrating T 
cells might have a role in carcinogenesis at these sites (Stamenkovic et al., 1989) 
Agathanggelou et al., investigating undifferentiated nasopharyngeal carcinomas (UNPC) 
found C040 expression in virtually all tumour cells. UNPCs are characterised by the 
presence of an intense lymphoid stroma in most cases. A large number of these cells are 
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CD40-L positive T lymphocytes. The authors speculated that these infiltrating T cells 
might promote tumour cell growth through CD40/CD40-L interactions (Agathanggelou et 
al., 1995). This is rather reminiscent of the scenario in Hodgkin's Disease. The 
CD40/CD40-L growth loop seems to be important in the progression of malignant 
melanomas (MM) as well. 71 cases ofMM were investigated immunohistologically for the 
expression of CD40 in tumour cells and CD40-L in infiltrating cells. Tumours that were 
CD40+/CD40-L+ behaved more aggressively and had a significantly shorter tumour free 
survival period (Vanderoord et al., 1996). In this context one must also remember the 
protective effect ofCD40 expression on prostatic cancer cell lines (see Section 1.4.4.3). It 
is not difficult to imagine how such protection could lead to tumour progression. 
However, there are also instances where the lack of CD40/CD40-L interactions seems to 
lead to the progression of cancer. CD40 is expressed in normal keratinocytes of the skin, 
but in basal cell carcinoma and in squamous cell carcinoma its expression is drastically 
down regulated (Viac et al., 1997). In boys with the X-linked HIGM syndrome (see 
Section 1.4.4.1) there is a high incidence of carcinomas affecting the liver, pancreas and 
biliary tree. CD40 is normally expressed on these epithelial tissues but cannot be activated 
because of the congenital defect in CD40-L synthesis (Hayward et al., 1997). 
The clinical experience, therefore, parallels the conflicting evidence that is seen in in vitro 
experiments (see Section 1.4.4.3). The exact role of this surface molecule in epithelial 
cancers is still fir from clear. Its function might vary from organ to organ and might 
depend on other ambient features e.g. the co-expression of other oncogenes. Further 
investigations are needed to clarify this situation. 
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I.S A prelude to some experiments on lung cancer 
As the preceding discussion shows, the role of apoptosis in cancer is a new and vibrant 
field of research. In lung cancer much work has been done on this subject but still many 
fundamental questions remain unanswered, for instance the correlation of apoptosis and 
the genes controlling it with survival, and with markers of disease severity. To attempt to 
answer some of these questions we undertook some investigations, taking advantage of a 
set of cases of lung cancer for which extensive information was available. 
In 1991 DAR Boldy and his colleagues at the erstwhile East Birmingham Hospital 
(EBH) set out to investigate the role of interphase nucleolar organiser regions in 
squamous cell carcinoma of the bronchus in a 10 year follow up study of 138 cases. They 
identified patients treated by surgical resection of squamous cell carcinoma of the 
bronchus at EBH in 1977. After obtaining consent from the thoracic surgeons responsible 
for the care of the patients, they collected further information by examining the hospital 
case notes and the West Midlands Regional Cancer Registry forms. The data collected 
included the age and sex of the patient, the type of operation performed (lobectomy or 
pneumonectomy), histological diagnosis, pathological TNM staging and clinical outcome 
including cause of death. Boldy and his co-investigators then performed AgNOR staining 
on paraffin sections of the tumours. They also determined ploidy by DNA flow cytometry 
on suspensions of nuclei prepared from thick paraffin embedded sections. The results of 
this study were published in Thorax. (Boldy et al., 1991) 
We took this well defined and well documented series of cases and aimed to investigate 
some of the pathological parameters of apoptosis i.e. measurement of morphologically 
identifiable apoptotic bodies and the expression of apoptosis controlling genes. 
We also wished to determine whether it was practical to assess apoptosis by PI staining 
in cultured tumour cells as this could potentially give data on the rate of apoptosis. We 
chose to begin our experiments with pleural effusions and then moved on to fresh resected 
lung tumours. The material for these experiments was obtained from patients admitted in 
three nearby hospitals - Birmingham Heartlands Hospital (formerly EBH), Walsgrave 
Hospital, Coventry and St. Cross Hospital, Rugby. 
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The outcome of these experiments will be discussed in the next few chapters. 
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CHAPTER 2 
AIMS AND OBJECTIVES 
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2 Aims and Objectives 
The aim of this project was to investigate the role of apoptosis and two apoptosis 
controlling genes (bcl2 and CD40) in squamous cell carcinoma of the lung. 
1. We hoped to find a valid way of assessing apoptosis by morphological criteria in 
histological sections of lung cancer using Haematoxytin and Eosin (H&E) stain. The 
results obtained with this method were compared with that obtained by staining with 
monoclonal antibody to ASP (apoptosis specific protein). 
2. We looked for correlation between the amount of observable apoptosis in histological 
sections and clinico-pathological parameters i.e. survival, disease stage, histological 
differentiation, proliferation rate (AgNOR) and DNA ploidy. 
3. The expression of Bcl2 and CD40 in squamous cell lung carcinoma was quantified 
using immunohistochemical methods. We analysed if the expression of these proteins 
correlated in any way with clinical outcome (survival), with the amount of apoptosis in 
histological sections and with several established markers of disease severity e.g. disease 
stage, grade of differentiation, AgNOR and DNA ploidy. We also examined if the 
expression of one protein influenced the expression of the other. 
4. We aimed to determine apoptotic rate in cultured tumour cells derived from malignant 
pleural effusions and from disaggregated freshly resected lung tumours. Our main means 
of quantifYing apoptosis in these cells was calculation of sub-diploid fractions in DNA 
histograms obtained from flow cytometric analysis of cells stained by PI and BerEP4-
FITC. To allow comparison, several other methods of quantifYing apoptosis were also 
used in parallel i.e. analysis of H&E stained cytospins, analysis of histological sections 
stained with H&E and anti-ASP. 
CHAPTER 3 
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3 Introduction to experimental methods 
Preface 
To achieve our aims we conducted various experiments to identity and quantity 
apoptotic bodies and to identity and quantifY the expression of two of the genes that 
control apoptosis. Our experimental material consisted mainly of formalin fixed, paraffin 
embedded histological sections of lung tumours. We also did experiments on malignant 
pleural effusions and freshly resected lung tumours-both of which are culturable. 
The first section of this chapter is a critique of the techniques available for assessing 
apoptosis with special reference to those that we used in our experiments. Since we made 
extensive use of immunohistochemical methods throughout, the second section deals, in 
depth, with the principles underlying immunohistochemical staining. 
3.1 The detection and measurement of apoptosis 
Several different techniques are available to detect and quantity apoptosis-each based 
on some aspect of the biology of the process. As the forthcoming discussion will reveal 
each has its own limitations and therefore throughout our investigations we have used 
more than one method in parallel. 
3.1.1 Morphological assessment with Haematoxylin and Eosin 
Apoptosis had been originally defined as a morphologically distinct form of cell death 
that is characterised by cytoplasmic and nuclear condensation followed by fragmentation 
into small dense "apoptotic bodies" which are engulfed by neighbouring cells or 
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macrophages (see Section 1.2.2). Since the definition includes only morphological criteria 
it might be considered tautological to state that morphology is an invariant feature of this 
phenomenon. But it is all too easy to lose sight of this fact when faced with the huge 
amount of biochemical and genetic detail that has now emerged on the subject. It is also 
slowly emerging that some of this biochemistry and genetics is dispensable in individual 
cases and much of it is cell lineage specific or trigger specific. Therefore it might not be 
too far off the mark to claim that morphology is the only invariant feature ofapoptosis. 
Haematoxylin and eosin (H&E) is a widely employed staining technique that we used to 
detect and quantify apoptosis in paraffin embedded tissue sections and cytospin 
preparations. The following criteria distinguish H&E stained apoptotic cells:-
1. Retracted often pink to orange cytoplasm; 
2. Condensed nuclear chromatin: 
a) earliest stage shows condensation along the nuclear membrane; 
b) later uniformly condensed to round/oval, dark structures; 
c) finally breaking up into several small, round, dark fragments; 
3. Concerns isolated cells; 
4. No inflammatory reaction. 
In trying to quantify apoptotic cells with H&E there are several possible sources of error. 
Other cells that have condensed chromatin e.g. lymphocytes and mitotic bodies could be 
mistaken for apoptosis. Also small apoptotic fragments in the late stages are easy to miss. 
Both these mistakes can be substantially eliminated by counting at high magnification. In 
an elegant study on the methodology of counting apoptotic bodies in breast cancer, van de 
Schepop et al. have shown that counting at progressively higher magnification (x400, 
x630 and x 1000 ) led to (a) higher apoptotic counts (more small apoptotic bodies were 
recognised) and (b) greater intra-observer and inter-observer reproducibility of results 
(less confusion with lymphocytes and mitoses) (van de Schepop et al., 1996). 
Apoptosis is a rare event in tissues (less than 1 % in tumour sections) and there is a 
tendency for apoptotic bodies to cluster in adjacent fields. Thus if only a few fields are 
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examined, the count can vary widely from one examination to another. This variation can 
be eliminated considerably by increasing the size of the sample. As more and more cells 
are counted the variation decreases sharply and then plateaus off until counting more cells 
does not improve the results greatly. The "running mean" method can be used to 
determine the minimum number of cells to be counted for the results to be reliable. This 
method consists of calculating stepwise an apoptotic index (apoptotic cells 1100 malignant 
cells) for every 100 malignant cells until the difference between the successive means 
becomes negligibly small (less than 1 % of the index). In the lung cancer slides we found 
this to happen after counting 1500 cells. We found that examining 10 fields under the oil 
immersion lens was always enough to include 1500 cells. Again, van de Schepop et al 
have shown that such systematic sampling protocols greatly enhance the reproducibility of 
results and is therefore mandatory for any quantitative analysis. 
It is tedious to count such large numbers of cells, particularly in situations where 
apoptosis is a rare event, and several staining techniques have been devised to ease the 
process by enhancing the difference in staining intensity between condensed and nonnal 
chromatin. Examples of such special stains include:-
(i) Feulgen's staining ofBouin's fixed tissue~ 
(ii) Acridine orange stain; 
(iii) Gomori' s silver methenamine stain; 
(iv) Differential staining with toluidine blue and safranine. 
However these techniques cannot be applied to routinely fixed and processed specimens 
and have therefore not found wide usage. The annexin staining technique takes advantage 
of a biochemical change on the SUlface of apoptotic cells. Soon after the initiation of 
apoptosis phosphatidylserine (PS) is translocated from the inner face of the plasma 
membrane to the cell surface. Once on the cell surface PS can be easily detected by 
staining with an FITe conjugate of aMexin V, a protein that has a strong natural affinity 
for PS (Martin et 01., 1995). It is impractical to use electron microscopy routinely 
although even the subtle changes in early apoptotic nuclei can be confidently identified by 
this method. Another approach is to immunostain specific protein markers or DNA strand 
79 
breaks characteristic of apoptosis. However such techniques have their own peculiar 
disadvantages as discussed below. 
Compared with flow cytometry, counting in sections has the advantage of being able to 
select a specific morphological area for counting, thus avoiding benign cells. 
Reviewing the various available methods of quantifying apoptosis a recent editorial in the 
Journal of Clinical Pathology (Harrison, 1996) favoured morphological assessment with 
H&E as the method of choice, provided the various caveats are kept in mind. 
3.1.2 Detection of DNA strand breaks 
Two special staining techniques have been developed that detect apoptosis by identifying 
the DNA strand breaks that are created by the activation of endonucleases (see Section 
1.2.3.4 b). Both these methods can be used on formalin fixed, paraffin-embedded tissue 
sections. After protease treatment to permeate the tissue sections, biotinyliated nucleotides 
are in situ incorporated into DNA breaks by DNA polymerase in the in situ end labelling 
or ISEL technique (Wijsman et al., 1993) In the TUNEL [terminal deoxynucleotidyl 
transferase (TdT) mediated biotin-dUTP nick end labelling of DNA] technique (Gavrieli et 
al., 1992) the enzyme TdT is used instead of polymerase. The labelled DNA is identified 
imrnunohistochemically with DAB via peroxidase-conjugated avidin (see Section 3.2.7). 
Intense staining is obselVed in nuclei or nuclear fragments with the morphological 
characteristics of apoptosis. This eases the recognition of scattered apoptotic cells and 
avoids confusion with other cells that have condensed chromatin e.g. mitotic cells or 
lymphocytes. These staining methods also allow the use of automated image cytometry for 
evaluating apoptosis. Furthermore, these techniques can be adapted for flow cytometric 
analysis using avidin-tagged fluorescein isothiocyanate (FITe) (see Section 3.1.5 e). 
Although they facilitate the recognition of apoptosis, ISEL and TUNEL do not 
necessarily expand on the fraction of apoptotic cells that can potentially be identified by 
morphological criteria. Two studies have shown that ISEL and H&E staining recognise an 
almost identical proportion of cells as apoptotic (Ansari et al., 1993~ Wijsman et aI., 
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1993). This is because, contrary to previous opinion, the onset of morphological changes 
occurs simultaneously with or may even precede DNA fragmentation. 
There are several situations in which non-apoptotic cells can stain positively by these 
methods. Normal cells have low levels of DNA strand breaks caused artifactually by 
fixation and processing, or even by the act of cutting the sections. But even these may be 
detected if pre-treatment with proteinase is slightly excessive. Since in necrotic cells the 
DNA is degraded by release of lysosomal DNAses, these cells incorporate the label as 
well. Because necrosis affects tracts of contiguous cells, in tissue sections it does not 
interfere with the identification of individual cells undergoing apoptosis. A variety of other 
biological processes may lead to positive ISEL staining, such as the nicking of DNA 
thought to occur during cellular differentiation. DNA damage caused by radiation or 
chemicals also leads to the incorporation of labelled nucleotides by DNA polymerase 
(Ansari eta/., 1993). 
In other situations, cells which are morphologically obviously apoptotic may not take up 
any stain. It has been shown that in breast tissue, normal, tumourous or metastatic, ISEL 
fails to stain apoptotic cells whereas TUNEL stains them efficiently. It is proposed that 
these two staining methods work on different types of DNA strand breaks which in turn 
are produced by different types of endonucleases. Each tissue induces one specific kind of 
endonuclease and hence the difference in staining specificity (Mundie et a/., 1995). If 
apoptosis proceeds without intemucleosomal fragmentation (as is now known to be 
possible - see Section 3.1.3 below) neither stain would work. 
Thus it can be seen that these techniques are by no means specific or sensitive for 
apoptosis, and results must be interpreted with caution and correlated with morphological 
criteria of apoptosis. 
3.1.3 DNA chromatin ladder 
During the disintegration of the nucleus, initially large 50 kbp (kilo base pairs) and 300 
kbp fragments are detectable transiently. In many cells there is further rapid and extensive 
double strand cleavage of intemucleosomal DNA to yield a series of oligonucleosome 
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chains of 180-200 bp (base pairs) mUltiples (180 bp is the length of DNA in a single 
nucleosome). These are visualised as the characteristic "DNA ladder" on agarose gel 
electrophoresis. This is in contrast with the diffuse smear pattern of random DNA 
breakdown that occurs in necrosis. 
It is now known that the nuclear changes of apoptosis can occur without 
oligonucleosome generation e.g. TGF pI-induced rat hepatocyte apoptosis (Cohen et al., 
1992~ Oberhammer et al., 1992). Thus the "DNA ladder" is not as reliable a marker as it 
was once thought to be. Even when laddering is present, it does not help to quantifY 
apoptosis. 
3.1.4 Immunohistochemistry 
We have made extensive use of immunohistochemical methods in our investigations. 
Immunology can aid in the analysis of apoptosis in two different ways. 
3.1.4.1 Detecting the expression of genes controlling apoptosis 
There are several genes which control apoptosis (see Section 1.2.3.5) of which we chose 
to investigate only two - bcl2 and CD40. 
bcl2 is one of the key apoptosis-controlling genes. Its over-expression can block 
apoptosis in a wide variety cells. Bcl2 over-expression has been seen in many malignancies 
-both lymphoid and non-lymphoid -and is thought to have a significant role in the genesis 
of some cancers. 
CD40 is a less well known player in the field of apoptosis. It is a cell surface receptor, 
structurally similar to the TNFR group of receptors. When it is bound by its ligand, CD40 
prevents apoptosis in lymphocytes presumably with the help of Bcl2 or one of its family 
members. Though CD40 is known to be expressed in epithelial cells and carcinomas, its 
exact biological role in these cells has not been investigated completely yet. 
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3.1.4.2 Detecting apoptosis specific proteins in cells 
The identification, by immunological means, of chemicals which are specifically 
expressed in apoptotic cells aids their ready detection and facilitates rapid and confident 
assessment of apoptosis. Several proteins have been used as immunological markers of 
apoptosis. Examples include clusterin (product of SGP-2 or TRPM-2), Cathepsin 0 and 
tissue transglutaminase. Most of these proteins happen to be cell lineage or apoptotic 
trigger specific. This imposes obvious limitations on their use, but if a particular protein is 
properly validated in the cell lineage being studied, it can prove extremely useful. In our 
investigations we used one such protein which has been found to be a reliable marker of 
apoptosis in some situations. 
ASP This recently discovered cytosolic protein is expressed specifically within apoptotic 
cells. While investigating the role of c-Jun expression during apoptosis in Burkitt's 
Lymphoma (BL) cell lines it was observed that a protein of 45,000 molecular weight 
(M.W) could be detected at high level on Western blots with an antibody raised against a 
synthetic peptide equivalent to amino acids 73-87 of the human c-Jun protein [antibody-
c-junlAP-I(Ab-2)] (Grand et al., 1995). This protein was not found to be expressed in 
viable cells or in cells dying by necrosis. It was named apoptosis specific protein (ASP). 
ASP has been observed in apoptotic cells of diverse origin. In addition to BL cells, 
adenovirus early region I-transformed human embryonic retinoblastoma cell line (Ad12 
EI HERlO), baby rat kidney cell lines (Ad12 AcclH HLBRK) and hamster fibroblasts 
have all been shown to express this protein. A variety of apoptotic triggers are capable of 
causing ASP expression e.g. serum starvation, ionomycin (a calcium ionophore), 
actinomycin D and cycloheximide (RNA and protein synthesis inhibitors), anti-
immunoglobulin treatment and cold shock. Following UV or 'Y irradiation ASP can be 
detected only in the rodent lines, even though apoptosis occurs to the same extent in other 
cell types. Thus there is some degree of trigger specificity. 
Irrespective of the trigger used an excellent correlation is observed between the onset of 
apoptosis and the upregulation of ASP. However, if Bcl2 is over-expressed within these 
cells. it not onlv prevents apootosis but also blocks ASP exoression. This would indicate 
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that ASP is upregulated at a point immediately prior to or coincidental with an irreversible 
step in the apoptotic process. This would tally with the observation that in cells, ASP 
upregulation is detected at very early stages and is maintained at extremely high levels as 
apoptosis progresses. In fact ASP (which is mainly located in the cytoplasm) is also found 
in late apoptotic cells including phagocytosed apoptotic cells which lack any DNA. 
It is this predominant cytosolic location which first raised doubts about the true identity 
of this protein. C-Jun and c-Fos are immediate early gene products, transcription factors 
that are known to be involved in the activation of the apoptotic machinery. But their 
expression is confined to the nucleus and there are no reports to suggest gross over-
expression of c-Jun at late times in apoptosis which is seen in the case of ASP. Antibodies 
raised against other parts of the c-Jun molecule [a.a. 209-225-Abl; a.a. 46-59-JunB] 
show no reaction with ASP. Finally, ASP has a M.W. of 45,000 while that of c-Jun is 
39,000. Thus, Grand ct. aI. have concluded that the partial structural similarity between 
ASP and c-Jun is entirely fortuitous. ASP is clearly distinct from c-Jun and unlikely to 
represent any related transcription factor. 
The cytosolic location and the relative insolubility of the protein in non-denaturing 
buffers suggested that it may fonn part of the modified cytoskeleton on apoptotic cells. 
During apoptosis several structural proteins e.g. ~ .. actin, tubulin and vimentin are up-
regulated or down-regulated. ASP shares many similarities with ~-actin. They solubilise 
under similar conditions and their molecular weights are similar (~-actin M.W-43,OOO). 
However, they do not cross react with each other's antibodies and have now been found 
to have quite distinct peptide structures. Thus ASP though closely associated with p-actin 
is clearly distinct from it. 
It was thought that ASP might be a partially degraded product of nuclear lamins that is 
found in myeloid and epithelial cells undergoing apoptosis. This contention has also been 
proved wrong. 
Whatever the identity of this protein, several features make it an ideal candidate for an 
apoptotic marker. It is expressed in apoptotic but not in viable or necrotic cells and it is 
identifiable from a very early to a very late stage of apoptosis. Panchalingam et 01. have 
recently used the ASP antibody [c-junlAP-l(Ab-2)] to detect apoptosis in formalin fixed, 
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paraffin embedded tissue sections of Burkitt's Lymphoma and reactive lymph nodes. In a 
comparative analysis they found that ASP antibody seemed to be more sensitive and 
detected higher numbers of apoptotic cells within sections than the ISEL or TUNEL 
techniques. Furthermore, apoptotic macro phages in the subcapsular region of reactive 
lymph nodes stained positive with anti-ASP but were not detected by the other two 
techniques indicating the greater inherent sensitivity of this antibody (Panchalingam et al., 
1996). 
In our investigations we first established that anti-ASP was able to detect apoptotic cells 
of pulmonary origin. We then felt justified to use it to validate the apoptotic indices 
obtained from H&E staining (see Sections 4.2.4 and 5.2). 
3.1.5 Flow cytometric analysis 
The fluorescence activated cell sorter (F ACS) is a versatile tool for the investigation of 
the attributes of individual cells within larger populations. For every cell, numerous light 
scattering and fluorescent properties, each reflecting an underlying structural, biochemical 
and genetic attribute of the cell, can be measured simultaneously. Later sub-populations of 
cells with distinct characteristics can be discriminated and analysed in isolation. All this is 
done with speed and statistical precision. 
The method requires as its raw material a suspension of single cells or nuclei, which is 
usually obtained from fresh disaggregated biological tissues or cultured cells. In 1983, 
Hedley and co·worlcers introduced a method whereby thick (SOf.1I1l) paraffin~mbedded 
sections could be disaggregated with pepsin to produce a suspension of nuclei. This 
enabled archival samples to be examined flow cytometrically for DNA content and nuclear 
antigens (Hedley et a/., 1983). However, cell surface antigens cannot be examined. 
A part of our investigation was to detennine whether it was possible directly to analyse 
apoptosis in living tumour tissue. We planned to do this by disaggregating fresh lung 
tumours (see Section 4.2) and culturing the cells so that the kinetics of the process could 
be analysed. To do this it is necessary to be able to distinguish the tumour cells from the 
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non-epithelial stromal cells. We used the epithelial cell surface specific marker BerEP4 for 
this purpose. 
Several structural and biochemical properties of apoptotic cells have been used to flow 
cytometrically discriminate them from viable and necrotic cells. 
(a) Assessment of ON A stainability (content) by propidium iodide 
Dual staining with propidium iodide (PI) and BerEP4-FITC was the main method that 
we used to assess apoptosis in cultured tumour cells obtained from malignant pleural 
effusions and disaggregated fresh lung tumours (see Sections 4.2.11,5.5.1 and 5.5.2.1). 
When a cell suspension is fixed with ethanol, stained with the DNA dye propidium iodide 
[or, for that matter, any other DNA fluorochrome e.g. ethidium bromide, acridine orange, 
7-aminoactinomycinD (7-AAD), the Hoechst dyes (Hoechst 33258 and 33342) and DAPI] 
and flow cytometrically analysed for fluorescent DNA content, a distinct sub-population 
of cells with lower DNA fluorescence than the GO/G 1 celts becomes apparent. This "sub-
diploid" or "sub-G 1" population has been shown to consist of apoptotic cells. 
Why do these cells display less DNA than others? Activation of endonucleases in 
apoptotic cells cleaves DNA into single nucleosomes and oligonucleosomes which can 
diffuse outside the nucleus. Following fixation with ethanol when the cells are rinsed, these 
nucleosomes diffuse outside the cell resulting in a lowered DNA content as seen on the 
histogram. It has also been suggested that ethanol fixation, by causing a change in DNA 
conformation may reduce the accessibility of DNA to fluorochromes without altering total 
cellular DNA (Darzynkiewicz et a/., 1992; Telford et a/., 1994). 
The sub-diploid fraction has been shown to consist almost entirely of apoptotic cells. 
Necrotic cells generally do not show an immediate reduction in DNA stainability and 
therefore remain confined to the GO/GI compartment of the DNA histogram. Careful 
analysis of both propidium iodide fluorescence and forward scatter for several cell types 
has demonstrated that the sub-diploid region represents intact cells and is not debris. 
The proportion of cells in this region correlates well with apoptosis measured by other 
means e.g. the presence of chromatin degradation as measured by gel electrophoresis, 
DNA separation assays and nuclear morphology as determined by electron micrography. 
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On gel electrophoresis the chromatin of flow cytometrically sorted sub-diploid cells 
appears to be almost entirely fragmented in roughly 200 bp multimers, compared with the 
sorted GO/GI phase cells which have little or no fragmented DNA. Finally, the sub-diploid 
peak which is noticed when mouse thymocytes undergo apoptosis with glucocorticoids, 
disappears when the experiment is repeated with inhibitors of apoptosis (Tounekti et al., 
1995). 
Thus, this method of staining provides a reliable assessment of apoptosis. The method is 
easy, rapid and convenient because fixed samples can be prepared and analysed at a later 
time. But perhaps the greatest advantage of fixed cell assays is the ability to combine 
fluorescent surface phenotyping with DNA staining permitting the detection of apoptosis 
in small sub-populations of cells within heterogeneous tissues. 
Although ethanol is known to damage cell membranes, gentle ethanol fixation can 
preserve membrane structure and associated markers while still inducing the alterations in 
apoptotic chromatin responsible for reduced DNA dye fluorescence. In our experiments 
we labelled the heterogeneous tumour cells with a epithelial specific cell surface marker-
BerEP4-prior to fixation and DNA staining with PI. This allowed us to analyse for 
apoptosis within the epithelial population ignoring the non-tumour cells. 
BerEP4 is an antigen of unknown function which is found exclusively in epithelial cells 
(Latza et al., 1990). The monoclonal antibody to BerEP4 is directed against the protein 
moiety of two 34 kilodalton and 39 kilodalton glycopeptide chains, which are not 
covalently bound. This antibody has been used to examine BerEP4 expression in a wide 
range of normal and malignant tissues. 
All normal epithelial tissues express the antigen on the cell membrane and some in the 
cytoplasm as well. Only hepatocytes, gastric parietal cells and the superficial layers of 
squamous epithelia are negative. The BerEP4 antigen is not expressed in non-epithelial 
cells e.g. nerve, glial, muscle, mesenchymal or lymphoid tissue (see Section 5.5.2.3). 
All carcinomas including squamous lung cancer stain positive with this antibody. In a 
small series examined by Latza et al. 3 out of 6 lung adenocarcinomas and lout of 5 oat 
cell carcinomas did not stain (Latza et al., 1990). In another study on cells derived from 
malignant pleural effusions 57% of 23 pulmonary adenocarcinomas and 600.4 of 43 
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pulmonary carcinomas of all other histological types were BerEP4 positive (Illingworth et 
al., 1994). The antibody does not stain non-epithelial tumours especially mesotheliomas. 
This has prompted several investigators to use it to differentiate between malignant 
mesotheliomas and secondary pleural adenocarcinornas-a difficult clinical and 
pathological problem (Dejrnek and Hjerpe, 1994; Hartmann and Schultze, 1994; Sheibani 
et al., 1991). 
There are several other methods for assessing apoptosis some of which will be briefly 
mentioned here (for detailed review - Darzynkiewicz et al., 1992). 
(b) Plasma membrane integrity 
In unfixed apoptotic cells (as well as in live cells) the plasma membrane is intact and can 
exclude dyes such as PI. This is in contrast to necrosis where one of the earliest changes is 
loss of membrane integrity so that these cells stain with PI. With the Hoechst dye 33342 
live cells stain strongly, apoptotic cells less strongly and necrotic cells hardly at all. 
The simultaneous use of these two dyes can help distinguish between apoptotic, necrotic 
and live cells. 
(c) Cell organelles 
Intact mitochondria in apoptotic cells can retain the dye Rhodamine 123 resulting in 
green fluorescence. In necrotic cells, mitochondrial swelling and disruption is one of the 
earliest changes and therefore Rhodamine 123 is not retained. 
The ability ofapoptotic cells to accumulate acridine orange in lysosomes (resulting in red 
fluorescence) is not markedly changed from live cells. Necrotic cells on the other hand 
tend to lose their ability to concentrate this dye in lysosomes resulting in minimal red 
luminescence. 
(d) Light scatter 
The light scattering properties of apoptotic cells are affected by the changes in the 
morphology of these cells namely chromatin condensation, nuclear fragmentation, cell 
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shrinkage and shedding of .apoptotic bodies. Initially forward light scatter is reduced with 
minor increase in side scatter. Later both are reduced. In contrast, necrosis results in an 
immediate decrease of both forward and side scatter. 
(e) DNA strand breaks 
DNA strand break labelling using either DNA polymerase or TdT followed by FITC-
conjugated antibodies can be used to detect apoptosis. However, as discussed above 
(Section 3.1.2), such strand breaks are not unique to apoptosis and the results need to be 
interpreted with caution. 
(f) Protein content 
In addition to lowered DNA, apoptotic cells contain less protein a property which can be 
detected flow cytometrically by staining with sulforhodamine 101. 
(g) Sensitivity to DNA denaturation 
The condensed chromatin of apoptotic cells is highly susceptible to denaturation, higher 
even than the DNA of mitotic cells. This property can be measured by careful staining 
with acridine orange. 
Combinations of these various methods are often practised in an effort to increase the 
confidence in identifYing apoptotic cells. 
3.2 Immunohistochemical methods 
3.2.1 Introduction 
Immunohistochemistry can be considered as the demonstration of antigens in tissue 
sections by the use of specific antigen-antibody interactions which culminate in the 
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attachment of a marker to the antigen. Immunohistochemistry exploits the very specific 
binding exhibited by an antibody for its antigen. The reaction site can be identified in a 
specimen and associated with specimen structure by attaching a microscopically dense 
probe to the antigen-antibody complex. Proteins, carbohydrates, nucleic acids, lipids and 
many other naturally occuning and synthetic compounds can act as successful antigens for 
raising antibodies, and consequently there is a wide variety of molecules which can be 
correlated with specimen structure. Microscopical analysis by immunocytochemistry can 
therefore be used to obtain a unique view of macromolecular changes within individual 
cells. If the antibody is specific, immunocytochemistry can be performed on virtually any 
biological specimen provided (a) the antigen remains intact and able to bind the antibody 
and (b) the specimen preparation technique exposes the antigen for immunolabelling by 
the antibody. 
Immunocytochemistry is highly specific, relatively quick and relatively sensitive. Many of 
the reagents are commercially available and the techniques are now routine. 
Immunocytochemistry is now being used in almost every area of biological research from 
routine diagnostic work through to complex research projects. 
While the methodological details of the staining protocol are discussed in the methods 
section (see Section 4.2) what follows below is a discussion of the principles underlying 
the various steps. The several options available at each stage are discussed while 
mentioning the particular option that was chosen and the reasons for such a choice. 
3.2.2 Tissue Fixation 
A prerequisite for all histological and cytological investigations is to ensure preservation 
of tissue architecture and cell morphology by adequate and appropriate fixation. 
Furthermore, an ideal fixative should stabilise and protect tissues and cells from the 
damaging effects associated with subsequent treatment. Reagents used for this purpose 
may significantly diminish the antibody binding capability. The demonstration of many 
antigens depends heavily on the fixative employed and the immunocytochemical method 
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selected. Prompt fixation is essential to achieve consistent results. Poor fixation or delay in 
fixation causes loss of antigenicity or diffusion of antigens into the surrounding tissue. 
There is no one fixative that is ideal for the demonstration of all antigens and many 
antigens necessitate the use offrozen sections. 
In general many antigens can be successfully demonstrated in formalin-fixed paraffin-
embedded material. The most widely used fixatives in diagnostic hospital histology 
laboratories are formalin based; neutral buffered formalin, formal saline, or 10010 formalin 
in tap water being the three most commonly employed for general use. 
In cases where antigen demonstration is poor, improved immunocytochemical staining 
may be achieved by the use of specially formulated fixatives. Examples include the 
mercuric chloride based fixative B5 which is recommended for the fixation of lymph node 
biopsies. Periodate-lysine-paraformaldehyde (PLP) is a fixative designed to protect the 
carbohydrate moiety associated with cell membranes against the damaging effects of tissue 
processing and embedding. PLP is said to give a better demonstration of membrane 
associated antigens than formalin fixation. 
All the specimens that we used had already been fixed in formalin and embedded in 
paraffin. 
3.2.3 Pre-Treatment 
Tissue fixation in formalin results in cross linking of proteins via aldehyde groups 
reacting with cellular nucleopbiles (for example, NH2 groups on amino acids or nucleic 
acids) to produce methylene bridges. To reverse this cross linking and hence make the 
tissue amenable to molecular and immunohistochemical analysis, the sections are usually 
pre-treated with a proteolytic enzyme. Several such enzymes are in use e.g. proteinase K. 
trypsin, chymotrypsin and pepsin. The main problem encountered with this proteolytic 
procedure is that because of differences in tissues and in tissue fixation times, cross linking 
of proteins can occur to differing degrees. As a result, enzyme concentration, digestion 
time and temperature, which are all critical parameters, normally have to be optimised for 
each tissue preparation. Furthermore, tissue digestion may sometimes destroy various 
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surface molecules on cells, such as cluster of differentiation (CD) antigens, which may 
then interfere with their detection by immunostaining. A high concentration of proteolytic 
enzymes can also lead to false positive or negative detection of apoptosis, as well as to 
high non-specific background staining and destruction of tissue morphology. 
To overcome these problems several non-enzymatic alternatives have been used 
successfully. One of these involves pressure cooking the tissue sections prior to staining. 
We used the other alternative i.e. microwaving the tissue sections for 15 minutes in citrate 
buffer. We found that this procedure was simple, less time consuming and resulted in more 
consistent and enhanced staining, while not requiring complicated, expensive equipment. 
3.2.4 Quenching endogenous peroxidase 
A crucial step of immunostaining involves the conversion of a colourless chromogen to a 
coloured product by the enzyme peroxidase (see Section 3.2.8 below). To ensure that the 
staining produced is specific, peroxidase is added linked to an immunoreagent. However, 
peroxidase is a normal component of many tissues like macrophages and red blood cens 
and may lead to non-specific staining if its activity is not destroyed. Endogenous 
peroxidase activity can be inhibited with excess of its substrate, hydrogen peroxide, before 
beginning the immunoreaction. 
There are several ways of doing this. Sodium azide and nascent hydrogen peroxide is a 
mild blocking agent while a stronger method involves the use of periodic acid. We used 
the commonest method which involves incubating the tissue sections in 0.3% H2~ in 
methanol. 
3.2.5 Prevention of non-specific staining 
Non-immunological attachment of antibodies and dense markers to the specimen can 
result in non-specific staining. This can be reduced by reagents added to the buffers. These 
regents are of three types: 
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(a) Surfactant reagents such as Tween 20 and NaCl, reduce surface charges on the 
specimen, thereby reducing electrostatic attachment of molecules to the specimen. 
(b) Chemical reagents, such as 0.02 M glycine, or 1% sodium borohydride block free 
aldehyde groups on the tissue thereby preventing fixation of proteins to the specimen. 
(c) Blocking reagents such as bovine serum albumin are proteins which compete with the 
inununological reagents for non-immunological sticky sites on the specimen. 
We used an appropriate blocking serum for all our staining procedures. The tissue sections 
were incubated in blocking serum just prior to the addition of the primary antibody. 
3.2.6 The antibody 
The antibody is central to the success of immunocytochemical staining. Antibodies can be 
raised against any biological macromolecule such as proteins, carbohydrates, lipids and 
nucleic acids. A good antibody is highly specific, possessing a high titre (amount of 
antibody activity), high affinity (the exactness of stereochemical fit of an antibody-
combining site to its complementary antigenic determinant) and high avidity (the total 
binding strength of a multivalent antigen with the antibody). Both polyclonal and 
monoclonal antibodies can be used for immunocytochemistry (Beesley, 1993). 
Polyclonal sera contain a mixture of high affinity antibodies, each active against different 
epitopes on the antigen. Production of polyclonal antisera is relatively simple and of low 
cost. An antigen is injected into an host animal. usually either rabbit, sheep or goat and, 
after booster injections, the serum is periodically collected and tested for antibody. 
Antibodies, which are glycoproteins are produced in the spleen of the host animal by B 
lymphocytes and plasma cells, the latter being the terminal stage in the differentiation of B 
lymphocytes. The antiserum will probably contain antibodies to impurities in the 
inununogen. Antibodies raised against the contaminating immunogens are often of low 
titre and affinity and can be diluted out to zero activity for immunolabeUing. In 
consequence of the high possibility of a wide spectrum of antibodies being present in the 
host animal in response to previous antigen challenges, serum removed from the animal 
before injection of the immunogen is important as a negative, or pre-immune, control. 
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A monoclonal serum is a 'pure' preparation of one of the constituents of polyclonal 
antiserum. Monoclonal antibodies are specific to a single epitope on the antigen. 
Monoclonal antisera are useful as diagnostic reagents and for immunocytochemical 
research since large amounts of antibody with narrow specificity, titre and homogeneity in 
all batches can be produced. A low antigen dose is needed for immunoresponse and the 
antigen need not be purified with as much stringency as for the production of polyclonal 
antisera. The initial phase of preparation is to induce synthesis of a polyclonal antiserum in 
the host animal as described above. The plasma cells are removed from the host animal 
and each fused with a malignant myeloma cell to form hybridoma cells. Hybridoma cells 
are isolated and cultured and theoretically each will produce unlimited monoclonal 
antibodies raised against a specific epitope, each antibody being identical in reactivity and 
titre. These hybridoma cells are either cultured in vitro, in which the tissue culture 
supernatant fluid contains antibody, or in vivo in the peritoneal cavity of a suitable host 
and it is the ascites fluid which contains antibody. 
Whatever type of antibody is used it is important to be absolutely certain of its class and 
sub-class since this will determine the other reagents to be used. 
3.2.7 ImmunolabeUing methods 
After the primary antibody is attached to the antigen in question the next step is to label 
the antibody with a microscopically dense marker in order to make it visible. There are 
several ways of doing this (Jackson and Blythe, 1993). 
(a) Avidin-biotin methods 
Because of its reliability and ease of performance this is the method that we used in our 
experiments. The technique utilises the high affinity that is displayed between avidin, a 
basic glycoprotein (M.W. 68 kDa) and the small (M.W 244 Da) water soluble vitamin 
biotin. For technical reasons avidin is often substituted by streptavidin. 
A secondary biotinylated antibody raised against the primary antibody is added to the 
sections. Next, a complex formed between streptavidin and horseradish peroxidase is 
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added, which, because of its high affinity for biotin attaches itself very strongly to the 
secondary antibody. This results in the fonnation of a peroxidase-streptavidin-biotin 
complex, the so called ABC complex. at the antigen binding site. Since many biotin 
molecules can be attached to a single molecule of secondary antibody there is a several 
fold amplification of the signal at the antigen site. 
(b) Emyme-anti-emyme methods 
These indirect methods utilise a pre-formed, cyclic,· enzyme-anti-enzyme immune 
complex composed of three enzyme molecules and two antibody molecules. The methods 
are named after the particular enzyme-antibody complex that is used in the technique. The 
commonest used are the peroxidase-anti-peroxidase (PAP) technique and the alkaline 
phosphatase-anti-alkaline phosphatase (APAAP) technique. These methods are very 
sensitive and can be used for both paraffin processed material as well as for frozen 
sections. 
(c) Immunogold methods 
Immunogold reagents consist of immunological reagents adsorbed on to the surface of 
colloidal gold particles. Considerable amplification of the signal can be obtained by silver 
enhancement of the colloidal gold particles and this is often used for specimens to be 
examined light microscopically. 
(d) Protein A method 
Protein A derived from the cell wall of the bacterium Staphylococcus aureus binds to the 
Fc portion of IgG molecules from several mammalian species. Protein A may be used as a 
secondary reagent for the demonstration of antigens by light microscopy when labelled 
with suitable enzymes or colloidal gold. 
(e) Direct method 
In this technique a labelled antibody reacts directly with the antigen in the histological or 
cytological preparation. This method utilises only one antibody and can be quickly 
completed. The technique however provides little signal amplification and is rarely used on 
paraffin sections. The main application remains in immunofluorescence, where this 
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technique is used to identify immunoglobulin and complement in frozen sections of skin 
and renal biopsies. 
(f) Two step indirect method 
An unlabelled primary (first layer) antibody is visualised by a labelled secondary (second 
layer) antibody directed against the immunoglobulin of the animal species in which the 
primary antibody had been raised. This method is more sensitive than the direct method 
because several secondary antibodies may react with different antigenic sites on the 
primary antibody. 
3.2.8 Chromogens 
Except for the colloidal gold methods, immunocytochemical staining methods for light 
microscopy depend upon enzyme-substrate reactions which convert colourless 
chromogens into visible, coloured end products. Since the introduction of horseradish 
peroxidase as an antibody labe~ reliance has been placed on the sensitive hydrogen 
peroxide-diaminobenzidine reaction, which produces a brown end product insoluble in 
alcoho~ xylene, and other inorganic solvents. When freshly prepared diaminobenzidine 
(DAB) solution is added to the tissue section the peroxidase at the antigen binding sites 
converts it to a brown end product. Thus the antigen site is distinctly labelled. 
3.2.9 Validation 
It is possible to achieve 'credible' non-specific labelling on a specimen. Likewise the 
absence of immunolabelling does not always signify the absence of antigen. Controls are 
therefore absolutely essential and should be devised specifically to verify each experiment. 
A positive control is a tissue specimen that is known to contain the antigen in question. 
The same tissue can be used as negative control if the primary antibody is omitted from 
the staining protocol. 
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3.2.10 Quantitation 
It has been widely reported that tissues display heterogeneity after immunostaining. Of 
the tumours that we stained, only a small fraction were unifonnly positive or negative. The 
majority were heterogeneous with varying proportions of stained and unstained cells and 
also varying strengths of staining (see Sections 5.4.1 and 5.4.2). 
It is possible that this could be an artefact. During immunostaining, unless one is careful, 
air bubbles can fonn on the surface of the slide and prevent the reagents from coming into 
contact with the tissue. This can result in patchy areas of (false) negative staining. That 
this was definitely not the case is proved by the fact that even within negatively stained 
tumour cells, infiltrating lymphocytes and macrophages often stained strongly positive 
proving that the dyes had actually reached the area in question. 
Therefore, one must interpret such differences in staining within a tissue to represent a 
real difference in protein expression among cells. It is likely that in the late stages tumours 
consist of a heterogeneous population of cells each group with slightly different 
phenotypic and genotypic characteristics and each the progeny of a different ancestor that 
arose with successive mutations during tumour progression. 
Because of numerous confounding staining variables it is generally considered prudent 
not to equate intensity of staining with strength of gene expression. Rather the proportion 
of positively staining cells might be a better guide. Some investigators use a semi-
quantitative overall general impression to define whether a tumour is positive or negative 
for a given antigen. The majority prefer to count the numbers of stained and unstained 
tumour cells within a section to calculate an index of percentage positive cells. Again there 
is no consensus about how to interpret such an index and different investigators have 
arbitrarily used different cut-off points. Values of 30%, 20010 and even as low as 2% or 1 % 
have been variously used to define positivity. 
In our series we analysed the distribution of positivity for immunostaining among the 
tumours and the cut-off point was detennined based on this distribution (see Sections 
5.4.1 and 5.4.2.) 
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CHAPTER 4 
MATERIALS AND METHODS 
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4.1 Materials 
The main material used for this investigation was two series of lung tumours: one 
archival. for which extensive information was available but for which fresh tissue was not~ 
and the other current, as a source of fresh tissue which could be cultured but for which 
much other data e.g. length of post operative survival was not available. Paraffin blocks 
were available for the current series of lung tumours. In addition some malignant pleural 
effusions were also used. This material was in the fonn of fluid drained from the chest 
cavity. 
4.1.1 Paraffm blocks 
(a) The archival material used for our investigations was 134 paraffin blocks containing 
squamous lung tumours that had been resected in 1977. These cases were reported by 
Boldy et al. in 1991 as discussed in Section 1.4.7. We could find all but four of the 
original 138 paraffin blocks from the archives of the pathology department of Birmingham 
Heartlands Hospital (BHH). From each of these 134 blocks, three sections of 5J.1.m each 
were prepared on V ectabond (Vector Laboratories Inc.) coated Surgipath slides for 
staining with Haematoxylin and Eosin. and antibodies to Bcl2 and CD40. A random block 
of 26 cases was chosen from which an additional 5J.Ull section was obtained for staining 
with anti-ASP antibody. The clinical and pathological details of these patients are 
tabulated in Appendix C. 
(b) We also obtained paraffin blocks of the 21 patients whose fresh lung tumours we used 
for ceU culture experiments (see below - Section 4.1.3). From each of these blocks four 
5J.UD sections were obtained on Surgipath slides coated with Vectabond for staining with 
Haematoxylin and Eosin, antibodies to Bcl2, CD40 and ASP. Details of these patients are 
given in Table 5.33 in Section 5.5.2. 
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4.1.2 Malignant pleural effusions 
Pleural fluid was collected for experiments from 10 patients after consent had been 
obtained both from the patient as well as the physician concerned. Four of these patients 
were from Walsgrave General Hospital (WGH), Coventry and six were from St. Cross 
Hospital, Rugby. Fluid was taken only from those patients whose effusions had proved to 
be malignant by fluid cytology or pleural biopsy or both. None of the patients had had any 
chemotherapy prior to fluid collection. Details of these patients have been listed in Table 
5.32 in Section 5.5.1. Not all of these patients had primary bronchogenic carcinoma. Some 
had secondary involvement of the pleura from a primary elsewhere. However, this did not 
detract from the initial purpose of our experiments. 
Between 1-1. 5 Iitres of pleural fluid was aspirated from each patient. Immediately after 
aspiration the fluid was transferred into sterile containers and transported to the Biological 
Sciences laboratory at Warwick University. It usually took no more than 20 minutes to 
drive from either hospital to the University. 
4.1.3 Fresh resected lung tumours 
For our experiments 21 fresh resected lung tumours were collected from BHH and one 
from WGH, Coventry. Many of the patients operated at BHH had been referred from 
other peripheral hospitals. In some of these cases histology could not be determined pre-
operatively in spite of all effort (bronchial lavage cytology, percutaneous X-ray guided 
biopsy). In these cases lung resection was undertaken on the basis of strong clinical and 
radiological suspicion of malignancy. 
The full histology report was obtained later to detennine the tumour type, differentiation 
and pathological stage. These details are tabulated in Table 5.33. One of the cases (LC16) 
turned out not to be a tumour at all but a fungal infection - actinomycosis. The rest of the 
group comprised diverse pathological types of lung cancer but the majority (55%) was 
squamous cell carcinoma. 
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Once the lung, or a lobe, was resected, the specimen was immediately taken to the 
histopathologist who examined the sample and chose a representative area avoiding 
necrosis and normal lung tissue. Then, sugar cube sized portions of tumour (each about 1 
cm3) were cut out for our experiments. These cubes of tissue - usually 3 or 4 per tumour, 
occasionally 2 - were immediately transferred into 20ml universals containing cold RPM! 
medium to preserve viability during transport. The universals were placed in a Dewar's 
flask containing ice and immediately transported to the Biological Sciences laboratory at 
Warwick University. This journey took between 30-45 minutes depending on traffic on the 
A45. 
I am very grateful to Dr. S Jane Damton, senior research scientist at the Oesophageal 
Research Laboratory, BHH, for her tireless help with identifying and collecting the tumour 
samples. 
To corroborate and expand on the results obtained from the fresh lung tumours, the 
corresponding paraffin blocks were obtained and examined as described in Section 
4.1.1(b). 
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4.2 Methods 
Introduction and Scheme of experiments 
The various experimental methods that we used are described in this section as a series of 
protocols. 
As mentioned before paraffin sections were stained with H&E, antibodies to Bcl2, CD40 
and ASP. The staining methods are described in protocols 1-4. 
Pleural effusions and fresh lung tumours were processed to obtain a single cell 
suspension that could be cultured . The aim was to carry out serial measurements of 
apoptosis on these cultured tumour cells by (a) counting morphologically apoptotic cells 
on H&E stained cytospins and (b) measuring the sub-diploid fractions on DNA histograms 
obtained by F ACS analysis. These methods are described in protocols 5-13. 
Before that a flow chart is given (overleaf) describing the sequence of the experiments 
conducted on lung tumours. For pleural effusions, with one exception, an identical scheme 
was followed. There was no need to disaggregate effusions as the cells were already in 
suspension. In fact this was the main reason why we started our experiments with 
effusions rather than solid tumours. 
Key to the flow chart 
After disaggregation and density centrifugation to remove RBC, a mixture of tumour cells, 
stromal cells and lymphocytes was obtained. 
At 0 hours the following experiments were done with this cell suspension. 
(a) Cytospins were obtained for staining with H&E and BerEP4. 
(b) Cell culture was started in two flasks containing complete RPMI medium. 
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(c) An aliquot of cells was fixed and stored at 4°C to be dual stained with PI and BerEP4-
FITC for F ACS analysis later. 
(d) A portion was set aside for freezing in liquid nitrogen. 
At 24 hours cells were harvested from one of the flasks. Cytospins were obtained for 
H&E staining. A portion of the cells was dual stained with PI and BerEP4-FITC. 
At 48 hours cells were haIVested from the other culture flask and processed as at 24 
hours. 
Thus, at the end of the experiments, three H&E stained slides and three flow cytometric 
samples were available for parallel measurements of apoptosis. The corresponding paraffin 
embedded histological sections provided information about the expression of Bcl2 and 
C040 and apoptosis measured by H&E and ASP. These results are discussed in Section 
5.5. 
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4.2.1 Haematoxylin and Eosin staining of tissue sections 
1. Paraffin sections were dewaxed by soaking them twice in a xylene bath for 5 minutes 
each time. 
2. Xylene was removed by treating with 90% alcohol and then with 70% alcohol each for 
3 minutes. 
3. Sections were then transferred to water 
4. Stained with Harris' haematoxylin (Sigma) for 10 minutes. 
5. Washed in water for 3 minutes. 
6. Dipped in acid alcohol (1% hydrochloric acid and 70% alcohol) for 10 seconds. 
7. Washed in water for 2 minutes. 
8. Sections "blued" by dipping in 2% sodium bicarbonate for 30 seconds. 
9. Washed in water for 3 minutes. 
10.Stained in 1% Eosin (Sigma) for 5 minutes. 
1l.Washed briefly in water for 30 seconds. 
12.Dehydrated by passing through ascending grades of ethyl alcohol (70%, 90%) to 
absolute ethyl alcohol-for 2 minutes in each. 
13.Alcohol removed by clearing the sections in xylene for 3 minutes. 
14.Finally, sections mounted with cover-slips using DPX (Sigma). 
4.2.2 Staining tissue sections with Bel2 
1. Dewaxing and hydration of sections was carried out as described in Steps 1-3 of 
Protocol 1. 
2. The sections were then placed in a microwave-proof plastic bowl and immersed in 10% 
citrate buffer (pH = 6.0). The bowl was covered with cling film which was punctured to 
allow steam to escape. This was boiled in a microwave at full power (7S0W) for 15 
minutes and allowed to cool for 10 minutes. 
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3. Washed in PBS for 5 minutes. Endogenous peroxidase activity quenched by soaking in 
0.6% H202 in methanol for 15 minutes. 
4. Washed in water for 5 minutes. 
5. Slides were next transferred to a Sequenza (Shandon Scientific) and washed with PBS 
for 5 minutes. 
6. Three drops of diluted normal blocking serum (Vectastain Elite kit, diluted in PBS) 
were added and incubated for 10 minutes. 
7. 150J,l1 of primary anti-Bcl2 antibody was added to the slides and incubated for 30 
minutes. 
Antibody specifications:-
Monoclonal mouse anti-human bcl2 antibody 
Clone 124 
Isotype IgG 1, kappa 
Dilution 1 : 150 
Source Dako (High Wycombe) 
8. After a 5 minute PBS wash, 3 drops secondary biotinylated antibody (Vectastain Elite 
kit, diluted in PBS) were added and incubated for 30 minutes. 
9. After another wash the slides were incubated for 30 minutes with 3 drops ABC reagent 
(Vectastain Elite kit, diluted in PBS) 
lO.The slides were once more washed in PBS before incubation for 1-3 minutes in the 
peroxidase substrate solution (DAB Substrate Kit for Peroxidase, Vector Laboratories 
Inc.). 
II.Slides rinsed in cold running water and then counter-stained for 20-30 seconds in 
Mayer's haematoxylin (Sigma). 
12.Slides allowed to stand for 5-10 minutes in cold running water to "blue up" and wash 
off excess haematoxylin. 
13.Slides passed through 70% ethanol, 100% ethanol and xylene (2 minutes in each) 
before mounting in DPX (Sigma). 
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4.2.3 Staining tissue sections with CD40 
1. Staining was carried out exactly as described in Protocol 2 for Bcl2 except that step 2 
was omitted. There was no need for microwave pre-treatment for the antibody that we 
used. 
2. Antibody specifications:-
Mouse ascites antibody G 28.5 
Dilution 
Source 
1: 1000 
Prof. L. Young 
Cancer Research Campaign, Birmingham 
4.2.4 Staining tissue sections with ASP 
1. Staining carried out exactly as described in Protocol 2 for Bcl2. 
2. Antibody specifications:-
Polyclonal rabbit antibody against c-jun [ c-juniAP-l (Ab-2)]. 
Lot No. 3095-03-03 
Dilution 1 :50 
Source Oncogene Science (Cambridge). 
4.2.5 Disaggregation of tumours 
1. Tumour tissue was placed in a standard 8.5 cm petridish (Sarstedt Ltd.) containing 
2mls ofRPMI medium (Gibco BRL). 
2. Adherent pleura and small bronchial airways carefully dissected out. Specimen finely 
minced using a pair of forceps and a scalpel pre-sterilised in absolute alcohol. 
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3. Contents of petri dish transferred into a 50ml universal (Sarstedt Ltd.) containing lO mls 
of complete RPMI to which the following enzymes had been added:-
Collagenase (Boehringer-Mannheim) 2 mg/ml; 
Hyaluronidase (Boehringer-Mannheim) 
DNAse (Boehringer-Mannheim) 
0.04mg/ml; 
0.04 mg/ml. 
4. Enzymatic digestion at room temperature for 2 hours with continuous gentle 
mechanical agitation in a tissue rotator. 
5. Digested tissue filtered through a 70J.1m Falcon cell filter (Sarstedt Ltd.). A small 
aliquot of the fIltrate examined microscopically in a haemocytometer to ensure 
formation of a single cell suspension. If necessary digestion allowed to continue for 
another 30 minutes. 
6. Filtrate centrifuged at 1200 rpm, brake set3 for 5 minutes in Mistral 2000 MSE. 
7. Supernatant discarded and pellet resuspended in complete RPMI (Gibco BRL). 
4.2.6 Density centrifugation 
1 10 mls ofLymphoprep (Nycomed) poured into an universal container (Sarstedt Ltd.). 
2 10 mls of the tumour digest obtained at the end of Protocol 5 gently layered on top of 
Lymphoprep. 
3 Centrifuged at 2000 rpm, brake set zero, for 25 minutes in a Mistral 2000 MSE. 
4 Buffy coat at the interface of the bi-Iayer gently pipetted out and resuspended in RPMI 
medium. RBC at the bottom of the universal discarded. 
5 A small aliquot was examined using a Neubauer haemocytometer and a cell count 
obtained. For each of the subsequent steps the cell suspension was diluted down 
appropriately. 
4.2.7 Cytospin preparation 
1 About 5,000 cells in lOOJ.1l of RPMI medium placed in each cytospin chamber. 
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2 A Shandon Cytospin 3 (Shandon Scientific) was used at 600 rpm for 3 minutes to spin 
cells on to Vectabond coated Surgipath slides. 
3 Slides air-dried and fixed by dipping in 50% methanol and acetone for 5 minutes 
4.2.8 Staining cytospins with Haematoxylin and Eosin 
1. Slides with fixed cytospin preparations were washed in water. 
2. Stained with Haematoxylin and Eosin as described in steps 4-14 of protocol 1. 
4.2.9 Staining cytospins with BerEP4 
1. Slides with fixed cytospin preparations were washed in water. 
2. Staining was carried out exactly as described in Protocol 2 for Bcl2 except that step 2 
was omitted. There was no need for microwave pre-treatment for the antibody that we 
used. 
3. Antibody specifications:-
Purified monoclonal mouse antibody to BerEP4 
Clone BerEP4 
Isotype IgG 1, kappa 
Dilution 1 : 50 
Source Dako (High Wycombe) 
4.2.10 Tissue culture 
1. All operations were carried out using standard sterile techniques in a laminar flow 
cabinet (Gelaire BSB 4A, Flow Laboratories). The cabinets were routinely sterilised 
overnight by exposure to ultra-violet radiation and then washed with disinfectant (10% 
Savlon) and 70% ethanol prior to use. Periodic fumigation with formaldehyde was also 
carried out. 
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2. From the cell suspension obtained at the end of protocol 5 two aliquots of about a 
million cells each were added to two separate culture flasks. Cell culture was carried 
out in bicarbonate buffered Roswell Park Memorial Institute (RPMI) 1640 medium 
(Gibco BRL) which was supplemented with 10% (v/v) foetal calf serum (FCS), L-
Glutamine (2mM) penicillin (SOOIU/ml) and streptomycin (5001-1g/ml). All cells were 
grown in tissue culture grade flasks of 75 cm2 or lS0cm2 (Nunc.). These contained 
25ml or 50mt of medium respectively. The flasks were incubated at 37°C in a 
humidified incubator containing 5% CO2 in air. 
3. At 24hrs and 48hrs respectively, cells from each of the flasks were harvested for 
analysis. Some of the cells were in suspension in the medium while a variable 
proportion were adherent to the culture flask. To collect the cells in suspension the 
medium was aspirated and centrifuged at 1200rpm for 5 minutes. 
4. The adherent cells were removed by trypsinisation. Following aspiration of the medium 
culture flasks were rinsed briefly in 25mls PBS. Ten millilitres of Trypsin-EDT A 
solution [0.5mg/ml trypsin, 0.2mg/ml ethylene-diamine-tetra-acetic acid (EDTA), 
Gibco-BRL] was then added and the flasks incubated at 37°C until the cells had 
detached (l-S minutes). The cell suspension was mixed gently with lOml complete 
medium and the cells recovered by centrifugation at 1200rpm for 5 minutes. 
5. The pellet was resuspended in fresh medium and added to the pellet obtained 
previously from the cells in suspension This mixture of cells was then used for all 
further tests e.g. cytospin staining and flow cytometric analysis 
4.2.11 Dual staining with PI and BerEP4-FITC 
1. About 500,000 cells aliquoted into an Eppendorftube. 
2. This was centrifuged at 1000rpm for 2 minutes (MSE Mistral 6L centrifuge) and the 
supernatant discarded. The rest of the procedure was carried out with minimum 
exposure to light to prevent quenching of the fluorescence label. 
3. Pellet of unfixed cells suspended in 201-11 of BerEP4-FITC and incubated at 4°C for 20 
minutes. 
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Antibody Specifications:-
FITC-Conjugated monoclonal mouse Anti-human epithelial antigen 
Clone BerEP4 
Isotype IgG 1, kappa 
Source Dako (High Wycombe) 
4. After 20 minutes unbound antibody was discarded by washing with PBS, centrifuging 
at 1000rpm for 2 minutes and aspirating the supernatant. 
5. Cells fixed by adding 1 ml of ice cold 70% ethanol and incubating at 4°C for 10 
minutes. 
6. Excess ethanol washed off with PBS as above. 
7. Pellet resuspended in lml of Propidium Iodide solution [propidium Iodide (Sigma) 
100J.1g1ml, RNAse (Boehringer-Mannheim) 20Ilg/ml]. 
4.2.12 Cryogenic storage and retrieval of ceUs 
1. Cells pelleted and resuspended in RPM! containing 10%(v/v) dimethyl sulfoxide 
(DMSO, BDH) at an approximate concentration of 5 x 106cellsiml. 
2. Mixture transferred to a freezing vial (Costar Ltd.), wrapped in paper tissue and frozen 
at -70oC overnight. 
3. The next morning the vials were transferred to liquid nitrogen. 
4. To recover frozen cultures, vials were thawed in a 3,oC water bath for 1-2 minutes. 
The contents were transferred to a universal containing Smls of complete RPMI 
medium (warmed) and pelleted to remove DMSO. 
5. The cell pellet was resuspended in Sml complete medium and transferred to a 25cm2 
tissue culture flask. 
111 
4.2.13 Flow cytometric analysis 
Flow cytometric analysis of these cells was carried out USing a Beckton Dickinson 
F ACStar. This was operated as described in the users manual. To standardise the settings 
before each operation, stained and unstained (fixed) cells from two cell lines were used-
ID..60 a myelogenous cell line and OE33 an oesophageal cancer derived cell line. ID..60 
served as a negative control for BerEP4 staining while OE33 was the positive control. 
Both cell lines were maintained in culture continuously to serve as standards for FACS 
analysis. 
Typically 5,000 events were collected from each tumour sample. All data were collected 
in list mode and four parameters were checked; forward scatter-FSC, side scatter-SSC and 
fluorescence 2-FL2 (Le. PI staining) were collected in linear amplification. Fluorescence 1-
FLI (i.e. BerEP4 staining) data were collected in logarithmic amplification. 
Typical settings used were:-
Parameter Voltage AmglifiQAtiQo 
FSC 0 16 
sse 300 8 
FLl 600 log 
F12 500 8 
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4.2.14 Statistical analysis 
All statistical analysis was done with the help of C-Stat, a software programme published 
by Cherwell Scientific Publishing Limited, Oxford. For the comparison of means between 
two sets of data the Mann Whitney U test was used because the data were not normally 
distributed. For tests of association, regression analysis was done, or Spearman Rank test 
if the data were not normally distributed. 
CHAPTERS 
RESULTS 
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5.1 Assessment of apoptosis by morphological criteria in 134 
cases of squamous cell carcinoma of the lung 
Introduction 
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As discussed in Section 1.2.5 apoptosis takes place in tumours and it is important to try 
and quantify it. There are several ways of identifying and assessing apoptosis in 
histological sections. One could use immunohistochemical methods to identify DNA 
strand breaks or apoptosis specific proteins in cells. We chose the much simpler method of 
counting apoptotic bodies in H&E stained sections as the main method for establishing 
apoptotic index. As discussed in Section 3.1.1 this method is easy, cheap, widely available 
and can provide a reliable index. To quantify apoptosis we have taken advantage of a set 
of cases of lung cancer for which there was already extensive information about 
pathological parameters and clinical outcome (see Section 1.4.7 and Appendix C). 
Results 
Paraffin sections were stained with haematoxylin and eosin as detailed in Section 4.2.1. 
Under the microscope the sections showed areas of neoplastic tissue of squamous 
differentiation surrounded by fibrous tissue stroma (Fig. 1.1). Normal lung tissue was 
often seen at the edge of the section. The malignant cells were easily distinguishable from 
normal alveolar cells by their larger size and hyperchromatic nuclei. In the neoplastic areas 
normal lung architecture was replaced by tissue of squamous differentiation with 
stratification, formation of intercellular bridges and intracellular keratinization. 
Apoptotic cells were counted only in the neoplastic areas taking care to avoid normal 
epithelium and fibrous stroma. Also areas of necrosis were avoided. If any necrotic cells, 
stromal cells or normal epithelial cells abutted in the field being examined these cells were 
not counted. 
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Apoptotic cells are identified by the following criteria:- a) cells showing marked 
condensation of chromatin and cytoplasm b) cytoplasmic fragments containing condensed 
chromatin c) intra- and extracellular chromatin fragments (Fig. 1.2). 
Counting was always done under oil immersion producing a magnification of xl 000. 
Before formal counting was undertaken the minimum number of cells to be counted was 
determined on a sample slide by the standard running means method (see Section 3.1.1). 
Using this method we determined that counting 1500 cells or 10 oil immersion fields 
would ensure that there was minimum intra-observer variation. 
Thus 10 fields were chosen at random (observing the exclusion criteria explained above) 
from different parts of the tumour section. The number of apoptotic cells and the number 
of malignant cells in each field were recorded. Apoptotic bodies occurring in distinct 
groups and likely to be originating from one and the same cell were recorded as one 
apoptotic cell. The count in all 10 fields were added and expressed as an apoptotic index 
i.e. apoptotic ceUsllO,OOO malignant cells. Although it would have been much easier, we 
decided to avoid the more popular method of quantifYing apoptosis i.e. per mm2 or per 
number of microscopic fields. Cancer cells vary widely in size from tumour to tumour and 
also within the same tumour and therefore the number of malignant cells per unit of area is 
likely to be highly variable. Accordingly, the score of apoptosis per area would tell us little 
of the frequency of apoptosis per number of cells, which is of much greater biological 
significance. 
The value of the apoptotic indices obtained for all 134 cases ranged from 2.4/10,000 
malignant cells to 145.5110,000 malignant cells with a mean of 30.29, S.D of 24.75 and 
median 22.3. 
To check whether the results were indeed reproducible, each slide was counted again on 
a second occasion six months later while being blinded to the initial result. 10 fields were 
counted using the same protocol as before. The values obtained (A.I.2) are described in 
the table below. 
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On Spearman rank correlation test the sets of apoptotic indices obtained on the two 
separate occasions (A.I.l and A.I.2) were found to correlate very closely with Rs = 
0.9984 and p <0.001. This close correlation is also evident from the graph (Fig.5.1). 
The final apoptotic index (AI. Av) was calculated by averaging the two values obtained 
separately .. As can be seen from the table below these values are almost identical to the 
values obtained initially. 
Table 5.1 
AI. 1 
A. I. 2 
AI. Av. 
Apoptotic indices of archival lung tumours as counted on two 
separate occasions and the average apoptotic indices. 
Minimum Maximum Mean S.D Median 
2.4 145.5 30.29 24.75 22.3 
2.8 146 30.28 24.74 22.45 
2.6 145.7 30.17 24.78 22.4 
The average apoptotic index has been used in all future analyses and these are the values 
that have been tabulated in Appendix C. 
The frequency distribution of the apoptotic indices of these tumours is plotted in Fig.5.2. 
As can be seen the distribution is asymmetric with a suggestion of bimodality. It is clear 
from the graph that most cases have a relatively low rate of apoptosis-between 10-
25/10,000 malignant cells. There is a second peak at 50 beyond which the numbers 
dwindle rapidly. To divide the population into high apoptosis and low apoptosis groups 
we used the upper quartile (41.2) as the cut-oft' point. By this definition there were 33 
cases with a high apoptotic rate (i.e. AI>41.2) and 101 cases with a low apoptotic rate. 
Discussion 
The staining method we used is widely available in every pathological laboratory and is 
easy to perform and much cheaper than immunohistochemical methods. The counting 
protocol was tedious but led to a highly reproducible means of quantifying apoptosis. In 
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retrospect, we need not have recounted all 134 slides as an analysis of a much smaller 
sample would easily have revealed the strong correlation. As it happened, we undertook 
statistical analysis only after all the slides had been counted twice. In the next section we 
have compared this protocol with another established method of quantitying apoptosis. 
Although it was infrequent, there was some evidence of apoptosis in every lung tumour 
examined. The counts varied widely ranging from 3 to 145 per 10,000 malignant cells. The 
hint of bimodality in the distribution of the apoptotic indices suggests that the tumours 
could possibly belong to two distinct biological groups which have different propensities 
for apoptosis. This might be a reflection of the different underlying abnormalities of the 
apoptosis-regulating genes in different tumours. These possibilities are explored in many 
of the subsequent sections where we have tried to correlate apoptotic index with other 
clinical, pathological and genetic markers. 
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5.2 Assessment of apoptosis by immunostaining with anti-ASP 
antibody. 
Introduction 
Our method of counting apoptosis in H&E stained sections led to very consistent results. 
However, the possibility remains that in counting stained apoptotic bodies. artefacts may 
lead to systematic under- or over-estimation of apoptotic indices. Thus it is important to 
employ a second method for measuring AI. Of the available methods. discussed in Section 
3.1, we chose to stain with the monoclonal antibody against Apoptosis Specific Protein or 
ASP (see Section 3.1.4.2). 
ASP is a novel protein, structurally similar to the transcription factor AP-l, that is 
expressed at high levels in cells undergoing apoptosis but is not seen in viable cells or in 
cells dying by necrosis. However, as stated before in Section 3.1.4.2, some of these 
apoptotic marker proteins tend to be cell type specific and this antibody had not previously 
been tried on sections of lung tissue. Therefore, a primary aim of our investigation was to 
see if ASP was at all expressed in apoptotic cells originating from pulmonary epithelium. If 
it was found to be expressed it would serve as an excellent standard against which to 
compare our H&E results. The reliability of ASP staining has been shown in a recent 
comparative study on histological sections of Burkitt's Lymphoma, where staining with 
ASP led to the detection of more apoptotic cells than did ISEL or in situ nick labelling 
(Panchalingam et al., 1996). 
Results 
We picked at random twenty-six slides from the archival series. We also chose to stain all 
the twenty fresh lung tumours that we had studied. These latter tumours included I 1 
squamous cell carcinomas, 6 adenocarcinomas, and one each of leiomyosarcoma, 
broncho-alveolar carcinoma and a case of undifferentiated NSCLC (see Sections 4.1.3 and 
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5.5.2). Staining was done with the c-junlAP-l(Ab-2) antibody using standard 
immunohistochemical procedures as detailed in Section 4.2.4. 
Good staining was seen in all forty six test slides. Apoptotic cells displayed a brown 
cytoplasmic staining in addition to the dark, condensed (and in many cases fragmented) 
nucleus (Fig. 5.3). Remains of apoptotic cells within phagosomes also took on a brown 
stain. These apoptotic cells stood out starkly amidst the malignant cells which had only 
taken up the light blue counterstain of Mayer's haemallum. 
Apoptosis was quantified using the same protocol as for H&E. In brief, 10 oil immersion 
fields were chosen at random and the number of apoptotic and malignant cells in each field 
was counted. These slides were counted while being blinded to the result of the AI 
obtained from the corresponding H&E stained sections. The final apoptotic index was 
expressed as apoptotic cellsllO,OOO malignant cells. 
Our study has proved that ASP is expressed in apoptotic pulmonary epithelium and 
therefore it is a valid way of assessing apoptosis in lung tissue. 
The table below describes the apoptotic indices of these 46 tumours obtained by anti-
ASP staining and H&E staining. 
Table S.2 
A.I.(ASP) 
A.I.~E) 
Comparison of apoptotic indices using two ditTerent staining 
techniques (anti-ASP and H&E). 
Min Max Mean S.D. Median 
6.6 159 60.7 39.8 50.9 
4 90.8 36.7 24.2 27.3 
When these two sets of values were subjected to Spearman rank correlation test they 
correlated very strongly with Rs = 0.9760 and p <0.001. This close correlation is also 
evident from Fig. 5.4. 
As stated above this group of tumours included 9 that were not sees. For the next part 
of the analysis we excluded these non sec tumours. The apoptotic indices of this 
particular group are described in the next table. 
Table 5.3 
A.I.(ASP) 
A.I.(H&E) 
Comparison of apoptotic indices (SCCs only) using anti-ASP and 
H&E. 
Minimum Maximum Mean S.D. Median 
13.9 159 62.18 38.97 51.3 
9.2 90.8 37.18 23.17 27.6 
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On Spearman rank correlation test this second set of apoptotic indices correlated with 
each other just as strongly with Rs = 0.9861 and p <0.001. Fig. 5.5 shows the regression 
graph for SCCs alone. 
Discussion 
Evidently, the two methods of assessing apoptosis in lung cancers correlate very 
strongly. This correlation is not confined to SCCs alone but holds true even when other 
histological types are included in the analysis. 
In all the cases the count obtained by anti-ASP staining was higher than that obtained by 
H&E staining. This was not unexpected as ASP staining had clearly picked up cells in the 
very early and very late stages of apoptosis which would not have been identified by their 
morphological features alone. What is important for our purposes is that the two sets of 
values correlated so very strongly. This indicates that compared to ASP, H&E under-
estimated apoptosis by an almost fixed proportion in every case. Thus although the 
absolute value of apoptosis obtained by H&E would certainly be an under-estimate of the 
'real' value, the indices are still valid for comparing the apoptotic states of different 
tumours. 
However, there still remains the possibility that the apoptotic index as assessed in fixed 
sections by histological techniques is not a good reflection of the true apoptotic rate as 
this will be related to the rate of removal of the apoptotic bodies as well as to their rate of 
generation., and both these parameters may vary independently. The only way to measure 
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apoptotic rate is by serial estimation of apoptosis which of course is only possible in 
cultured lung tumour cells. We have attempted to do this by culturing cells obtained from 
malignant pleural effusions and freshly resected lung tumours. The results of these 
experiments will be presented in Section 5.5. 
Having established a reliable index of apoptosis in 134 lung tumours, we moved on to 
determine whether this had any relevance to the biology and clinical behaviour of the 
tumours: particularly and primarily survival, but also other pathological parameters and 
markers related to apoptosis. 
Fig. 5.3 Section of squamous cell lung cancer (x630) stained with 
monoclonal anti-ASP antibody. The cytoplasm of apoptotic 
cells have stained dark brown. 
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5.3 Correlation of apoptosis and clinico-pathological 
parameters 
The series of cases that we investigated had very well documented records of several 
clinieo-pathological parameters. Survival data had been collected from the West Midlands 
Cancer Registry. Pathological staging was done following surgical resection and details of 
tumour size (T) and lymph node status (N) were available. The histological grade of 
differentiation was also known. In addition to these more traditional markers of disease 
progression, information was also available about two other less commonly used 
parameters i.e. AgNOR count (an index of cell proliferation) and DNA ploidy. The 
availability of all this data gave us the opportunity to detennine whether apoptosis was 
related to any of these. 
5.3.1 Apoptosis and survival 
Introduction 
Apoptosis plays an important role in various stages in the natural history of a tumour, as 
discussed in detail in Section 1.2.5. During the stages of tumour initiation and promotion 
resistance to apoptosis favours the survival of a clone of transformed cells. Later during 
tumour progression a low apoptotic rate should theoretically lead to a faster rate of 
tumour growth. Also, metastasis is more likely to be successful if the cell has a low 
inherent tendency to apoptose. Overall, suppression of apoptosis should make a tumour 
more aggressive. Thus, it is not unreasonable to expect tumours with a low apoptotic rate 
to do less well than those with a high rate of apoptosis. This expectation, however, has not 
been universally fulfilled in all tumours that have been studied. (See General Discussion 
Section 6.3.) 
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We wanted to test this proposition in our series of cases. Survival data for this series had 
been collected by Boldy et al. (1991). They had contacted the West Midlands Cancer 
Registry to provide data on the clinical outcome, including cause of death from the death 
certificate, for all patients. Deaths in the first 30 days after surgery were regarded as post-
operative deaths and were not included in the subsequent analysis. Patients were classified 
as having died as a result of their tumour if such a diagnosis was mentioned in part I of the 
death certificate. 
Patients who were still alive at the last scheduled clinic follow up date at 10 years were 
assumed to have survived only up to that date and their survival was calculated 
accordingly. This assumption is certainly erroneous, but since follow up was terminated at 
10 years this is the best that could be done under the circumstances. 
Results 
Of the 138 patients undergoing surgical resection 17 died in the first 30 days after 
surgery. Follow up was complete, apart from one patient who was lost to follow up after 
110 months. 33 (27%) patients were alive at five years and 23 (17%) were alive at 10 
years. Of the 99 deaths during the follow up period, carcinoma of the bronchus was 
reported as the main cause of death in 8S patients. 
No correlation was seen between apoptotic index and survival. On Spearman rank 
correlation of the survival times and apoptotic indices of all patients (excluding post 
operative deaths), Rs = -0.0096 and p = 0.911. 
We performed the same analysis excluding those cases who had died of causes other than 
lung cancer. Again no correlation was found, Rs = -0.0199 and p = 0.834. The graph is 
shown in Fig. 5.6. 
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Finally, we excluded patients whose survival was more than 100 months. They occupy one 
end of the graph in Fig. 5.6 above. These long lived patients might comprise a distinct 
biological group and we wanted to see how the rest of the group behaved in isolation. 
Also, by excluding this group we eliminated every patient whose survival time was in 
doubt. All but two members of this group had had a survival time assigned to them 
according to their date of last contact. 
Even in this group there was no correlation between apoptosis and survival as shown in 
Fig. 5.7, Rs = -0.0852 and p = 0.440. 
We next looked at survival times in groups with high and low apoptotic rates as defined in 
Section 5.1. In this and in all subsequent analyses of survival times, unless otherwise 
stated, we have excluded post-operative deaths and deaths due to causes other than lung 
cancer. 
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Survival times of patients in high apoptotic (i .e. AI >41.2) and low apoptotic groups are 
described in the table below (5.4). 
Table 5.4 
High A.I. 
Low A.I. 
Survival times (in months) of squamous lung cancer patients with 
high or low apoptotic indices. 
n Min Max Mean S.D. Median 
27 2 132 34.4 43 .3 15 
78 4 138 46.4 SO 20 
Although the mean survival in the low A.!.. group was higher, on Mann Whitney U test 
this difference was not statistically significant, p = 0.131 . 
We then looked at the data from the opposite angle i.e. we divided the cases into long 
survival and short survival groups and analysed the apoptotic indices in each group . 
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The upper quartile of survival amongst all patients was 72 months which we assigned as 
the cut-off point. By this definition, patients who had survived for more than 72 months 
were considered as long survivors. Those who had survived for less were short survivors. 
The table below (5.S) describes the apoptotic indices in these two groups. 
There was no significant difference between the means and on Mann Whitney U test, p = 
0.717. 
Table 5.5 Apoptotic indices of long and short survivors among lung cancer 
patients. 
n Min Max Mean S.D. Median 
Long survivors 25 2.6 87.7 28.8 19.9 23.6 
Short survivors 80 3.1 145.7 30.5 26.6 22.2 
Discussion 
No matter which way we looked at it, A.I. could not be demonstrated to be a predictor 
of survival. The implications and the possible reasons behind this finding are discussed in 
detail later (see Section 6.3). Clearly, if it is accepted that apoptosis does influence the 
development of a tumour, there are other factors in individual cases which mitigate the 
effects of apoptosis. For instance disease stage, histological grade, proliferative state, 
oncogene expression-each could independently influence outcome and nullify any 
prognostic value of A.I. In our subsequent analyses we seek to determine whether these 
factors correlate with apoptosis and whether when we control for these factors, apoptosis 
correlated with survival. Although this is a dubious procedure because of small numbers in 
each subgroup, and potentially could generate significant correlations by chance, we felt 
that as we had a large group of cases it was worth the attempt. 
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5.3.2 Apoptosis and Disease Stage 
Introduction 
Disease stage, which is a composite index of tumour size, nodal metastasis and distant 
metastasis is one of the most important prognostic indicators in cancer. In this present 
series of cases pathological TNM staging was undertaken independently by two of the 
original investigators who reviewed all the information available from the hospital case 
notes. The UlCC classification was used (see Appendix B) and patients were allocated in 
one of five pathological stages - I, II, Ilia, IIIb and IV. Where there was disagreement, 
all available data were re-examined for a consensus opinion. 
Boldy et al. found lower disease stage to be a strong indicator of good prognosis in this 
series. We investigated if the apoptotic index bore any relation to the disease stage. Also 
we investigated if apoptosis and survival correlated within each disease stage 
Results 
The apoptotic indices of patients in each of the five pathological stages are described in 
Table 5.6. 
Table 5.6 Apoptotic indices of patients in each pathological stage. 
n Min Max Mean S.D. Median 
Stage I 45 4.9 87.7 30.8 18.9 25.6 
Stage n 47 3.8 107.2 24.7 22.1 18.3 
Stage IlIa 27 3.1 108.7 35.2 28.6 22.7 
Stage IIIb 11 2.6 145.7 38 40.7 30.8 
Stage IV 4 4.7 69.7 30.5 27.9 23.9 
On Mann Whitney U test there was no significant difference between the means in the 
five groups. Thus we concluded that apoptosis does not correlate with disease stage. 
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We next divided patients according to their disease stage and looked for correlation 
between apoptosis and survival within each stage by Spearman rank correlation test. 
Table 5.7 below describes the survival times of patients in each stage. The last two 
columns describe the coefficients of correlation between A. I and survival. As stated 
before, when assessing survival, patients who died in the immediate post-operative 
period and patients who died later of causes other than lung cancer were excluded from 
the analysis. Thus the number of entries in this table is less than in the table above. This 
discrepancy will be noticed in subsequent pairs of tables as well. 
Table 5.7 
Stage I 
Stage II 
Stage IlIa 
Sti!Ke IIIb 
Survival times of patients in each pathological stage and 
correlation between AI and survival in each stage. 
n Min Max Mean S.D. Median Rs 
34 4 133 57.6 52.5 30.5 -0.0639 
39 4 138 42.1 49 16 0.1474 
20 2 134 30.3 39.7 14.5 -0.2635 
11 5 135 30 42.9 15 -0.0455 
p 
0.716 
0.373 
0.259 
0.883 
There was only one patient in Stage IV who survived beyond a month. He lived for 15 
months and had an A.I. of4.7. 
As the coefficients of correlation in the table indicate no correlation could be 
demonstrated within any disease stage. 
Discussion 
This series is not truly representative of a group of patients with lung cancer. The 
higher disease stages have been grossly under-represented here because they would not 
have been offered surgical resection as treatment. For instance only 10.9% of patients in 
this series were in Stages IIIb and IV whereas in actual fact when patients first present 
with lung cancer, about 7()oIo of them will be in these stages. Also the actual numbers 
involved in the two higher stages are quite low. Therefore, from these results, it is 
difficult to draw any definite conclusions about the relevance of apoptosis in high disease 
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stage. However even among the lower disease stages-I, II, Ilia-no trend is observed 
in the apoptotic indices and no correlation is seen between A.I. and survival. 
5.3.3 Apoptosis and Lymph Node Metastasis 
Introduction 
Having failed to discern any correlation between apoptosis and disease stage, we next 
planned to look more closely at one particular determinant of stage i.e. metastasis. This 
present series comprised patients who had been chosen for surgical treatment and those 
with distant metastases were largely excluded. Yet there were four patients in this series 
who despite metastases had undergone surgical resection but the numbers were too low 
to draw any meaningful conclusions. We therefore concentrated only on lymph node 
metastasis. Patients could be divided into three groups - NO, Nt & N2 - according to the 
degree of lymphatic spread (see Appendix B) and we wanted to see if the apoptotic 
index bore any relation to this. 
Reduced susceptibility to apoptosis should make it easier for a cancer cell to survive in 
the alien environment of a metastatic organ where the lack of many of the usual growth 
factors is likely to push the cell towards apoptosis (see Section 1.2.5.3). Indeed 
metastatic prostatic cancer cells have been shown to be less prone to apoptosis. Thus 
theoretically one could expect to see an inverse correlation between apoptosis and lymph 
node spread. 
Results 
The apoptotic indices of patients within the three groups are described in Table 5.8 
below. 
Table 5.8 
NO 
Nl 
N2 
Apoptotic indices of patients grouped according to lymph node 
status. 
n Min Max Mean SD Median 
54 4.7 87.7 30.4 19.3 25.1 
62 2.6 145.7 27.9 26.9 18.8 
16 3.1 108.7 35.5 29 22.3 
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On Mann Whitney U test there was no significant difference between these three means. 
Thus the apoptotic rate of a tumour does not seem to influence its ability to metastasise 
to lymph nodes. 
Discussion 
Our findings do not conclusively rule out the possibility of a link between apoptosis and 
lymph node metastasis. From the main tumour a sub-clone of cells with a lower 
apoptotic rate ( among other changes) might have been selected out to colonise lymph 
nodes. This could have been apparent if we had checked the apoptotic rate in the 
metastatic lymph node rather than in the parent tumour. 
5.3.4 Apoptosis and histological differentiation 
Introduction 
It was once generally believed that less well differentiated tumours were more 
aggressive and more metastatic than more differentiated tumours. It is now appreciated 
that this is an oversimplification and, in fact, not a very accurate way to assess the degree 
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of malignancy for all kinds of tumours. However, for certain epithelial tumours, such as 
carcinoma of the cervix, uterine endometrium, colon, and thyroid, histologic grading is a 
fairly accurate index of malignancy and prognosis. 
In their study Boldy et al. graded the tumours in their series into three groups 
according to the degree of histological differentiation. They found no significant 
difference in survival between well differentiated, moderately differentiated and poorly 
differentiated tumours. 
In our own study we have investigated if any correlation exists between the degree of 
differentiation and the amount of apoptosis in a tumour. 
Results 
It was possible to grade 114 tumours according to their degree of differentiation. The 
apoptotic indices for the three groups are described in Table 5.9. 
Table 5.9 
Well diff 
Apoptotic indices of patients in each grade of histological 
ditTerentiation. 
n Min Max Mean S.D. 
12 6.5 75.8 27.6 21.1 
Moderate diff 58 3.1 108.7 28.4 23.5 
Poor diff 44 2.6 96.8 29.5 22.3 
Median 
21.3 
21 
23 
On Mann Whitney U test there was no significant difference between the means. 
We next investigated if apoptosis correlates with survival within any of these 3 groups. 
Table 5.10 below describes the survival times of patients within each group of 
histological differentiation. The last two columns indicate the coefficients of correlation 
(Spearman rank) between apoptosis and survival. 
Table 5.10 Survival times of patients in each grade of differentiation and 
correlation between AI and survival within each group. 
n Min Max Mean S.D. Median Rs p 
Well diff 9 5 135 60.5 56.5 29 -0.3333 >0.05 
Mod diff 49 2 132 30.5 38.6 15 0.0367 0.810 
Poor diff 33 4 134 48.3 52.3 19 0.0307 0.869 
The high p values indicate the lack of correlation within any group. 
Conclusion 
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No correlation exists between apoptotic index, the degree of histological differentiation 
and survival in this series of tumours. 
5.3.5 Apoptosis and AgNOR 
Introduction 
Measurement of the AgNOR count of a histological section is a convenient and reliable 
way off assessing the proliferative state of a tissue. 
The nucleolus is composed of structural and functional units called nucleolar organizer 
region (NOR). Each NOR contains a cluster of ribosomal ribonucleic acid (rRNA) genes 
and the enzymes and proteins necessary to transcribe these genes and pack the products 
into ribosomes. Many of the associated proteins within a NOR have a very high affinity 
for silver -a property that is utilised in staining them (Ploton et aI., 1986). The method 
involves staining dewaxed 3J.1m sections with a 1:2 mixture of gelatin and formic acid 
and 50% aqueous silver nitrate. On silver staining of histological sections the NORs 
appear as dark black dots called AgNOR which can be easily identified and counted. 
The AgNOR count of a cell depends on its proliferative state. Resting cells have been 
found to have only one NOR. In proliferating cells the need for increased ribosomal 
biogenesis is met by increased rRNA transcriptional activity within nucleoli. 
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Morphologically this is reflected by an increased number of NORs and therefore a high 
AgNOR count. A large number of studies have proved that the AgNOR count of a tissue 
correlates very closely with its rate of proliferation. These studies have been done on a 
wide range of tissues where AgNOR has been compared to other reliable measures of 
cell proliferation e.g. Ki-67 immunostaining, bromodeoxyuridine (BrdU) labelling and S-
phase estimation on DNA flow cytometry. A very strong correlation was seen in all but a 
few instances. The main advantage of AgNOR over all these other methods is that it can 
be done on paraffin embedded, routinely processed histological sections and there is no 
need for fresh tissue (flow cytometry) or frozen sections (Ki-67). A high AgNOR count 
has been found to adversely affect prognosis in a wide range of malignant conditions 
(Derenzini and Ploton, 1994: for a review of studies demonstrating correlation between 
AgNOR quantity and cell proliferation and of studies demonstrating the prognostic 
relevance of interphase AgNOR quantity in tumour sections). 
Boldy et.a1. were able to obtain good AgNOR staining of histological sections in all but 
10 of the 138 cases of this series by using the method mentioned above. All the tumours 
had significantly higher AgNOR counts than some areas of normal pseudostratified 
columnar epithelium that were also examined for comparison. AgNOR scores were not 
related to survival in the group as a whole. Nor was there any correlation with survival 
when patients were grouped according to disease stage Although AgNOR numbers 
tended to be higher in the less well differentiated tumours the range of AgNOR scores in 
each histological subgroup was wide and there was considerable overlap between the 
groups. There was no correlation between AgNOR count and DNA ploidy. 
Combining our own investigations with these results obtained by Boldy et al. we 
wanted to investigate if any correlation exists between the AgNOR count and the 
apoptotic index of a tumour. Seeing that the same genes are often involved in the control 
of both cell proliferation and apoptotic cell death it is not entirely illogical to expect 
some degree of reciprocal relationship between these two indices. 
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Results 
AgNOR counts could be obtained in 104 cases. The counts ranged from 4.6 to 24 per 
cell nucleus per specimen. Mean AgNOR was 11.3 and S.D. 3.9. Speannan rank 
correlation test between AgNOR and the corresponding AIs showed no correlation with 
Rs = 0.1070 and p = 0.280. The graph displaying this lack of correlation is shown in Fig. 
5.8. 
For the purpose of analysis Boldy et al. had divided the tumours into four groups 
according to the AgNOR counts. 
Group I AgNOR <8 
Group II AgNOR 8--<12 
Group III AgNOR 12--<16 
Group IV AgNOR 16+ 
We looked for a correlation between A.!. and survival within each of these four groups. 
Table 5.11 describes the survival times in each group. The last two columns describe the 
coefficients of correlation (Speannan rank correlation) between A.!. and survival. 
Table 5.11 Survival times of patients in each AgNOR group and correlation 
between AI and survival within each group. 
n Min Max Mean S.D. Median Rs p 
Gr. I 14 5 134 50.6 54.7 15.5 0.1011 0.736 
Gr. II 37 4 135 36.0 41.4 17 -0.0065 0.966 
Gr. III 21 3 133 35.3 46.9 16 -0.0951 0.678 
Gr. IV 9 5 132 52.7 57.3 19 0.1333 >0.05 
Conclusion 
Thus we concluded that apoptosis and AgNOR counts are not related in these tumours. 
In other words there is no correlation between cell death and cell proliferation. 
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Although apoptosis or cell proliferation taken each in isolation might not predict 
prognosis, reason would persuade us that the two taken together might have a better 
chance of correlating with outcome. Our analysis proves that thjs does not hold true for 
squamous lung cancers. 
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5.3.6 Apoptosis and DNA ploidy 
Introduction 
• 
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Aneuploidy is considered to be a marker of aggressive tumour behaviour. 
The genetic instability manifest during tumour progression is characterised by a variety 
of aberrations in the genome. While the more subtle changes- point mutations, gene 
11& 
deletions and rearrangements-may be associated with the initiation of the 
transformation process, gross changes in the number of chromosomes usually occur as 
tumours progress in malignancy. Loss or duplication of chromosome segments or of 
whole chromosomes is common in these late stages and is often associated with the 
acquisition of a more aggressive phenotype (see Section I. 1.4.5). 
DNA flow cytometry is one way of assessing such changes in a cell's total DNA 
content. It is a relatively crude way because abnormalities become detectable only when 
the DNA content varies from normal by at least 10010. A major stimulus to clinical flow 
cytometric DNA studies came in 1983, with the publication of the paper by Hedley and 
co-workers (Hedley et al., 1983). This study described a method of disaggregating thick 
paraffin embedded sections using pepsin, so as to produce nuclear suspensions suitable 
for the performance of DNA flow cytometry. This has allowed use of archival material to 
set up retrospective studies correlating DNA ploidy and patient outcome. Numerous 
such studies have been done in a variety of cancers. In general the frequency of 
aneuploidy increases with progressive stages of the disease. In most cancers DNA 
aneuploidy has been associated with adverse events like vascular invasion, lymph node 
metastasis and resistance to chemo- or radiotherapy (Camplejohn, 1994 - for a review of 
literature on this subject). 
In lung cancers controversy exists regarding the utility of tumour DNA content in 
predicting clinical outcome. While some studies have linked aneuploidy to decreased 
survival when compared to diploid tumours of similar stage (e. g. Isobe et 01., 1990; 
Zimmerman et al., 1987), others have been unable to confirm such a correlation (e.g. 
Carpetal., 1992; TenVeldeetal., 1988). 
Boldy et 01. prepared samples from 6OJ.1m paraffin sections by the method described by 
Hedley and colleagues. The nuclei were stained with propidium iodide and analysed flow 
cytometrically. Tumours were classified as DNA aneuploid if a discernible peak was 
visible that was separate from the main GO/G I peak of normal cells or if the apparent 
G2M peak channel:GO/GI peak channel ratio was greater than 1.1 or less than 0.9. In 
this particular series DNA ploidy did not correlate with survival. 
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Drawing on this data we have tried to find out if apoptosis correlates with ploidy in 
squamous cell carcinoma of lung. 
Results 
Ploidy data could be obtained in 107 cases. Of these 44 were diploid and 63 aneuploid. 
No satisfactory DNA histogram could be obtained for the others. The apoptotic indices 
for the diploid and aneuploid tumours are described in the table 5.12. 
Table 5.1Z Apoptotic indices of diploid and aneuploid tumours. 
n Min Max Mean S.D. Median 
Diploid 44 3.1 107.2 26.3 23.2 20.S 
Aneuploid 63 2.6 10S.7 29 20.9 22.4 
On Mann Whitney U test there was no significant difference between the means, p = 
0.241. 
We next investigated if apoptosis correlated with survival within each of these groups 
The table below describes the survival times of patients who were diploid or aneuploid. 
The last two columns describe the coefficients of correlation (Speannan rank correlation) 
between apoptosis and survival. 
Table 5.13 Survival times of patients with diploid and aneuploid tumours and 
correlation between AI and survival within each group. 
n Min Max Mean S.D. Median Rs p 
Diploid 39 2 135 42 49.4 16 -0.0444 0.7S0 
Aneuploid 49 3 133 3S 43.5 IS -0.OSI1 0.575 
Thus, even when the variable of tumour ploidy was eliminated, apoptosis did not 
correlate with survival. 
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Conclusion 
There is no correlation between apoptotic index, DNA ploidy and survival in this series 
of tumours. 
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5.4 Immunohistochemical staining of lung cancer 
Having comprehensively analysed the interrelationship of apoptosis and the more 
traditional pathological markers, we shall now move on to examine directly some of the 
proteins known to be important in apoptosis. There are many potential targets for 
investigation, but given that we were analysing 134 tumours we needed to be very 
selective. We have chosen two proteins. One of them is Bcl2, a key player in the control 
of apoptosis in most cells. The other is CD40 - a cell surface protein known to protect B 
lymphocytes from apoptosis, although its exact role in epithelial cells has not been fully 
defined yet. CD40 activation has been shown to cause upregulation of bcl2 in some cells, 
so the function of the two proteins may be inter-linked. For each protein we first 
analysed its expression among the series of lung tumours. We then proceeded to examine 
for correlation between gene over-expression and other clinico-pathological parameters. 
5.4.1 Expression of Bel2 in squamous cell carcinoma of lung 
Introduction 
bc12 is one of the key apoptosis regulating genes (see Section 1.3). Over-expression of 
Bcl2 protein renders a cell fairly resistant to apoptosis without increasing the rate of 
proliferation. Activation of this oncogene with consequent over-expression of the protein 
is seen in a wide variety of lymphoid and non-lymphoid tumours. Bcl2 over-expression 
has been reported in several series of non small cell lung cancers (see Section 6.5). 
We investigated the expression of Bcl2 in our series of 134 cases of squamous cell 
carcinoma of lung. We wanted to see what fraction of squamous cell carcinomas 
displayed activation of this oncogene. We also attempted to quantify the strength of this 
activation in each tumour separately by counting the percentage of Bcl2 +ve malignant 
cells. 
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Method 
Paraffin sections were stained with monoclonal antibody to Bc12. The method is 
described in detail in Section 4.2.2. The stained sections were examined under the 
microscope using an oil-immersion lens producing a magnification of xl 000. Bcl2 
positive cells appeared brown (Fig. 5.9). This stain was distributed predominantly in the 
cytoplasm of the positive cells. Infiltrating lymphocytes in the fibrous stroma often 
stained positive for Bc12 and served as an internal positive control for the staining 
method. 
The staining was heterogeneous. In many tissue sections there were both areas of 
strongly stained cells and completely unstained cells in varying proportions (Fig. 5.10). 
There were also instances where all the malignant cells had behaved identically i.e. they 
had all taken up the stain or had all remained unstained. We assumed that such 
differences in staining within a section was a reflection of the strength or degree of bcl2 
activation. We quantified this by calculating a Bc12 index for each tumour. 
Ten fields were chosen at random from different parts of the tumour section. The 
number of stained and unstained malignant cells in each field was recorded. The final 
percentage of stained malignant cells in all ten fields was expressed as Bcl2 index i. e. 
number of Bc12 +ve malignant cells/IOO malignant cells. The values for individual 
tumours have been tabulated in Appendix C. 
Results 
In all 75 cases (55.6%) expressed Bcl2 in at least some of their cells while 59 cases 
(44.4%) showed no expression of this protein whatsoever. 
Of the tumours that did express this protein the Bcl2 index ranged from 1.4 to 100 with 
a mean of 54.4 (S.D. 39.1). When the Bcl2 indices were charted in a frequency 
distribution graph (Fig. 5.11) a bi-modal distribution was clearly evident. A sizeable 
number of tumours had values at the two extremes while there were very few if any 
14 3 
tumours with a Bel2 index in the range 40-50 . Thus for this series a Bel2 index of 50 or 
. 
above could be taken as a cut off point to detemline if a tumour was Bel2 positive or 
Bel2 negative. 
By this definition 42 tumours (3l.6%) in this series were Bel2 positive and 92 tumours 
(68.4%) were Bel2 negative. 
Fig. 5.9 Section of squamous cell lung cancer (x 125) stained with monoclonal 
antibody to Bcl2. The tumour cells ha"c stained unifonnly brown while 
the stromal tissue bas remained unstained. 
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Fig. 5.10 Section of squamous cell lung cancer (x630) stained with monoelonal antibody 
to Bel2. Tumour cells at the top half of the picture have stained positive (brown). 
Adjacent tumour cells in the lower half of the picture are unstained (blue). 
Infiltrating lymphocytes have stained posith'c. 
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5.4.2 Expression of CD40 in squamous cell carcinoma of lung 
We next examined the expression of CD40 in our series of cases. As in the case of 
Bcl2, we quantified the number of CD40 +ve malignant cells in each tumour to obtain a 
CD40 index. 
Results 
Paraffin sections were stained with monoclonal antibody to CD40 by a method detailed 
in Section 4.2.3. These stained sections were examined under the oil immersion lens 
(magnification x 1000). In CD40 positive cells brown staining was seen on the cell 
surface as well as in the cytoplasm. CD40 negative cells appeared faint blue due to the 
counter-stain of Mayer's Haemallum. Many lymphocytes as well as parts of the fibrous 
stroma were seen to stain positively with CD40 as well (Fig. 5.12). 
As in the case of Bc12 many sections contained a variable mixture of stained and 
unstained malignant cells whereas others were unifonnly positive or negative. We 
calculated a CD40 index for each tumour based on the percentage of positively staining 
cells. 
Ten fields were chosen at random and a CD40 index (i.e. number of CD40 positive 
malignant cells/IOO malignant cells) was calculated using the same protocol as for Bc12. 
(See Section 5.5.1). The values for individual tumours have been tabulated in Appendix 
C. 
Altogether 56 cases (41.3%) expressed CD40 in at least some of their cells. 78 cases 
(58.7%) showed no CD40 expression at all. In the tumours expressing the antigen the 
CD40 index ranged from 1.2 to 100 with a mean of53.95 (S.D. 39.44) 
The CD40 indices were plotted on a frequency distribution graph (Fig. 5.13). Again a 
bimodal distribution similar to that of Bcl2 was seen. There seemed to be a natural break 
in the distribution ofCD40 at around 50. Thus we defined an index of 50 to be the cut-
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off point above which a tumour would be deemed to be CD40 positive. By this definition 
29 tumours (21.8%) in this series were CD40 positive and 105 tumours (78.2%) were 
CD40 negative. 
In subsequent sections we have investigated if Bcl2 or CD40 expression correlates with 
apoptosis, survival or any other clinical or pathological parameter. But first, we looked 
for cross correlation between Bcl2 and CD40. 
Fig.5.12 Section of squamous ceU lung cancer (x250) stained with monoclonal 
antibody to CD40. The stromal elements are starkly negative. 
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5.4.3 Cross correlation of Bel2 and CD40 expression in squamous cell 
carcinoma of lung 
In epithelial cells and carcinomas the relation between Bcl2 and CD40 has not been 
elucidated yet (see Section 1.4.5.3). In our series of lung cancers we examined if the 
expression of one oncogene influenced the expression of the other. Cases were divided 
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into four groups according to their Bcl2 and CD40 status as defined in the previous two 
"' 
chapters. This grid-table shows the number of cases in each of the four groups. 
Table 5.14 Lung tumours grouped according to Bel2 and CD40 status. 
Bcl2 +ve Bcl2 -ve 
CD40+ve 6 23 
CD40 -ve 36 69 
Chi-square test was perfonned on these values. 
Chi square = 1.952. Degree of Freedom = 1. Yates correction = 1.371. 
The tabulated value for one degree of freedom at 95% probability is 3.841. Therefore the 
distribution is not significantly skewed. 
Next we perfonned a Spearman rank correlation test on the Bcl2 and CD40 indices. 
There was a tendency towards inverse correlation between the two (Rs = 0.005 and p := 
0.064) which is also evident from the graph shown in Fig. 5.14. When Kendall's rank 
correlation was done on the same set of values, p = 0.OS7. However, when the zero 
values ofBcl2 and CD40 were excluded there was no correlation on Speannan rank test, 
Rs = 0.2141 and p = 0.300 (see Fig. S.IS). 
Conclusion 
Thus, Bcl2 and CD40 expression in lung tumours tend to correlate inversely when 
considered as a continuous variable, but not when considered as a dichotomous variable 
(i.e. positive or negative). 
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5.4.4 Bel2 and apoptosis 
Over-expression of Bc12 is associated with resistance to apoptosis. Thus one would 
expect that cases with a high Bel2 index should have a low apoptotic index and vice 
versa. We looked for differences in A.I. between tumours that were Bel2 +ve ( i.e. Bel2 
Index >50) and Bel2 -ve (i.e. Bel2 Index <50) (see Table 5.15). 
Table 5.15 Apoptotic indices of Bell +ve and Bell -ve tumours. 
n Min Max Mean S.D. Median 
Bel2 +ve 42 2.6 108.7 35.9 24.2 28.5 
Bc12 -ve 92 3.1 145.7 27.5 24.6 20.3 
On Mann Whitney U test the difference between the means was significantly different, p 
= 0.008. 
We then performed Spearman rank correlation test between B.I. and A.I. to ensure that 
the correlation demonstrated above was not an effect of the way we had defined Bel2 
positivity The values showed significant correlation (Fig. 5.16), Rs =0.2135 and p = 
0.041. This tendency towards correlation persisted even when the analysis was 
perfonned after ignoring the zero values for Bel2, Rs = 0.2425 and p = 0.041 (Fig. 
5.17). 
Next we looked at high apoptosis and low apoptosis groups (as defined in Section 5. 1 ) 
and investigated ifBc12 expression was significantly different in these tumours (see Table 
5.16). 
Table 5.16 Bell indices of high AI and low AI tumours. 
n Min Max Mean S.D. Median 
High AI 33 0 100 36.6 43.3 12.2 
Low AI 101 0 100 28 38.4 3.6 
lSI 
Though the High AI group had a higher mean Bel2 index the on Mann Whitney U test 
.\ 
the difference was not statistically significant, p = 0.824. 
Conclusion 
Although it was not evident on every method of analysis, on the whole, tumours that 
expressed a high level of Bel2 also had a high rate of apoptosis but the statistical 
significance was not always very strong. This is contrary to our expectations based on 
the known biological role of Bel2. We are not immediately able to explain this finding . 
Eerola el al. in their study involving 40 small cell lung cancers have recently described a 
similar positive correlation between bcl2 expression and apoptosis (Eerola et al.. 1997). 
It may be that the concomitant expression of other Bel2 family members holds the key to 
this enigma. (see Section 6.6) 
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To investigate if the expression ofBcl2 in lung tumours had any bearing on survival, we 
performed a regression analysis between B.I. and survival times. There was strong 
correlation between the two, higher B.I. being associated with longer survival, r = 
0.2720 and p = 0.005. When Spearman rank correlation test was done between B.I. and 
survival times Rs = 0.1794 and p = 0.053. 
We next investigated if the survival times in Bcl2 +ve and Bcl2 -ve tumours were 
significantly different (see Table 5.17). 
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Table 5.17 Survival times of Bel2 +ve and Bel2 -ve tumours. 
n Min Max Mean S.D Median 
Bcl2 +ve 37 2 134 67 54.1 65 
Bc12 -ve 68 4 138 32.1 41.5 16 
The mean survival time in Bcl2 +ve tumours was little more than twice that of Bcl2 -ve 
tumours. On Mann Whitney U test this was statistically significant, p = 0.013. 
Discussion 
Over-expression ofBc12 is expected to reduce the apoptotic rate of malignant cells and 
thus aid in tumour expansion. Therefore, theoretically, one would expect Bcl2 positive 
tumours to be associated with a shorter survival. However, the results above indicate a 
correlation in the opposite direction. This was not an isolated finding and several other 
investigators of lung cancer have reported similar results (e.g. Pezzella et al., 1993; 
Fontanini et al., 1995). The fact that in our series there was a some positive correlation 
between Bcl2 and apoptosis probably does not entirely explain the large difference in 
survival times that was noted. 
In our subsequent analyses we sought other explanations for Bc12' s ability to prolong 
survival. 
5.4.6 Bel2, disease stage and lymph node metastasis 
We investigated if there was any difference in Bc12 expression among patients in 
different disease stages and if the Bc12 index influenced in any way the propensity of a 
tumour to spread to regional lymph nodes. The Bcl2 indices of patients in the different 
disease stages can be seen in Table 5.18. 
154 
Table 5.18 Bel2 indices of tumours in ditTerent disease stages. 
n Min Max Mean S.D. Median 
Stage I 45 0 100 37.4 42.6 16.2 
Stage II 47 0 100 25.9 37.3 4.8 
Stage IlIa 27 0 100 29.1 39.8 4.2 
Stage IIIb 11 0 100 17.2 34 0 
Stage IV 4 0 100 40.3 47.8 30.6 
There was no visible trend in the mean Bel2 indices in successively higher disease stages. 
On Mann Whitney U test, no two means differed significantly. 
The Bc12 indices of patients in all three groups of lymph node involvement i.e. NO, N 1 
and N2 are described in Table 5. 19. 
Table 5.19 Bell indices of tumours grouped according to Iympb node status. 
n Min Max Mean S.D. Median 
NO S4 0 100 32.6 41.5 1.7 
NI 62 0 100 27.4 37.9 4.2 
N2 16 0 100 29.7 40.1 8.7 
On Mann Whitney U test, there was no significant difference between the means. 
Conclusion 
Bcl2 expression in lung cancer does not influence disease stage or the ability to spread 
to regional lymph nodes. 
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5.4.7 Bel2 and other pathological markers 
To check if the influence of Bcl2 on survival was the result of its effect on anything 
other than apoptosis we investigated for possible correlation between Bcl2 expression 
and other pathological markers. The other markers that we checked were differentiation, 
AgNOR and ploidy. The general pathological significance of these markers has already 
been discussed in previous chapters (See sections 5.3.4, 5.3.5 and 5.3.6 respectively for 
discussions on these topics). 
Bcl2 and differentiation 
Bcl2 indices in each of the three groups-well differentiated, moderately differentiated 
and poorly differentiated tumours are described in Table 5.20. 
Table 5.20 Bell indices of tumoun in ditTerent grades of histological 
differentiation. 
n Min Max. Mean S.D Median 
Well diff. 12 0 100 24 43.1 0 
Mod. diff 58 0 100 30.4 40.5 3.3 
Poorly diff 44 0 100 34.4 40.6 11.1 
Although there was a discernible trend for the mean Bcl2 index to increase with 
worsening histological differentiation, these differences were not significant on Mann 
Whitney U test. 
Bc12 and AgNOR 
Spearman rank correlation test was perfonned between B.I and AgNOR counts. No 
correlation was found between the two, Rs = 0.0108 and p = 0.764. 
Bc12 and ploidy 
Bcl2 indices of tumours that were diploid or aneuploid can be seen in Table 5.21. 
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Table 5.21 Bel2 indices of diploid and aneuploid tumours. 
n Min Max Mean S.D. Median 
Diploid 44 0 100 22.3 35 1.2 
Aneuploid 63 0 100 35.4 42.6 8 
Aneuploid tumours had a higher mean Bcl2 index but this was not statistically 
significant, p = 0.160. 
Conclusion 
Thus a higher Bcl2 index was seen in aneuploid tumours and in histologically less well 
differentiated tumours (both statistically insignificant trends). Both these are, in general, 
considered negative prognostic factors and therefore it still does not explain why a high 
Bcl2 index should be associated with a better prognosis. One must remember that in this 
particular series of lung tumours neither ploidy nor histological differentiation could be 
demonstrated to have any independent prognostic significance. 
5.4.8 CD40 and apoptosis 
In lymphocytes when CD40 is bound by its ligand, apoptosis is inhibited (see Section 
1.4.4.1). To investigate if the expression ofCD40 in lung cancer cells had a similar effect 
on apoptosis we performed Spearman rank correlation test between CD40 Index (C.I.) 
and A.I. No correlation was seen between the two, Rs = O. 1088 and p = 0.211. This lack 
of correlation is also very evident from the graph shown in Fig. 5.18. 
We repeated the analysis after excluding the 78 cases which had a C.I. of zero. Again 
no correlation could be demonstrated, Rs = 0.0223 and p = 0.870. See Fig. 5.19. 
We then looked for differences in A. I. between CD40 positive and CD40 negative 
tumours. See Table 5.22 
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Table 5.22 Apoptotic indices of CD40 +ve and CD40 -ve tumours. 
n Min Max Mean S.D. Median 
CD40 +ve 29 3.6 10S.7 33.1 29.S 20.S 
CD40 -ve lOS 2.6 145.7 29.3 23.3 22.4 
On Mann Whitney U test there was no significant difference between the means, 
p=O.926. 
Finally we looked at High A. 1. and Low A. I. tumours and investigated if there was any 
substantial difference in CD40 expression. See Table S.23. The table below describes the 
CD40 indices of High AI and Low AI tumours. 
Table 5.23 CD40 indices of high AI and low AI tumours. 
n Min Max Mean S.D. Median 
High AI 33 0 100 27.3 41.6 1.2 
lawAI 101 0 100 20.S 34.S 0 
On Mann Whitney U test there was no significant difference between the means, p 
=0.2S0. 
Conclusion 
Thus CD40 expression in lung cancer does not seem to influence the rate of apoptosis. 
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5.4.9 CD40 and survival 
One of the main questions to be asked when analysing the expression of a gene in a 
cancer is, does it have any influence on survival? To answer this we perfonned a 
regression analysis of CI and survival times of all patients. No correlation was evident, r = 
-0.0376 and p = 0.702. On Spearman rank correlation, too, there was no correlation, Rs = 
-0.0553 and p = 0.574. 
Next we looked at survival times of patients who were CD40 +ve and CD40 -ve 
according to our definition. Table 5.24 below describes their survival times. 
Table 5.24 Survival times of CD40 +ve and CD40 -ve tumours. 
n Min Max Mean S.D. Median 
CD40+ve 25 3 133 40.7 48.2 15 
CD40 -ve 80 2 138 44.1 48.8 18.S 
On Mann Whitney U test there was no significant difference between the means, p =0.285. 
Conclusion 
CD40 expression in lung cancer does not influence survival. 
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5.4.10 CD40, disease stage and lymph node metastasis 
We investigated if there was any difference in CD40 expression in patients in different 
disease stages and if CD40 expression influenced the ability of a tumour to spread to 
regional lymph nodes. Table 5.25 below describes the CD40 indices of patients in different 
disease stages. There were four patients in Stage IV all of whom had a CD40 Index of 
zero. 
Table 5.25 CD40 indices of tumours in different disease stages. 
n Min Max Mean S.D. Median 
Stage I 45 0 100 20.2 35.4 0 
Stage II 47 0 100 26.2 38.5 0 
Stage IlIa 27 0 100 20 34.8 0 
Stage IIIb 11 0 100 26.1 44.4 0 
On Mann Whitney U test there was no significant difference between the four means. 
Next we tabulated the CD40 indices of patients in all three groups of lymph node 
involvement i.e. NO, Nt and N2 (Table 5.26). 
Table 5.26 CD40 indices of tumours grouped according to lymph node status. 
n Min Max Mean S.D. Median 
NO 54 0 100 21.6 36.5 0 
Nl 62 0 100 25 38.3 0 
N2 16 0 100 16.1 32.3 0 
On Mann Whitney U test there was no significant difference between the means. 
Conclusion 
CD40 expression in lung cancer does not influence disease stage or the ability to spread 
to regional lymph nodes. 
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5.4.11 CD40 and other pathological markers 
Next we investigated if there was any correlation between CD40 and other pathological 
markers e.g. differentiation, AgNOR and ploidy. 
CD40 and differentiation 
CD40 indices of patients with well, moderate and poorly differentiated tumours are 
described in Table 5.27. 
Table 5.27 CD40 indices of tumours in different grades of histological 
differentiation. 
n Min Max Mean S.D. Median 
Well diff 12 0 100 26.9 44 0 
Mod. Diff 58 0 100 24.4 37.1 0.6 
Poorlydiff 44 0 100 20.6 35.3 0 
On Mann Whitney U test there was no significant difference between the means. 
CD40 and AgNOR 
Spearman rank correlation test was done between CI and AgNOR in all patients. No 
correlation could be demonstrated, Rs = 0.0849 and p = 0.892. 
CD40 and ploidy 
The CD40 indices of diploid and aneuploid tumours can be seen in Table 5.28 below. 
Table 5.28 CD40 indices of diploid and aneuploid tumours. 
n Min Max Mean S.D. Median 
Diploid 44 0 100 32.3 40.9 8.7 
Aneuploid 63 0 100 15.6 31.7 0 
On Mann Whitney U test the mean CD40 indices were significantly different, p=O.029. 
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Conclusions 
Thus, a higher CD40 index was associated with diploid tumours. There was no difference 
in C040 expression among other pathological groups created on the basis of disease stage 
or histological differentiation. 
5.4.12 Bel2, CD40, apoptosis and survival 
Having looked at Bcl2 and CD40 expression in isolation we next investigated if the two 
taken together had any influence on apoptosis or survival. Bc12 and CD40 are both anti-
apoptotic and there are suggestions that they might act synergistically (see Section 
1,.4.5.3). Thus one could expect their co-expression in tumours to have an additive effect 
on apoptosis or survival. 
Tumours were divided into four groups according to their Bcl2 and CD40 status as 
defined in Sections 5.4.1 and 5.4.2. 
a) Bc12 -ve and CD40 -ve 
b) Bcl2 +ve and CD40 -ve 
c) Bc12 -ve and CD40 +ve 
d) Bcl2 +ve and CD40 +ve 
BLCL 
BHCL 
BLCH 
BHCH 
The apoptotic indices in each of these four groups is described in Table 5.29. 
Table 5.29 Apoptotic indices in four groups created according to Bel2 and 
CD40 status. 
n Min Max Mean S.D. Median 
BLCL 69 3.1 145.7 26.9 24.7 19.8 
BHCL 36 2.6 88.4 34 20 28.5 
BLCH 23 3.6 107.2 29.2 24.9 20.8 
BHCH 6 9.2 108.7 47.8 42.6 34.7 
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Only one pair of means were statistically different. When BLCL was compared to BHCL 
by Mann Whitney U test, p = 0.010. There was no significant difference between the other 
means. 
The survival times in each of the four groups is described in Table 5.30. 
Table 5.30 Survival times in four groups created according to Bel2 and CD40 
status. 
n Min Max Mean S.D. Median 
BLCL 49 5 138 29.7 38.8 16 
BHCL 31 2 134 66.9 54.6 54 
BLCH 19 4 133 38.1 48.3 15 
BHCH 6 3 128 49.1 51.2 41 
BHCL differed significantly from BLCL (p = 0.014) and there was tendency to 
significance when compared to BLCH (p =0.067). The p values between the other pairs of 
means were not significant. 
Within each of the four groups we performed Speannan rank correlation test between AI 
and survival. The coefficients of correlation are shown in Table 5.31. 
Table 5.31 Coefficients of correlation between apoptosis and survival in four 
groups created according to Bel2 and CD40 status. 
Rs P 
BLCL 0.0019 0.996 
BHCL -0.0944 0.614 
BLCH -0.0640 0.786 
BHCH -0.3714 >0.05 
None of the p values were significant. 
Conclusions 
164 
There was no correlation between apoptosis and survival in any of the groups. Thus even 
when differences of Bcl2 and CD40 expression were eliminated, apoptosis in lung cancer 
did not influence survival. 
AI in the two Bc12 positive groups was higher than that in the two corresponding Bcl2 
negative groups. This might be a reflection of our previous finding (in Section 5.4.4) that 
AI was higher in Bcl2 +ve cases compared to Bcl2 -ve cases. One could conclude that 
Bcl2' s effect on apoptotic rate in this series of cases is not neutralised by differences in 
CD40 expression. It must be remembered that CD40 expression on its own was found to 
have no effect on apoptotic rate (Section 5.4.8). 
Among the four groups, those in BHCL survived the longest (66.9 months) and those in 
BLCL the shortest (29.7 months). This difference was significant statistically (p = 0.014). 
This is in parallel with the large difference in survival that was noted when Bcl2 expression 
was considered on its own (See section 5.4.5). In contrast there was little difference in 
survival between BHCH and BLCH (p = 0.634). Thus the expression of CD40 seems to 
have negated the survival prolonging effects ofBcl2. 
We have already established that CD40 does not influence apoptotic rate either on its 
own or in conjunction with Bc12. Could it be that CD40 influences some other biological 
action of Bc12? Although the only known biological action of Bcl2 is prevention of 
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apoptosis, it is almost impossible to explain its salutary effect in NSCLC on the basis of 
this fact. Several authors have speculated that there must exist some other biological role 
for BcI2 in lung cancer. To add fuel to this speculation, BcI2 expression has been found to 
paradoxically inhibit the growth of some solid tumour cell lines (derived from colon, lung 
and brain) in culture (pietenpol et al., 1994). Is the expression of this speculated 
alternative role of Bc12 only confined to specific tissues e.g. lung tissue? And is CD40 
really involved in this role as our data would seem to indicate? 
These questions will be dealt with in depth in the General Discussions Section. 
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5.5 Measurement of apoptosis in cultured tumour cells 
The assessment of apoptosis in histological sections, no matter how specific and sensitive 
the staining technique employed and no matter how accurate the counting protocol used, 
is limited in its scope. Indices obtained by such methods might provide a true description 
of the state of apoptosis at the moment that the biopsy specimen was obtained, but they 
can say very little about the kinetics of the process. Apoptosis is after all a dynamic 
process and at any given moment of time the amount of apoptosis detectable within a 
tissue is a balance between the process of production of apoptotic bodies and the process 
of phagocytosis by neighbouring cells and macrophages. These processes vary 
independently and by all accounts they can both be very rapid and a high rate of 
production might be balanced by an equally high rate of phagocytosis resulting in very 
little detectable apoptosis (see Section 1.2.2). This would misrepresent the effect that 
apoptosis may have on cell numbers in a tumour. Histological sections are unable to 
provide any information about these nuances. 
Theoretically, one way of studying the underlying dynamics of apoptosis in tumours 
would be to carry out serial measurements of apoptosis of tumour cells. For this the cells 
would need to be in culture from where they could be sampled at pre-set time intervals. 
From these serial measurements one could try to calculate a rate of apoptosis since there 
would be no phagocytosis. If this scheme could be implemented on disaggregated fresh 
tumours (rather than on cell lines) one could potentially obtain data about the state of 
affairs that exists in tumours in vivo. Such data would have considerable biological and 
clinical value. However, an important proviso is that the tumour cells would be removed 
from the influence of cytokines and growth factors in vitro and of course the tissue 
architecture would be destroyed, eliminating the influence of interactions between 
tumour cells and other cells and the extra cellular matrix (see Section 1.2.3.2). 
We wanted to investigate if this was a feasible option for lung tumours. For this the 
tumours would first need to be disaggregated into a single cell suspension and cultured in 
medium. There are several ways by which to measure apoptosis in cell suspensions. Our 
167 
main method was to stain the cells with propidium iodide (PI) and detennine the 
subdiploid fractions in DNA histograms. This method has been shown to be effective for 
leukaemia cells (Chant et 01., 1996). To distinguish tumour cells from non-tumour cells 
in the suspension we used the epithelial specific monoclonal antibody BerEP4 (see 
Section 3.1.5 a). Throughout the experiments we also used several other methods to 
measure apoptosis (cytospins, histological sections) to back up the results obtained by 
flow cytometry. 
We chose to begin our experiments with malignant pleural effusions and then moved on 
to solid lung tumours. 
5.5.1 Malignant pleural effusions 
Introduction 
There were several reasons to prefer to begin our experiments with pleural effusions 
rather than with solid lung tumours. Malignant pleural effusion is (sadly) a relatively 
common condition encountered in the medical wards (see Section 1.1.2.5). Aspiration of 
these effusions is a simple bedside procedure done under local anaesthetic. Within the 
effusion the malignant cells are held in a single cell suspension and thus there would be 
no need for complicated disaggregation protocols. 
Apart from these practical considerations, there were some theoretical attractions as 
well. In bronchial epithelial cells (as indeed in many other cell types) apoptosis has been 
shown to be modulated by cell-extracellular matrix (ECM) and cell-cell interactions (see 
Section 1.2.3.2). Anchorage of cells to ECM sends a powerful survival message 
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mediated by integrins. Loss of contact with neighbouring cells and ECM makes a cell 
more prone to apoptosis (Aoshiba et aI., 1997). Thus it would be interesting to examine 
if malignant cells floating freely in the pleural cavity had a particularly high rate of 
apoptosis. 
We collected malignant effusions from 10 patients whose details are tabulated below in 
Table 5.32. As described in the Methods Section (Section 4.2) we conducted a series of 
experiments on these effusions in an effort to measure apoptotic rate. 
Table 5.32 Clinical and pathological parameters of pleural effusions used for 
cell culture experiments. 
Sample Age Sex Diagnosis Amount of fluid 
coUected 
PEl 81 F Bronchial carcinoma 11 
PE2 76 M Bronchial carcinoma LSI 
PE3 65 F Bronchial carcinoma 11 
PE4 69 M Bronchial carcinoma 1.21 
PES 76 M Adenocarcinoma-unknown site II 
PE6 73 M Bronchial carcinoma 11 
PE7 62 F Metastatic breast cancer 1.41 
PE8 68 M Adenocarcinoma-unknown site LSI 
PE9 74 M Mesothelioma 11 
PElO 72 M Bronchial carcinoma 1.51 
Results 
Unfortunately, our experiments on pleural effusions did not prove to be very 
informative. Only one effusion, PE8, produced the type of results that we had hoped to 
see. F ACS analysis of a dual stained sample of this effusion clearly demonstrated two 
populations of cells - BerEP4 positive and negative (Fig. 5.20). A DNA histogram was 
obtained of the tumour cells (Fig. 5.21). This showed that 1.7% of the tumour cells were 
apoptotic on DayO. The corresponding figure for Days 1 and 2 were 7.6% and 13.2% 
respectively. (See Section S.5.2.1 for a description of the analytic methods). 
MONIIU)03 fU'fLl UnGotod 
102 • BerEP4 
~ 
. -: 
o I I I I 
rL2 
Fig. 5.20 Dot plot display of PE8 Day 0 sample. 
A gate has been drawn around the BerEP4 positive cells. 
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Fig. 5.21 
Io4ONln.OO3 fL2 e .. EP4 
DNA histogram of the BerEP4 positive 
gated cells in Fig. 5.20. 
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There were several reasons why we failed to obtain good results from the other samples. 
Contrary to our expectations, it often proved difficult to obtain sufficient numbers of 
tumour cells for analysis. The pleural effusions in our study had different grades of 
cellularity. PE4 and PElO were particularly hypocellular and each yielded only about 
500,000 cells in total. From this again a significant fraction was lost during procedures 
like washing and staining, leaving an insufficient amount to carry out all the experiments 
satisfactorily. During the short time that it took to bring the sample from the bedside to 
the laboratory, often a coagulum would form within the effusion,-malignant effusions are 
exudative and contain a large amount of protein (see Section 1.1.2.5). Some of the cells 
are likely to have been trapped within this protein coagulum. It might have been possible 
to increase the yield of cells by disaggregating this coagulum enzymatically. 
The effusions contained variable numbers of malignant cells and in some samples these 
were largely outnumbered by non-malignant cells (i.e. lymphocytes, neutrophils and 
reactive mesothelial cells). PE3, PE6 and PE7 each contained less than 5% BerEP4 
positive cells. There were also technical difficulties with staining. PE9 was a 
mesothelioma and therefore the tumour cells were BerEP4 negative. This prevented the 
proper assessment of apoptosis in the tumour cell fraction of this effusion. (see also 
Section 5.5.2.1). 
Inspite of these various disappointments, we were heartened by the positive results that 
we obtained with PES. This demonstrated that our experimental protocol was indeed 
based on sound principles and that results were obtainable using this protocol. 
We therefore proceeded with similar experiments on solid lung tumours. This proved to 
be a much more rewarding experience. 
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5.5.2 Fresh lung tumours 
Twenty one freshly resected lung tumours were collected and analysed as per the 
protocol described in Section 4.2. The clinico-pathological details of these patients are 
described in Table 5.33 below. 
Table 5.33 Clinical and histopathological parameters of fresh lung tumours used for cell 
culture experiments. 
Sample Age Sex Histology 
LCI 73 M Squamous 
LC2·· 76 F Adenocarcinoma 
LC3 69 F Squamous 
LC4 72 M Squamous 
LC5 85 M Squamous 
LC6 54 M Adenocarcinoma 
LC7 68 M Squamous 
LC8 66 F Squamous 
LC9 64 M Squamous 
LClO 61 M Adenocarcinoma 
LCll 73 F Broncboalveolar 
LCl2 54 M Squamous 
LC13 65 M Adenocarcinoma 
LC14 53 M Adenocarcinoma 
LCIS 62 F Undifferentiated 
(NSCLC) 
LC16 52 M Actinomycosis 
LCl7 63 F Adenocarcinoma 
LCl8 74 M SQuamous 
LCl9 76 F Squamous 
LC20 53 M Leiollly~""ma 
LC21 70 M Squamous 
Key RUL = Right upper lobe 
RML = Right middle lobe 
RLL = Right lower lobe 
• = Stage: No M value was assigned 
•• = Sample obtained from WGH, Coventry. 
Differentiation Location 
Welt RLL 
Well RLL 
Poor LLL 
Mod RML 
Poor LLL 
Poor LUL 
Mod LLL 
Mod RUL 
Mod LUL 
Poor LLL 
Mod RLL 
Mod LLL 
Mod RLL 
Well LUL 
Undi1f LLL 
no tumour 
Well RUL 
Poor LLL 
Poor RML 
Poor RUL 
Poor LLL 
LUL = Left upper lobe 
LLL = Left lower lobe 
Size Stage· 
2.5cm TI NO = 1 
2em T1 NO=I 
6cm T2 Nt = II 
4cm T2 Nl = II 
4cm T2NO=I 
4cm T2 Nl = II 
4.5em T2 Nt = II 
3cm T1 NO = 1 
7em T2 NI = II 
4.5cm TI Nl = II 
Scm T2 NO =1 
6cm T2 NI = II 
2cm T1 NO =1 
5em T2NO =1 
4cm T2 NO =1 
found 
l.3cm T1 NI = II 
7em TINO-I 
4. Scm T2 Nl = II 
llem TI NO-I 
4.5em T2 NI =11 
The main aim of these experiments was to obtain serial data on apoptotic rate using 
several methods in parallel e.g. flow cytometry, analysis of cytospins, analysis of 
histological sections stained with H&E and anti-ASP. Data from each of these 
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experiments have been described and summarised in the next few sections, while in the 
final section (5.5.2.6), apoptotic indices of DayO of individual tumours have been 
tabulated for comparison. The expression of the apoptosis controlling genes Bcl2 and 
CD40 in this series of lung tumours was also quantified. These results have been 
summarised in Section 5.5.2.5 and described in detail in Section 5.5.2.6. 
5.5.2.1 Flow Cytometric Analysis 
Our main method of determining the apoptotic rate of these tumours was by serial flow 
cytometric analysis of tumour cell suspensions. As described in Section 4.2 three aliquots 
of tumour cells were obtained at intervals of 24 hours and dual stained with BerEP4-
FITC and PI (Section 4.2.11). 
Results 
Flow cytometric data obtained for each tumour was analysed and manipulated using the 
Becton Dickinson Consort 30 programme and also the Dakomate programme (Dako). 
The aim of the analysis was to isolate the BerEP4 population (presumed tumour cells as 
discussed in Section 3.1.5 a) by electronic gating so that the PI staining could be 
analysed separately for this population, so giving the proportion of apoptotic tumour 
cells. This procedure will be described in detail by analysis of the data from tumour 
LCI4. 
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The data was first displayed as a dot plot using FL2 and FLI as the x- and y-axes 
respectively (see Fig. 5.22). From the plot two distinct populations of cells can be easily 
distinguished based on FL 1 staining i.e BerEP4 positivity. The low FL 1 cells represent the 
non-tumour population i.e. fibrocytes, lymphocytes and endothelial cells which are not of 
epithelial origin and so are BerEP4 negative. The high FL I cells represent the tumour 
population. Gland G2 can be identified in both the groups. 
To analyse the tumour cells separately, a gate was drawn around the high FLI cells (Fig. 
5.23). Events at the extreme left of the plot were excluded as they were likely to represent 
sub-cellular debris. Similarly, events at the extreme right were likely to be multicellular 
clumps and were therefore avoided. 
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Dot plot display of LC14 DayO showing 
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Fig. 5.23 Dot plot display of LC14 DayO with a 
gate drawn around the BerEP4 positive cells. 
A DNA histogram was obtained of the gated (tumour) cells (Fig. 5.24). All the phases of 
the cell cycle - G 1, S, G21M - can be identified. The population to the left of G I -
variously known as Ao or sub-G 1 or sub-diploid - represents apoptotic cells (Section 
3.1.5 a). Gates were drawn on the DNA histogram to delineate these subpopulations. The 
percentage of cells belonging to each phase of the cell cycle was then calculated from the 
histogram using the computer's programme. 
The same operation was repeated on the Day 1 sample. Comparing the dot plot of Day 1 
(Fig. 5.25) with that of DayO clearly shows the increased number of cells in the sub-G 1 
region of the former. This is more evident in the DNA histogram (Fig. 5.26) obtained from 
the gated cells ofLC14 Day!. The two DNA histograms have been overlaid in Fig. 5.27 
to show the stark contrast in the Ao region. 
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DNA histogram of tbe DerEP4 
positive cells in LC14 DayO. 
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Dot plot of LC14 Dayl with a gate drawn 
around the DerEP4 positive cells. 
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Fig. 5.26 DNA histogram of the DerEN positive 
cells of LC14 Dayl. 
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Fig. 5.27 Overlay of the DNA histograms obtained from 
LC14 on two consecutive days showing an 
increase in apoptosis with time. 
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Of the 21 tumours that we examined, not all yielded evaluable results. A common problem 
was clumping of cells in the suspension making it impossible to run the sample without 
clogging the flow cytometer. Weak: fluorescent staining was another problem especially 
with the initial few samples. Some of the samples yielded very low cell numbers especially 
at 48 hours. Only five of the tumours (LC5, LC8, LCIO, LC12 and LC21) yielded enough 
cells to be evaluated on Day 2. Fungal infection of culture flasks was another cause for 
failure. Given the nature of the tissue source, this was perhaps unavoidable. 
LC20 was BerEP4 negative and on the dot plot there was no separation between tumour 
and non-tumour cells (Fig. 5.28). Thus, from this sample, using our protocol, it was not 
possible to glean any information about the tumour cell specifically. Comparison of the 
BerEP4 histograms ofLC20 with the two control cell lines HL60 (BerEP4 -ve) and OE33 
(BerEP4 +ve) shows that most of the cells in LC20 were BerEP4 negative (Fig. 5.29). 
f'l2 
Fig. 5.28 Dot plot display of LC20 DayO. 
Fig. 5.29 Comparison of BerEP4 histograms of LC20 
with OE33 and HL60 cell lines. 
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Altogether 11 samples produced infonnative DNA histograms of tumour cells. Of these 
only two produced good samples on all three days. These results are shown in Table 5.34. 
Table 5.34 Percentage of cells in ditTerent phases of the cell cycle on 
successive days. 
Ao Gt S G2 
LC5 Day 0 13.5 36.5 27.8 23.2 
Day 2 16.9 48.1 20 13.5 
LC8 Day} 8.8 45.3 29 13.7 
Day 2 25.7 40.5 24.5 11 
LC9 Day 0 1.4 57 25 10 
Day} 29.1 24.5 14.5 20.3 
LC to Day 0 9.7 37.8 15.5 30.2 
Day 1 25.9 38.9 20.1 14.5 
Dax2 26.3 39.4 20.4 9.1 
LCn Day 0 6.8 67.7 18.5 11.3 
Day} 9.7 64.7 16.6 12.1 
LC12 Day 0 14.8 64.7 12.8 6.4 
Day 2 28.5 51 9.1 6.1 
LCt4 Day 0 0.7 73.8 9.5 1l.4 
Day 1 20.9 54.5 14.9 9 
LCtS Day 0 14.2 66.6 11.6 6.1 
Da)'_1 16.3 49.9 16.7 13.2 
LCt8 Day 0 5.5 48 17 19.5 
Day 1 7.5 56.1 12 15.8 
LC19 Day 0 6 61.1 15 11.4 
Day 1 12.3 53.4 15.9 11.5 
LC21 Day 0 3.3 66 10.6 15.2 
Day 1 15.2 65.1 10.1 13.9 
Day 2 16.3 57.1 11.6 15.2 
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It can be seen that the fraction of cells in the different phases of the cell cycle differed 
widely from one tumour to another. As an example the values of DayO are described in 
Table 5.35. The wide range for each phase emphasises the wide differences in cell kinetics 
that must exist among tumours. Such diversity is due to the presence of multiple variables 
which control the passage of a cell through the cell cycle. 
Table 5.35 Summary of DayO cell cycle fractions in the fresh lung tumours 
shown in Table 5.34. 
Min Max Mean SO Median 
Ao 0.7 14.8 7.7 4.9 6.8 
G1 36.5 73.8 56.7 12.8 61.1 
S 9.5 29 17.4 6.8 15.5 
G2 6.1 30.2 14.4 7.3 1l.4 
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A close look at Table 5.34 will show that while the fraction of cells in the other phases 
usually declined with time, the fraction of apoptotic cells increased in every tumour that 
we examined. Since the measurements were carried out after a fixed interval of time (24 
hours) it was possible from these values to calculate the rate of apoptosis (see Table 5.36). 
For instance, [Ao(Dayl)-Ao(DayO)]/24 hours would give the percentage increase of 
apoptotic cells per hour in the first 24 hours (AR1 in Table 5.36). Similarly, subtracting 
Ao(Day1) from Ao(Day2) (where this value was available) would provide the rate for the 
next 24 hours (AR2). In those instances where only DayO and Day2 values were available 
(LC5 and LC12), the rate was calculated as [Ao(Day2)-Ao(DayO)]/48 hours (ARJ). It can 
be seen that apoptosis proceeds at different rates in different tumours. Also, in the same 
tumour the rate varies with time. In those two instances (LC 1 0 and LC21) where it was 
possible to make such measurements, apoptotic rate was seen to drop sharply in the 
second 24 hours compared to the first 24 hours. 
Another observation that can be made at this point is the apparent lack of correlation 
between the apoptotic rate and the fraction of apoptotic cells on DayO. For instance LC9, 
LC 14 and LC21 all start off with small fractions of apoptotic cells on DayO which give no 
indication of the sharp rise that is seen on the following day. Others (LC 11, LC 15 and 
LC 18) contained a relatively larger fraction of apoptotic cells initially but subsequently 
failed to register a significant rise. These observations were statistically corroborated by a 
total lack of correlation between apoptotic rate and apoptotic fraction on DayO. On 
Spearman rank correlation, Rs = -0.4182 and p = 0.201. 
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Similarly, there was no correlation between apoptotic rate and apoptotic index obtained 
from the corresponding histological sections (AI). On Spearman rank correlation Rs = -
0.3727 and p = 0.259. The significance of this finding is discussed later in Section 6.10. 
Finally we looked for correlation between apoptosis and proliferation as we had done 
with the archival lung tumours (Section 5.3.5). Instead of using AgNOR counts, here we 
used the S phase fraction as a measure of cell proliferation. No correlation was found on 
Spearman rank test between apoptotic rate and the S phase fraction of these tumours; Rs 
= -0.0909 and p = 0.79. 
Table 5.36 Correlation of apoptotic rates with apoptotic fraction on DayO, 
AI from histological sections, and S phase fraction. 
ARI AR2 AR3 
LC5 0.0708 
LC8 0.7041 
LC9 1.1541 
LCIO 0.675 0.0166 
LCll 0.1208 
LCI2 0.5708 
LC14 0.8416 
LC15 0.0875 
LCI8 0.0833 
LCI9 0.2625 
LC21 0.4958 0.0458 
Key ARI = Apoptotic rate between 0-24 hours 
AR2 = Apoptotic rate between 24-48 hours 
AR3 = Apoptotic rate between 0-48 hours. 
Ao AI S 
13.5 65.3 27.8 
8.8 19.1 29 
1.4 26.7 25 
9.7 39.7 15.5 
6.8 18.1 18.5 
14.8 66.2 12.8 
0.7 20.1 9.5 
14.2 27.3 11.6 
5.5 48.8 17 
6 74.7 IS 
3.3 64.7 10.6 
Ao = Apoptotic fraction on Day 0 
AI = Apoptotic index from sections 
S = S phase fraction on Day O. 
182 
5.5.2.2 Analysis of Cytospins 
In parallel with flow cytometric analysis, we also attempted to measure apoptotic 
rate in the cultured tumour cells by serial examination of cytospins stained with H&E. 
For each tumour three cytospin slides were prepared at intervals of 24 hours. These 
slides were stained with haematoxylin and eosin and 10 fields were examined using an 
oil immersion lens (x 1000). Apoptotic malignant cells were identified by the 
morphological criteria mentioned in Section 3.1.1. An apoptotic index (apoptotic 
cellsllO,OOO malignant cells) was calculated for each slide. These values have been 
tabulated below (TableS.37). Not all tumours yielded cytospin slides of adequate 
quality for evaluation. In some tumours (LC6, LC7 and LCI3 ) slides obtained on all 
three days only contained clumps of cells. In other instances cells were sparse and too 
few in number to yield any reliable results. 
A quick comparison of the cytospin apoptotic indices (apoptosisllO,OOO malignant 
cells) in Table 5.37 and the flow cytometric apoptotic fractions (apoptosis/IOO 
malignant cells) in Table 5.36 will reveal that in the same sample, a larger number of 
cells were identified as apoptotic by F ACS analysis than by morphological 
assessment. This indicates that cells might become subdiploid in DNA content before 
they acquire all the morphological features of apoptosis. However in comparison to 
the histological sections, there was a larger fraction of apoptotic cells in the cytospin 
preparations (see Table 5.41 in Section 5.5.2.6). This is not unexpected because in 
the culture flasks, cells are deprived of many of the anti-apoptotic signals that they 
would receive in vivo from close contact with other cells or with ECM (see Section 
1.2.3.2). 
In most lung tumours there was usually a rise in the fraction of apoptotic cells with 
time, but this was not invariable. In LClO, LCI2 and LC15 the apoptotic index fell 
from OayO to Dayl and in LCI9 it fell from Oayl to Day2. Also, the rate of change 
of the apoptotic rate was not unifonn but varied from the first 24 hours to the second 
24 hours as in LCS, LC8 and LC9. 
Table 5.37 Apoptotic indices obtained from H&E stained cytospins on 
successive days. 
Sample No. Day 0 Day I Day 2 
LCI 69 -- --
LC2 96 -- 113 
LC3 141 208 --
LC4 53 85 --
LC5 156 182 274 
LC6 -- -- --
LC7 -- -- --
LC8 92 190 253 
LC9 105 203 238 
LClO 269 193 235 
LCll 66 153 --
LC12 277 131 206 
LCl3 -- -- --
LC14 28 122 --
LCI5 148 137 144 
LC17 32 114 202 
LC18 7S 161 --
LC19 81 210 196 
LC20 86 180 --
LC21 27 215 --
5.5.2.3 BerEP4 Staining 
183 
The BerEP4 status of all tumours was detennined routinely by immunostaining of 
cytospin preparations. Cells that express BerEP4 display a strong brown stain on the 
surface as well as in the cytoplasm (See Fig S.30). Since this antigen is epithelial cell 
specific, positive staining can be used to distinguish between epithelial and non-
epithelial cells. As discussed in the previous section, during FACS analysis, we used 
BerEP4-FITC staining as the sole criterion to distinguish tumour cells (of epithelial 
origin) from non-tumour cells i.e. fibrocytes, lymphocytes and endothelial cells. 
However, not all lung cancer cells are known to stain positively with this antibody 
(Latza et al., 1990). Therefore, it was crucial to know the BerEP4 status of a tumour 
from the cytospin to be able to properly interpret the results ofFACS analysis. 
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Cytospins obtained on DayO were immunostained with BerEP4 as described in 
Section 4.2.9. The stained slides were then examined under the oil immersion lens. 
The results are shown in Table 5.4l. 
The cytospins obtained from tumours LC6, LC7 and LC 13 contained mainly clumps 
and it was impossible to determine the BerEP4 status of individual tumour cells. 
Tumour cells of LC20 were BerEP4 negative. The histological diagnosis of this 
tumour was leiomyosarcoma-a tumour arising from smooth muscle cells which do 
not express the BerEP4 antigen. As explained in section 5.6.2.1 this precluded the 
proper flow cytometric analysis of this tumour. All other tumours showed positive 
BerEP4 stained tumour cells. 
Fig. 5.30 Cytospin prepared from disaggregated lung tumour (x630) stained with 
monoclonal BerEP4 antibody. The large tumour cells show positive 
staining on the cell surface as well as within the cytoplasm. 
5.5.2.4 Assessment of apoptosis in histological sections 
To corroborate with the results obtained from flow cytometric analysis and 
cytospins, apoptosis was also assessed in the corresponding histological sections of 
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these tumours using H&E and ASP stains. SJ.1m paraffin sections were stained with 
H&E and ASP as described in Sections 4.2.1 and 4.2.4 respectively. 
Haematoxylin and Eosin 
H&E stained slides were examined under the oil immersion lens (x 1,000) to identify 
apoptotic bodies by their morphological criteria i.e. condensed cytoplasm and 
pyknotic fragmented nuclei (See Section 3.1.1). Using the counting protocol 
described in Section 5.1 an apoptotic index (apoptotic cellS/lO,OOO malignant cells) 
was calculated for each tumour. The indices for individual tumours are tabulated 
together with other data for comparison in Table 5.41. In Table 5.38 a summary of 
both AI(H&E) and AI(ASP) is given. 
ASP 
Sections stained with ASP were examined microscopically using the oil immersion 
lens (xl,OOO). As described in Section 3.1.4.2, with this staining method, other cells 
remain unstained but apoptotic cells are coloured brown thus aiding their 
identification. The counting protocol described in Section 5.2 was used to calculate 
an apoptotic index for each tumour. These indices [AI(ASP)] are shown in Table 
5.41 and in Table 5.38 below. 
Table 5.38 Apoptotic indices of fresh lung tumoun assessed by H&E and 
ASP 
staining of histological sections. 
n Min Max Mean S.D. Median 
AI(H&E) 20 4.0 90.2 43.9 24.3 46.7 
AI (ASP) 20 6.6 130.7 72.9 38.3 76.5 
5.5.2.5 Assessment of Bel2 and CD40 in histological sections 
As an adjunct to the measurement of apoptotic rate, expression of two apoptosis 
controlling genes (Bc12 and CD40) was also examined in the histological sections. 
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5J..lm paraffin sections were stained with Bc12 and CD40 as described in protocols 
4.2.2 and 4.2.3 respectively. 
Bel2 expression 
Bc12 stained slides were examined microscopically and a Bcl2 index (Bcl2 positive 
malignant cells/l00 malignant cells) was calculated for each slide using the protocol 
described in Section 5.5.1. These indices (BI) have been shown in Table 5.40 and are 
summarised in Table 5.38 below. For comparison Bcl2 indices of the 134 squamous 
tumours that we studied separately ("Archival series") have also been shown in Table 
5.38. 
Table 5.39 Bell indices of fresb and arcbivallung tumours. 
n Min Max Mean Median S.D. 
All tumours 20 0 100 29.0 1l.7 37.5 
OnlySCC 11 0 100 39.4 12.1 44.8 
Only AC 6 0 72 15.0 4.9 28.1 
Archival series 134 0 100 30.3 4.2 39.8 
Of the 11 squamous cell carcinomas in this group 4 (36.3%) were Bcl2 positive (i.e. 
81>50). In comparison in the Archival series of squamous cell lung carcinomas 
31.6% were Bc12 +ve. 
Of the 6 adenocarcinomas only 1 (16.6%) was Bc12 positive. The mean BI among 
adenocarcinomas was less than the mean BI among squamous cell carcinomas, but 
this difference was not significant (p = 0.25). 
CD40 expression 
Slides stained with anti-CD40 antibody were examined using the standard protocol 
(See Section 5.5.2) to calculate a CD40 index -CI (CD40 +ve malignant cells/tOO 
malignant cells) for each lung tumour. These indices have been tabulated in Table 
5.41 and Table 5.40 below. Again the CD40 indices of the archival series have been 
included in Table 5.40. for comparison. 
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Table 5.40 CD40 indices of fresh and archival lung tumours. 
n Min Max Mean Median S.D. 
All tumours 20 0 100 27.5 5.0 40.2 
OnlySCC 11 0 100 20.4 0 38.5 
Only AC 6 0 100 45.6 36.9 50.2 
Archival series 134 0 100 22.2 0 36.5 
Of the 11 squamous cell carcinomas in this group 2 (18. 1 %) were CD40 positive 
(i.e. CI>50). In comparison in the Archival series of squamous cell lung carcinomas 
21.8% were CD40 +ve. 
Of the 6 adenocarcinomas in this group 3 (50%) were CD40 positive. The mean CI 
among adenocarcinomas was higher than the mean CI among squamous cell 
carcinomas, but this difference was not statistically significant (p = 0.264). 
5.5.2.6 Correlation between the various methods of measuring 
apoptosis in cultured tumour cells 
As discussed in Section 3. 1 every method of measuring apoptosis has its own 
advantages and disadvantages. We had an ideal opportunity to compare some of 
these methods because during the course of our experiments on lung tumours we had 
used several methods in parallel to measure apoptosis on the same tumour samples. 
To facilitate comparison, data obtained by the different methods has been summarised 
in Table 5.41. The indices obtained from the sections AI(H&E) and AI(ASP) (the 
unit for both is apoptotic cellsllO,OOO malignant cells) can be thought to represent the 
apoptotic state of the tumour in vivo. Once the tumour was disaggregated and the 
cells had spent some time in culture medium the apoptotic state is likely to have 
changed considerably because in the new environment the cells would be deprived of 
many of the usual survival signals. But the apoptotic index obtained immediately after 
disaggregation (DayO) is still likely to bear some resemblance to the apoptotic state 
in vivo. Therefore when comparing the histological sections with the cultured cells, 
we only considered the DayO apoptotic values of the latter. 
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Results 
Flow cytometry and AI(H&E) 
We performed a regression analysis between the DayO F ACS indices, AI(F ACS) 
and the corresponding AI(H&E) values. There was a tendency towards correlation 
between these indices (p=O. 1010) which was also apparent from the graph Fig 5.31. 
One must recall that when apoptotic rate rather than apoptotic fraction on DayO was 
compared with AJ(H&E) there was no relation between the two (Section 5.5.2.1). 
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Fig. 5.31 Correlation between apoptotic index (FACS) 
and apoptotic index (H&E) of fresh lung tumours. 
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Cytospin and AI(H&E) 
On regression analysis between AI(Cyto) and the corresponding AI(H&E) values, no 
correlation was apparent, p = 0.8715 . See also Fig. 5.32. 
Flow cytometry and cytospins 
Next, a regression analysis was performed between the apoptotic indices obtained from 
flow cytometry and cytospins on DayO. A tendency towards correlation was noted. 
between these two sets of values (p = 0.0818). This is also evident in the graph (Fig. 
5.33). 
H&E and ASP 
A strong correlation between these two methods of measuring apoptosis has already 
been established in Section 5.2. The data in that analysis also included 26 squamous cell 
carcinomas of the archival series. Here we performed a regression analysis exclusively on 
the fresh tumours. Again a very strong correlation was demonstrated, p=<O.OOl and 
r=0.968. 
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Table 5.41 
Serial 
No 
LCI 
LC2 
LC3 
LC4 
LC5 
LC6 
LC7 
LC8 
LC9 
LCIO 
LCll 
LC12 
LCl3 
LC14 
LCI5 
LCl7 
Lel8 
LC19 
Le20 
Le21 
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Fig. 5.33 Correlation between apoptotic index (FACS) 
and apoptotic index (cytospin) of the fresh lung tumours. 
Comparison of apoptotic indices of tumours measured by different methods and 
description of the expression of BerEN, Bel2 and CD40 in each tumour. 
Histo AI AI AI AI (ASP) BerEP4 BI CI 
(FACS)· (Cyto)· (H&E) 
S -- 69 49.1 83.5 +ve 12.1 0 
A -- 96 4 6.6 +ve 0 0 
S - 141 58.9 95.6 +vc 0 12.6 
S -- 53 49.2 84.1 +ve 100 7.8 
S 13.5 156 65.3 126.5 +ve 3.6 0 
A -- -- 16.8 36.9 -- 8.5 0 
S -- - 44.6 70.5 -- 0 0 
S 8.8 92 19.1 50.5 +ve 86.3 95.6 
S 1.4 105 26.7 51.3 +ve 19.7 100 
A 9.7 269 39.7 70.8 +ve 72 2.3 
B 6.8 66 18.1 25 +ve 15.9 30.5 
S 14.8 277 66.2 93.2 +ve 11.3 0 
A -- - 18.8 15.8 -- 0 100 
A 0.7 28 20.1 32.2 +ve 3.2 100 
U 14.2 148 27.3 53.7 +ve 23.8 22.6 
A 
--
32 77.4 123.9 +ve 6.6 71.5 
S 5.5 75 48.8 82.3 +ve 95.4 0 
S 6 81 74.7 127 +ve 100 0 
L 19.5 86 90.2 130.7 -ve 17.9 0 
S 3.3 27 64.7 99.4 +ve 5.2 9 
Key Histology 
S = Squamous cell carcinoma 
A = Adenocarcinoma 
B = Bronchoalveolar carcinoma 
L = Leiomyosarcoma 
U = Undifferentiated NSCLC 
Discussion 
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* = DayO indices 
-- = No data available 
No statistically significant correlation was seen between the apoptotic indices obtained 
from cultured cells (by flow cytometry or cytospins) and that obtained from histological 
sections. This is not surprising because cells in the culture flask exist under conditions 
very different from that in the tumour nodules in vivo. Also several artefacts may distort 
the estimation of apoptosis in cultured cells. These issues are discussed more fully in 
Section 6.10. 
CHAPTER 6 
DISCUSSION 
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6.1 Introduction 
Lung cancer is a dreadful disease and its incidence world wide is rising. We still do not 
possess adequate means of treating this disease. Development of new treatment 
protocols and new chemotherapeutic agents have not had a significant effect on the 
dismal mortality figures from this disease which have remained unchanged in the last 25 
years. There are many reasons why lung cancer is so difficult to treat. When patients first 
present with symptoms often the disease is well advanced and therefore potentially 
curative treatment cannot be undertaken. For those with localised NSCLC surgical 
resection (lobectomy or pneumonectomy) offers the best chance of cure but it is not 
invariably successful. A significant fraction of those who are operated upon will die of 
local recurrence or distant metastasis within the first two years. To delay or prevent this 
from happening, adjuvant chemotherapy was introduced a few years ago. Chemotherapy 
is also often prescribed for those with advanced NSCLC who cannot be operated. 
Patients seem to vary in their response to chemotherapeutic treatment and even in those 
who do respond, the systemic side effects caused by such drugs often results in a very 
poor quality of life. 
When, not long ago, the role of apoptosis in the biology of cancer was revealed, it 
kindled hope that a proper understanding of this process and its regulatory genes might 
provide answers to several of the problems faced by physicians dealing with lung cancer: 
In animal models of carcinogenesis derangement of apoptosis is one of the earliest 
events in the neoplastic process (Schulte-Hermann et al., 1981~ Schulte-Hermann et al., 
1990; see also Section 1.2.5). It is expected that detection of such derangements in the 
pre-neoplastic lesions of high-risk individuals (i.e. heavy smokers) might hasten the 
process of diagnosis (see Section 1.1.4.3). 
Secondly apoptosis might provide a good prognostic marker for lung cancer. It is 
rational to assume that a physiological process that leads to the elimination of cells 
should have at least some bearing on the outcome of lung cancer. Therefore quantifying 
194 
apoptosis within a tumour to arrive at some kind of apoptotic index should provide a 
valuable prognostic tool. 
Thirdly, since it is now known that most forms of anti-cancer treatments produce their 
effects by inducing apoptosis in tumour cells (Lowe et al., 1993; McDonnell et al., 1992; 
see also Section 1.2.5.4), the ability of a tumour to undergo apoptosis, judged either by 
quantifying apoptotic cells or by assessing the state of the apoptosis controlling genes, 
should help to predict the tumours response to treatment. 
Finally, it has been demonstrated that the process of apoptosis can be manipulated 
genetically. Both in cell culture experiments as well as in animal models cancer cells can 
be induced to die quickly by modifying their apoptosis controlling genes (Reed et al., 
1990~ Debatin et aI., 1990). Such treatments have recently been tried successfully in 
small groups of patients with lung cancer (Roth et al., 1996). Larger trials are needed 
before these modes of treatment become common practice. 
But before such ambitious projects are undertaken some very fundamental questions 
still remain to be answered. In real life what is the relative importance of apoptosis in 
lung cancer when compared to other pathological parameters? Does the amount of 
apoptosis in a tumour help to predict outcome in an individual case? How do the genes 
regulating apoptosis affect clinical outcome? The answers to these questions are being 
sought in many laboratories throughout the world both by experiments on animal models 
and cell lines and also by analysis of histological material by standard staining techniques 
and immunological methods. The latter is particularly necessary because the situation in 
vivo in human cancer is often very different from that prevailing in cell cultures or animal 
models. Even if one were to ignore lymphoid neoplasms and consider only epithelial 
malignancies, wide differences will be seen to exist in the results obtained from various 
tumour types which is a reflection of the underlying biological diversity in cells of 
different lineage. 
Even in tumours at the same site there are often conflicting reports. One of the reasons 
for such variation might be a lack of uniformity in gathering and reporting information. 
Several methods are available for measuring the same parameter and there are various 
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ways of reporting the same information which may make comparison impossible in some 
cases. For instance it is usual for apoptosis to be quantified in histological sections as 
apoptotic cells/IOO malignant cells. However many investigators have reported it as 
apoptotic cells per high power field or apoptosis per mm2. While this might serve the 
purpose of comparing the apoptotic rates of the various tumours in that particular series, 
it makes it virtually impossible to compare it to data obtained from elsewhere. Similarly, 
there is a singular lack of unifonnity in reporting the results of immunohistochemical 
tests as different groups tend to use different cut-off points. What is reported as positive 
in one series could be regarded as negative by another group of investigators. What is 
worse is that often no indication is given of the criterion that was used to classify 
positive and negative. Therefore one needs to be cautious when interpreting results of 
clinical and laboratory investigations. 
Inspite of such reservations several conclusions can be confidently drawn from the data 
available. Some of these conclusions are the converse of what is known or can be 
deduced from known biological facts. This just highlights that great lacunae still must 
exist in our understanding of this most fundamental physiological process. 
The aim of this thesis was to attempt to learn more about apoptosis in lung cancer, and 
relate this to the clinical situation. The experimental data obtained are presented and 
discussed in Chapter 5. The aim of this chapter is to put my results into the broader 
context of the study ofapoptosis in cancer. 
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6.2 Quantification of apoptosis in cancer and pre-malignant 
conditions: the relationship of apoptosis to tumour 
progression. 
To understand the role of apoptosis in lung cancer it is very important to first quantify 
it in cancer specimens so as to be able to relate it to other pathological markers and to 
outcome. In our series of 134 cases of squamous cell carcinoma (SCC), the apoptotic 
indices (examined by Haematoxylin and Eosin) ranged from 2.4/10,000 malignant cells 
to 145.5/10,000 malignant cells (see Section 5.1) i.e. 0.024% to 1.455% with a mean of 
0.302% and SD 0.247% (conversion into percentage will facilitate comparison with 
other published results). 
After an extensive search of literature we could find comparatively little quantitative 
data on the extent of apoptosis in lung cancer. A similar low frequency and wide range 
of apoptotic indices in lung cancer has been reported by other investigators. Stammler 
and Volm counted apoptosis using the TUNEL technique in a series of 178 cases of 
NSCLC (Stammler and Volm, 1996). They reported apoptotic indices that ranged from 
0.0-1.7% (mean value ± standard deviation: 0.37 ± 0.29; median 0.25%). These values 
are remarkably close to those that we obtained in our series. 
Earlier Tormanen and co-workers had counted apoptosis in 75 cases oflung cancer [47 
squamous cell cancers, 24 adenocarcinomas (AC), 3 small cell lung cancers (SCLC) and 
1 large cell cancer] in order to look for prognostic significance (Tormanen et al., 1995). 
They too had used the 3' end labelling technique to identify apoptosis. Among squamous 
cell carcinomas they found a mean apoptotic index of 0.38 ± 0.05% (mean ± SD). In 
ACs they reported a higher index of 0.48 ± 0.08%, while in their 3 SCLCs the index was 
even higher at 0.92 ± 0.3%. In the 6 ACs in our series of 20 fresh lung tumours the AIs 
were not very different from that among the secs - 0.29 ± 0.26 (see Table 5.41). 
However the higher incidence of apoptosis in SCLCs has been confinned by the only 
other group who have quantified apoptosis in this category of lung cancers. Eerola et al 
197 
have found a mean apoptotic index of 0.97 (range: 0.01-6.5%) in a series of 40 cases of 
SCLC (Eerola el al., 1997). 
Two other groups have counted apoptosis in lung cancers. Komaki et al found 
apoptotic indices to range from 0.2-2.8% (median 1.0%) in 173 cases of NSCLC 
(Komaki et al., 1996). In their much smaller series of 38 lung cancers, Kargi et al found 
the median AI to be 9.52% (range: 2-26%) (Kargi et al., 1997). 
There are several quantitative studies of apoptosis in other epithelial tumours. In 
squamous cell carcinoma of the oropharynx and oral cavity, Birchall et al reported the 
mean AI to be 0.14 ± 0.14% and in SCC of the oesophagus Ohashi et al found AIs to 
range from 1.09-2.59"10 (Birchall et al., 1995; Ohashi et al., 1997). In carcinoma of the 
cervix (which is another example of squamous cell cancer) Sheets et al found a mean AI 
of 0.4 ± 0.1 % (Sheets et al., 1996). 
In adenocarcinomas too the incidence of apoptosis is very low. In the prostate, 
apoptosis has been estimated as 1.7% (range: 0.2-2.4%) in nine solid undifferentiated 
carcinomas (Gaffitey, 1994), between 0.09-1.73% in 26 adenocarcinomas (Coiecchia et 
al., 1997) and between 2.69-2.75% in 16 cases (Drachenburg et al., 1997). In colorectal 
cancer Baretton et al. found a mean apoptotic index of 1.9 ± 0.15% in 93 cases 
(Baretton et al., 1996). 
None of the cases reported above had received any fonn of therapy which could have 
caused apoptosis (e.g. chemotherapy, radiotherapy, hormone ablation therapy) and 
therefore what was observed can be considered to be "spontaneous" apoptosis. It will be 
recalled that such spontaneous apoptosis in tumours is caused by both intrinsic factors 
like oncogenes (P53) that are activated by the presence of genetic abnormalities within 
the cell, and extrinsic factors like cytotoxic T cells and lack of nutrients and oxygen. It is 
generally presumed that as a lesion progresses from pre-malignancy to malignancy such 
spontaneous apoptosis decreases and as a consequence the tumour increases in size (see 
Section 1.2.5.3). 
However this is not what is usually observed in real life. In most cases the incidence of 
apoptosis is seen to increase or remain static as a tumour progresses. In prostatic cancer 
both Drachenburg and Wheeler found apoptotic rates to rise from benign glands to high 
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grade intraepithelial neoplasia to adenocarcinoma (Drachenburg et al., 1997; Wheeler et 
aJ., 1994). In addition Tu et aJ. found a higher rate of apoptosis in foci of metastatic 
prostatic cancer than in localised cancer (Tu et al., 1996). In squamous cell carcinoma of 
the oesophagus (Ohashi et aJ., 1997) and oral cavity (Birchall et aJ., 1995) apoptosis 
increased as lesions progressed from pre-malignancy to malignancy. Two groups of 
investigators have found the apoptotic indices in colonic carcinomas to be no different 
from that in the adenomas which precede them (Barreton et al., 1996; Koike, 1996). 
However, another group (Bedi et aJ., 1995) found a progressive inhibition of apoptosis 
during the transformation of normal colorectal epithelium to carcinoma. In cervical 
carcinoma Shoji et aJ found a positive correlation between apoptosis and rising 
malignant grade i.e. cervical intraepithelial neoplasia, microinvasive carcinoma and 
invasive squamous cell carcinoma (Shoji et al., 1996). Only Sheets et al found a 
significant (p < 0.001) drop in apoptosis as the degree of cervical neoplasia increased 
(Sheets et aI., 1996). 
In lung cancer we could find no such comparative study of apoptotic rates in pre-
malignant and malignant lesions. Tormanen et al. had counted apoptosis in 11 samples of 
normal bronchial epithelium and found an apoptotic index of 0.02 ± 0.02% which was 
much lower than what they had found in any sample of malignant lung tissue (see above). 
Unlike cervical cancer and colonic cancer where it is standard clinical practice to obtain 
serial histological or cytological samples from patients known to be at risk of developing 
cancer, in the case of lung cancer obtaining such serial pre-neoplastic samples might 
prove to be very difficult. The only other alternative might be to take a sample of 
resected lung cancer and to examine the adjacent areas of normal and dysplastic 
epithelium for apoptosis. Such a study is urgently required to answer some very 
fundamental questions on the importance (or otherwise) of apoptosis during progression 
of lung cancer. The evidence available from other cancers would seem to indicate that 
decreased apoptotic cell loss is probably not an important factor during the stage of 
tumour progression, although in the earlier stages of neoplasia (i. e. initiation and 
promotion) apoptosis may playa more decisive role as indicated by the experiments on 
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rat hepatocarcinogenesis by Schulte-Hermann and co-workers (Schulte-Hermann et al., 
1981 and 1990). 
Why does apoptosis seem to increase as the tumour progresses? Is increased apoptosis 
a marker of tumour progression or is it merely an epiphenomenon, a sign of rapid tumour 
growth outstripping the rate of new vessel formation? Theoretically such an imbalance 
would create more competition for nutrients and oxygen among the increasing number of 
new cells and inevitably lead to some amount of cell death by apoptosis. There is 
experimental evidence to support this contention. In transgenic mice treatment with the 
angiogenesis inhibitor AGM-1470 has been shown to result in a 40% reduction of new 
vessel density in islet cell tumours and a 100% increase in apoptotic rate (Parangi et al., 
1996). Other investigators have reported similar findings in separate models of animal 
carcinogenesis (Oreilly et al., 1996; Saji et al., 1997). Recently, Lu and Tanigawa have 
demonstrated that in gastric carcinoma, there is a highly significant inverse correlation 
between intratumoral microvessel densities and AI (p < 0.0001) (Lu and Tanigawa 
1997). Theoretically it is at least conceivable that as the fledgling tumour increases in 
size, the rate of microvessel formation may not always be able to keep pace with the rate 
of cell proliferation. This imbalance would result in increased apoptosis. 
Tumours seem to thrive inspite of this increasing death rate which indicates that the 
proliferative rate must usually keep up with and exceed the rate of cell loss. In other 
words the rate of cell loss is probably not an important determinant of growth once the 
tumour has proceeded beyond a certain phase of its natural history. 
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6.3 Apoptosis and survival 
It might be expected that a high level of apoptosis suggesting slower tumour growth 
would be linked to better survival in lung cancer. In our series patients with a high 
apoptotic rate tended to have a shorter survival than the low apoptotic group, but this 
did not reach statistical significance (p = 0.131). No significant correlation between 
apoptosis and survival emerged even when various other pathological parameters like 
stage, grade proliferation rate and ploidy were corrected for (see Section 5.3). 
Three other groups have investigated the value of apoptosis in predicting survival in 
lung cancer. Stammler and Volm divided the 178 NSCLC cases of their series into high 
apoptosis and low apoptosis according as they were above or below the median 
apoptotic index for the group. Those with a high apoptotic index had a mean survival 
time of 65 weeks while those with a low apoptotic index survived on average for 89 
weeks. This difference was not statistically significant (Stammler and Volm, 1996). 
Komaki et al undertook a retrospective analysis on 173 cases who had undergone lung 
resection for NSCLC. Their series included 86 SCCs, 73 adenocarcinomas (AC), 3 large 
cell carcinomas (LC), 6 adenosquamous carcinomas and 5 unclassified NSCLCs. Patients 
were observed from 2 to 209 months (median 27 months). The overall survival of the 
patients, which was 33% at 5 years, did not depend on the level of apoptosis. However, 
on multi-variate analysis, in the ACILC group high apoptosis was associated with a 
significant chance of distant metastasis at 5 years (Kornaki et al., 1996). 
Tormanen et al found a significant correlation between high apoptosis and shorter 
survival. Among their 75 lung cancers those with apoptotic indices greater than 1.5% 
showed a significantly shorter survival time than the patients with apoptotic indices of 
1.5% or less (p < 0.01). By multivariate analysis enhanced apoptosis in NSCLC showed 
a 1.9 fold risk (95% CI, 1.04-3.60; P = 0.04) for a shortened survival (Tonnanen et al., 
1995). 
A similar trend between high apoptosis and short survival has also been noted in 
cancers at other sites. In carcinoma of the cervix (squamous cell carcinoma) Levine et al 
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found that patients with a high (greater than median) AI had a lower 5 year recurrence 
free rate (p = 0.012) as well as lower 5 year survival rate (p = 0.003) (Levine et aI., 
1995). In a retrospective analysis of 400 cases of transitional cell bladder carcinoma, 
followed up for a mean of 9.5 years (range: 3.2-25.2 years), high AI was found to 
predict shorter survival (p < 0.0001) on univariate analysis but did not emerge as an 
independent prognostic factor on multivariate analysis (Lipponen and Aaltoma, 1994). 
Similarly in breast cancer, high AI predicted shorter survival in both axillary lymph node 
positive as well as lymph node negative groups, but was shown to be of no value in 
multivariate analysis (Lipponen et al., 1994). In contrast, Shao and co-workers found a 
high apoptotic count to be associated with better prognosis in the 91 cases of breast 
cancer that they investigated (Shao et al., 1996a). 
A complete lack of correlation between apoptosis and prognosis has been described by 
two groups who investigated 82 cases of gastric cancer (Koshida et al., 1997) and 148 
cases of ovarian cancer of all histological types (Diebold et al., 1996). 
Thus apoptotic rate does not promise to be a good prognostic marker in most cancers. 
In many organs high apoptosis in cancer is associated with a trend towards worse 
prognosis. In some others it has no relation to prognosis at all. In lung cancer (NSCLC) 
on the whole there is a trend for high apoptosis to be associated with worse prognosis 
but in most series (including ours) this trend is not statistically significant. A study 
involving a larger number of patients might be able to give clearer answers. 
Overall it is fair to comment that in most cancers apoptosis does not seem to have the 
effect on survival that is expected on theoretical grounds i.e. high apoptosis does not 
lead to better prognosis. There are several possible explanations: 
Firstly, it may be that what is being measured as apoptosis in histological sections is 
inaccurate and therefore the conclusions derived from such measurements are likely to be 
false. If we could find a more reliable way of measuring apoptosis it would probably 
show that high apoptosis is associated with a better survival rate. Even without the 
contrary results mentioned above there have always been serious doubts about the 
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rationality of measuring a dynamic process like apoptosis in histological sections. As part 
of our investigations we performed some experiments to devise a better way of 
measuring apoptosis. The results of these experiments have been described in Section 5.5 
and the implications of these results will be discussed later in Section 6.10. 
Secondly, does apoptosis actually increase as tumours progress? If one believes that the 
present ways of measuring apoptosis are valid, this would be the inescapable conclusion 
from the clinical studies and the studies in pre-neoplasia mentioned in the previous 
section (Section 6.2). Such an increase could be a result of tumour expansion 
outstripping new vessel formation as discussed before (Section 6.2). It could also be a 
marker of disease progression. This would be contrary to our theoretical expectations 
but would certainly explain much of the empirical observations. We and several others 
before us have considered this question as we investigated the relation of apoptosis and 
other pathological markers of disease progression. The observations and results obtained 
from these various investigations will be discussed in the next section. 
Thirdly, there remains the possibility that the rate of apoptosis does not actually change 
as the tumour progresses. The trend for shorter survival that has been noticed in some 
studies (including ours) is only a statistical aberration which will disappear when more 
studies are done with larger numbers of patients. 
Fourthly, apoptosis might be important in some tumours but not in others. 
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6.4 Apoptosis and pathological markers 
In our study we sought to determine whether there were correlations between 
apoptosis and other parameters of disease severity i.e. pathological stage, lymph node 
metastasis, histological differentiation or DNA ploidy. None was found (see Sections 
5.3.2 to 5.3.6). Here we shall first discuss the correlation of stage and differentiation 
with apoptosis and then go on to discuss cell proliferation separately. 
In their previously mentioned study, Stammler and Volm found no significant relation 
between apoptosis and disease stage or lymph node metastasis (Stammler and Volm, 
1996). They had also investigated the relation between apoptosis and in vitro drug 
resistance assays, the findings of which have already been discussed in the previous 
section. 
For their investigations Komaki et al. had selected only those patients ofNSCLC who 
were pathologically staged as Nl, therefore no inference about correlation with lymph 
node metastasis could be drawn from their study. They found no association between 
apoptosis and tumour size (T), grade of histological differentiation, location of tumour, 
age, performance status and weight loss of patients (Komaki et al., 1996). Kargi et al. in 
their series only looked for possible correlation between apoptosis and disease stage and 
found none (Kargi et al., 1997). 
Tormanen et aI., who were the only group to find a prognostic significance for 
apoptosis in lung cancer, could not discern any association between the TNM status of a 
tumour and its apoptotic index, but the percentage of apoptotic cells was significantly 
higher in high grade carcinomas than in low grade carcinomas (p = 0.019). 
A similar association between high apoptosis and poor histological differentiation has 
also been described in cervical carcinoma (Shoji et al., 1996), ovarian carcinoma 
(Diebold et al., 1996), prostatic adenocarcinoma (Vesalainen et al., 1994), gastric 
carcinoma (Koshida et al., 1997; Saegusa et al., 1995c) and breast carcinoma (Lipponen 
et al., 1994). A significant correlation in the opposite direction (i.e. higher apoptosis in 
well differentiated tumours) has been reported in breast cancer (Shao et al., 1996a), 
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oesophageal carcinoma (Ohashi et aI., 1997). as well as in gastric carcinoma (Shinohara 
et al., 1996) The latter could not find any correlation between apoptosis and disease 
stage. 
In bladder cancer high apoptotic index has been found to correlate with several 
parameters of disease progression e.g. high pathological stage, high histological grade, 
more lymph node metastases, more distant metastases and DNA aneuploidy (Lipponen 
and Aaltoma, 1994). 
In breast cancer Lipponen et aJ. found no correlation between apoptosis and tumour 
size (T) or lymph node status (N). They found high AI to correlate with poor histological 
differentiation (mentioned above), DNA aneuploidy and loss of oestrogen receptors 
(Lipponen et al., 1994). The latter is a sign of advanced breast cancer and carries a poor 
prognosis. This association between apoptosis and loss of honnone receptor was also 
apparent strongly in another series (Frankfurt et al., 1996). In contrast to this two 
groups have found that high apoptosis in breast cancers is associated with a significantly 
lower risk oflymph node metastasis (Sierra et al., 1996; Shao et al., 1996b). 
Thus there seems to be no consistent association between apoptosis and other 
pathological parameters in the various tumours that have been investigated. In lung 
cancer only one group have found apoptosis to be associated with a marker of disease 
progression. In breast cancer there are conflicting reports by different groups. Even if 
one particular marker is selected (e.g. differentiation) it seems to have different 
associations with apoptosis in different tissues. Further investigations are called for 
before one can come to any firm conclusions. This is particularly true in the case of lung 
cancer where other than ourselves only one other group (Tormanen, 75 patients) have 
comprehensively investigated apoptosis against a range of pathological markers. 
From the present evidence one would be tempted to draw the conclusion that while in 
some cancers increasing severity of disease is accompanied by increasing apoptosis, in 
lung cancer there does not seem to be any such correlation. 
Several investigators have focussed on the relation between apoptosis and proliferation 
in tumours. Lipponen and Aaltoma were the first to report on a close correlation 
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between these two parameters in human epithelial malignancies. In a study involving 400 
transitional cell bladder carcinomas they estimated cell proliferation from S phase 
fraction (SPF) and mitotic indices. They found a strong correlation between high AI and 
high proliferation rate (p < 0.001) (Lipponen and Aaltoma, 1994). Later that year they 
along with two other colleagues reported a similarly strong correlation between 
apoptosis and proliferation in 288 cases of breast cancer (Lipponen et al., 1994). In both 
these series the cases with high AI had a shorter survival. After multivariate analysis the 
authors concluded that the prognostic value of AI in predicting survival was more likely 
to be related to cell proliferation than to cell death. Both processes were, after all, under 
common regulatory mechanisms. The oncogene c-myc is capable of causing both cell 
proliferation and apoptosis depending on whether the cell cycle is supported by growth 
factors or is inhibited by growth factor deprivation. Furthermore, cyclin dependent 
kinases normally stimulate proliferation, but if activated at an inappropriate time during 
the cell cycle they can cause apoptosis. 
Following this two other studies in breast cancer (Samoszuk et al., 1996~ Frankfurt et 
al., 1996) and one study involving 93 colonic carcinomas (Barreton) have found a strong 
direct correlation between apoptosis and proliferation. 
In our series there was no correlation between AI and cell proliferation as assessed by 
AgNOR counts. Only two other groups have carried out similar investigations in lung 
cancer. Tormanen et al used PCNA to assess cell proliferation in their 75 lung cancers, 
while Eerola et al used Ki-67 staining for their 40 cases of SCLC. Neither of them found 
any statistically significant correlation between the two parameters. In gastric cancer a 
similar lack of correlation has been reported (Shinohara et al., 1996). 
An inverse correlation between apoptosis and proliferation has been reported in a series 
of69 oesophageal squamous cell carcinomas (Ohbu et al., 1995) and more recently in 92 
skin neoplasms - both squamous cell and basal cell carcinoma (Shigihara and Lloyd, 
1997). 
Thus, like many other aspects of tumour biology, the relation between apoptosis and 
proliferation seems to depend on the type and site of the cancer. 
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In analysis of survival there was no difference in outcome between lung tumours with 
high AgNOR/low AI which are expected to accumulate cells much more quickly than 
those with low AgNORihigh AI (see Section 5.3.5). One could conclude that mere 
numerical superiority is not as important in tumour progression as the nature of the 
malignant cells that are being produced. Whether the cells are able to invade locally or 
metastasise to distant organs is likely to be a key determinant of outcome. Of course 
aberrant apoptosis could influence some of these characteristics as well. 
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6.5 Expression of bel2 in lung cancers 
The expression of bcl2 is associated in many systems with resistance to apoptosis, and 
so a primary aim of this work was to investigate bcl2 expression in a series of lung 
cancers and relate it to apoptosis and clinico-pathological parameters of disease severity. 
In our series of cases, 55.6% expressed bcl2 in at least some of their cells. 31.6% of the 
tumours were bcl2 positive i.e. more than 50% of the malignant cells had Bcl2 (see 
Section 5.4.1). 
Although the expression and the pathological correlates of bcl2 had been studied 
extensively in lymphoid neoplasms, Francesco Pezzella and his co-workers were the first 
to demonstrate that bc12 is expressed in epithelial malignancies as well (pezzella et al., 
1993). In a series of 122 non small cell lung cancers (NSCLC) they reported bcl2 
positivity in 20010 of the whole group. Among squamous cell carcinomas (SCC) taken 
separately 25% were bc12 positive while only 12% of the adenocarcinomas (AC) were 
positive. They also reported that bc12 was important in predicting survival in certain sub-
groups of lung cancer. This caused considerable interest in the oncogene and in the last 
four years a vast body of literature has been published documenting the expression and 
role of bc12 in carcinomas at different sites of the body. In lung cancer alone at the last 
count there were 15 major publications, each comprising more than 100 patients on an 
average, which have investigated the correlation of bcl2 expression with various 
pathological markers and with survival. 
In the majority of publications on the subject, the incidence of bcl2 positive cases 
among NSCLCs taken as a whole has ranged between 20-35% (Higasbiyama et al., 
1997~ Kargi et al., 1997; Ohsaki et al., 1996; Ritter et al., 1995; Tormanen et al., 1995). 
Fontanini et al., reported 67% of their 101 NSCLCs as bcl2 positive, but this is probably 
because they classified as positive any tumour where more than 1 % of the cells stained 
positively with the monoclonal antibody (Fontanini et al., 1995). 
Among SCCs taken as a separate group the incidence of bcl2 positivity has been 
consistently reported between 25-35% (Jiang et al., 1996; Ohsaki et al., 1996; Oneill et 
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al., 1996; Pezzella et aI., 1993; Ritter et al., 1995; Tormanen et al., 1995; Volm and 
Mattern, 1996). Among ACs a much lower incidence has been generally observed -
between 6-12% (Jiang et al., 1996~ Ohsaki et aI., 1996; Oneill et al., 1996; Pezzella et 
aJ., 1993; Tormanen et al., 1995), but one group (Ritter et al., 1995) have found a 
higher percentage ofbc12 positives among ACs (44%) than among SCCs (25%). 
Among SCLCs a much larger fraction of tumours are bcl2 positive -65-90% in most 
studies (Benezra et al., 1994; Jiang et 01., 1995; Jiang et 01., 1996; Kaiser et 01; 1996; 
Tormanen et 01., 1995; Van et 01., 1996) and the lowest figure reported is 50% (Eerola 
et 01., 1997). Almost 100% of SCLC derived cell lines are bc12 positive (Ikegaki et 01., 
1994; Jiang et 01., 1996). 
In squamous cell carcinoma of the head and neck three groups have recorded bc12 
positivity of between 17-36% of tumours (Friedman et 01., 1997; Gallo et 01., 1996; 
Wilson et 01., 1996). One of these groups (Gallo et 01.) observed a suggestive 
association between tobacco exposure and bcl2 expression (p < 0.1). In oesophageal 
SCCs the bc12 oncogene is overexpressed by a large fraction of tumours - between 45-
60% in four large studies (Koide et 01., 1997; Ohbu et 01., 1997; Patel et al., 1997; 
Puglisi et 01., 1996). Interestingly 100010 ofbasaloid carcinomas of the oesophagus were 
bc12 positive (Koide et 01., 1997). Among skin neoplasms too, 100% of BCCs are bc12 
positive compared to only 10010 of SCCs (Moralesducret et 01., 1995; Verhaegh et 01., 
1995). 
In breast cancer, where the role of bcl2 has been examined minutely, several large 
studies have reported almost identical incidence figures (between 43-48%) (Hurlimann et 
aI., 1995; Joensuu et 01., 1994; Olopade et 01., 1997 ; Yamaguchi et al., 1997), with only 
two reporting higher figures (62% and 65%) (Barbareschi et al., 1996; Gasparini et 01., 
1995). In glandular carcinomas elsewhere, substantial numbers of tumours express this 
gene e.g. 48% of prostatic adenocarcinomas (Apakama et 01., 1996), 37% of colonic 
cancers (Watson et al., 1996), 18% of gastric cancers (Saegusa et al., 1995b) and 57% 
of ovarian cancers (Herod et 01., 1996). 
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Thus, it can be seen that bel2 is overexpressed in a substantial number of cancers at 
different sites of the body. In lung cancer its expression seems to vary with histological 
type being almost universal among SCLC tumours and cell lines, present in a third of 
SCCs and in 10% of ACs. A closer inspection of the pattern of bcl2 expression in 
various tumours will lead to some basic questions about the biology of NSCLCs. 
(a) Are bc12 positive non-small cell lung cancers of neuroendocrine origin? 
Just as the great majority of small cell lung cancers overexpress be12, they also 
commonly express various markers of neuroendocrine (NE) cells. Neuroendocrine (NE) 
cells are dispersed widely throughout the human body. Tumours arising from NE cells in 
different organs are histologically and cytologically diverse but share some common 
biochemical features which are used to identify these tumours. Some commonly used 
biochemical markers include L-dopa decarboxylase, neurone specific enolase and 
chromogranin. Such markers are present in more than 80% of SCLCs and in 10-30% of 
NSCLCs (Richardson and Johnson, 1993; Sundaresan et al., 1991). Thus in small cell 
lung cancers the expression NE markers seems to go hand in hand with bc12 expression. 
Furthermore, one study in lung cancer showed bel2 overexpression to be associated with 
more aggressive neuroendocrine cell types (Coppola et al., 1996) raising the possibility 
that bc12 might be a marker of neuroendocrine differentiation in these cells (Higashiyama 
et al., 1995). 
A similar intimate correlation between neuroendocrine differentiation and bel2 
expression has been reported in prostatic carcinoma as well (Segal et al., 1994). To 
investigate the situation among NSCLCs, Jiang et al. stained a series of lung cancer 
sections (SCC and AC) for both bc12 and NE markers. The majority of be12 positive 
SCCs expressed multiple NE markers. Furthermore, bcl2 positive cells could be roughly 
divided into those with neuroendocrine differentiation features which had intense bc12 
staining and others which showed weak to moderate Bc12 staining. Thus bel2 appears to 
be closely associated with the neuroendocrine differentiation of lung tumour cells in 
general irrespective of whether they are NSCLCs or SCLCs. Jiang et al. have proposed 
that bc12 could be used as a NE marker in lung cancers (Jiang et al., 1996). 
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The existence among NSCLCs of a separate group with NE features has been known 
for a long time and these tumours have been classified as NSCLC-NEs. These tumours 
are completely indistinguishable from their non-NE counterparts in every other aspect 
including histological appearance and their true identity may not be revealed until special 
tests are done. Jiang et al. were the first to demonstrate that bcl2 is commonly 
overexpressed by this group. If other investigators were to find a similarly strong 
correlation one may eventually have to agree with Jiang et al. that the bcl2 positive 
NSCLCs actually represent this separate biological entity. Since NSCLC-NEs are 
clinically known to behave in a distinct fashion it could explain the prognostic 
importance ofbc12 expression in non small cell lung cancer. This issue will be discussed 
again in Section 6.8. 
(b) Are basaloid lung cancers more frequently found among bcl2 positive NSCLCs? 
The other interesting feature to emerge from these statistics is that basal cell 
carcinomas (BCC) of the skin and oesophagus are almost universally bc12 positive. 
These slow growing tumours arise from the basal cells of the epithelium, hence the name. 
As mentioned before, normal basal epithelial cells express bcl2 (see Section 1.3.3.2) and 
it seems that they maintain this original phenotype even after neoplastic transfonnation. 
Such bcl2 overexpression may contribute, in part, to the indolent nature of these skin 
neoplasms. BCCs have been shown to have a very low proliferative rate. Their growth is 
mainly dependent upon a slow apoptotic rate caused by excessive Bc12. This type of 
neoplastic growth is possibly associated with less aggressive tumour behaviour. 
Bc12 positive NSCLCs too have been shown to be relatively indolent. Could it be that 
these tumours represent the pulmonary counterparts of cutaneous BCC? Recently a new 
morphologic and phenotypic entity called basaloid (basal cell) carcinoma of the lung has 
been described which is thought to arise from the basal bronchial epithelial stem cells. It 
can exist either in a pure form or equally often in association with SCC, AC or LC (large 
cell carcinoma) (BrambiUa et al., 1992). There needs to be a careful review of 
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histological sections of bc12 positive NSCLCs to determine if basaloid carcinoma is more 
commonly found in association with NSCLCs which express this oncogene. 
(c) At what stage of the cancerous process is bc12 first seen to be overexpressed? 
Whether or not bc12 positive lung tumours are eventually proved to be basaloid 
cancers, there seems little doubt that most NSCLCs arise from the basal pluripotent 
reserve cells which are capable of differentiating along multiple lines. One of the earliest 
changes that is noticed in pre-malignant epithelium in the lungs and elsewhere is a change 
in the topographical location of bc12 positive cells. From being confined to basal cells 
only in normal epithelium, bcl2 positive cells are found more and more frequently in the 
superticiallayers as the lesions become more dysplastic (see Section 1.3.3.2). It can be 
argued that these initial changes in the location of bc12 positive cells is an inevitable 
consequence of the structural disorganisation that accompanies dysplasia. Later, both the 
percentage of bc12 positive cells as well as the intensity of staining continues to increase 
until in the most severely dysplastic lesions the entire thickness of the epithelium is often 
seen to be positively stained. This cannot be explained merely by structural 
reorganization and genetic mechanisms must be invoked. Reduced p53 expression can 
upregulate bc12 in other tumours but in preneoplastic lung lesions, investigators have 
failed to find any correlation between the two (Walker et al., 1995) and therefore it is 
unlikely to be the mechanism involved in lung neoplasms. An event primarily affecting 
the bc12 gene is more likely. The nature of this molecular event is still unknown, but it is 
certainly not t(14:18) translocation. Whatever the cause of the overexpression bc12 may 
serve to protect the growing pre-malignant lesion against excessive apoptosis and allow 
it to acquire yet more genetic mutations. 
Oddly, during the step from severe dysplasia to frank malignancy in many tumours the 
expression ofbc12 seems to be downregulated. The best example of this was provided by 
Saegusa and coworkers who studied bcl2 expression in several grades of cervical 
intraepithelial neoplasia (CIN) and invasive squamous cell carcinoma (lSCC). Bc12 
imunoreactivity was seen in 37% of CIN grades I and II, 64% of CIN III and only 20% 
of ISCC (Saegusa et aI., 1995a). Nakamura too has recently reported a similar trend in 
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bel2 expression in both gastric and colonic pre-neoplastic lesions (Nakamura et al., 
1997). Even in B cell lymphomas bcl2 expression is frequently lost during transformation 
from low grade into high grade lymphomas (Sander et aI., 1993). The paper of Walker et 
al provide indirect evidence that a similar terminal downregulation of bel2 must take 
place in NSCLCs as well. In their series 48/56 dysplastic lung lesions (85%) strongly 
expressed bc12 which was much higher than 14/31 carcinomas (45%) that expressed 
bcl2. From a teleological standpoint, does this indicate that protection from apoptosis is 
no longer an important factor once the threshold between pre-neoplasia and neoplasia 
has been crossed? 
213 
6.6 Apoptosis and bcl2 
Bcl2 is an inhibitor of apoptosis and tumours that over-express bcl2 are expected to 
have a lower apoptotic rate. In our series of cases, however, this certainly was not the 
case, and if anything the opposite was true. High Bcl2 expression was associated with 
high apoptotic rate (p = 0.041, see Section 5.4.4). 
Eerola et al have described similar results in their study involving 40 SCLCs. In their 
series bcl2 positive tumours exhibited higher apoptotic indices more often than bc12 
negative tumours (p = 0.02). 
Tormanen et a/ found bcl2 positive NSCLCs to have a slightly lower apoptotic count 
but this was not statistically significant (p = 0.13). Several other investigators have found 
a complete lack of correlation between apoptosis and bcl2 in lung cancer (Hellquist et 
aI., 1997; Kargi et a/., 1997; Kennedy et a/., 1997; Oneill et a/., 1996). Only one group 
studying a subgroup of lung cancers with neuroendocrine (NE) features ob8elVed that 
bcl2 over expression, bax downregulation and particularly a bcl2lbax ratio of greater 
than 1 correlated with lower apoptotic indices (p < 0.05) (Brambilla et a/., 1996) 
In cancers at other sites 0012 overexpression is almost universally associated with a 
lower apoptotic rate. For example in breast cancer (Lipponen et ai., 1994; Frankfurt et 
a/., 1996; Sierra et a/., 1996) prostate cancer (Taniguchi et a/., 1996) colonic cancer 
(Baretton et a/., 1996) gastric cancer (Saegusa et a/., 1995b; Koshida et a/., 1997) a low 
apoptotic rate is always seen with 0012 overexpression. Diebold and co-workers 
examining 148 cases of ovarian cancer found no correlation between bcl2 and apoptosis 
(Diebold et aI., 1996). 
Thus while in cancers at almost all other sites bcl2 expression is seen to have its 
expected effect on the rate of apoptosis, lung cancer goes against theory and observation 
in all other cancers. This does need to be thought about carefully - the next paragraphs 
review possible explanations for what appears as a major anomaly. 
(a) Is the Bcl2 that is overexpressed in lung cancer cells biologically inert? 
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In the laboratory specific point mutations can be engineered in the bcl2 gene to render it 
biologically inert. Such mutations alter the BHl and BH2 regions of BCl2 protein and 
prevent it from binding to Bax, its antagonist (Yin et al., 1994; see also Section 1.3.2). 
The possibility of such mutations taking place spontaneously in lung tumours has not 
been excluded. Theoretically, a point mutation in the gene might help explain another 
enigma surrounding Bc12 expression. The molecular mechanism underlying bc12 
overexpression in non-lymphoid tumours is not known yet. The t(14: 18) translocation is 
not seen, neither is there any evidence of gene amplification (Reeve et al., 1996). Point 
mutations in other genes, for instance p53, are known to stabilise the protein and 
increase its half-life within the cell, in addition to rendering it ineffective. 
Although this theory is attractive, in vitro experiments seem to point against it. In 
SCLC cell lines Bc12 protein levels (measured by Western blot analysis) were found to 
correlate with the amount of apoptosis. Treatment with antisense oligodeoxynucleotides 
targeting the 0012 coding sequence caused a dose dependent reduction of Bc12 level and 
there was a parallel increase in apoptosis assessed morphologically (Ziegler et al., 1997). 
Therefore the Bc12 protein nonnaUy present in these lung cancer cells seem to be fully 
functional and critical for maintaining the viability of the cells in vitro. It is important to 
remember however that a necessity for Bc12 for tumour cell survival in vitro does not 
guarantee a requirement for 8Cl2 in vivo. 
(b) Is the protective effect ofBC12 negated by other factors? 
Even though the Bc12 molecule may be biologically active, its effects could still be 
overcome by its antagonists within the cell. NSCLC cell lines have been shown to 
express both anti-apoptotic proteins like Bcl2 and Bel-xL and death accelerator proteins 
such as Bax and Bcl-xS (Reeve et aI., 1996). As mentioned before, these proteins can 
dimerise with each other and cancel out each others effects (see Section 1.3.4). An 
excess of Bax would neutralise the anti-apoptotic effect of Bcl2 and make the cell more 
prone to apoptosis. The relative ratio of the death suppressors and death promoters 
rather than the absolute amount of an individual protein may be more predictive of 
cellular susceptibility to apoptosis. It is not surprising therefore that Brambilla et al in 
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their study involving 121 neuroendocrine (NE) lung tumours found a Bcl2IBax ratio> 1 
to correlate with a lower apoptotic index while most other studies investigating Bcl2 
alone found no such correlation. Recently Apolinario et al. have evaluated bcl2 and bax 
expression in histological sections of a series of 121 NSCLCs, but, unfortunately they 
did not quantify apoptosis (Apolinario et al., 1997). Further studies, perhaps including a 
larger panel of Bc12 family members, are imperative to unravel the way these proteins 
control apoptosis in cancer tissues in vivo. 
(c) Does apoptosis in lung tumours take place by Bcl2 independent pathways? 
Not all forms of apoptosis can be blocked by bc12. A notable example is the apoptosis 
caused by cytotoxic T lymphocytes (CTL) (Vaux et al., 1992). 
There is abundant evidence that lymphocytes play a central role in the host response to 
tumours. (For a review of the subject see Graubert and Ley, 1996). Lymphocytes kill 
target cells (including tumour cells) by inducing them to undergo apoptosis. The 
granzymes (gzmA and gzmB) are a family of neutral serine proteases that are critical for 
this process. Bc12 fails to prevent apoptosis in targets of such cell mediated killing. 
Lymphocytic infiltration is commonly observed in lung cancers as in other cancers and 
lymphocytes are also often seen in very close association with apoptotic cells. It may be 
that in vivo lymphocytes provide a major stimulus for apoptosis in lung cancers which is 
why this process appears to be independent of the amount ofBc12 expressed by the cells. 
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6.7 Bcl2 and clinico-pathological features 
In order to investigate the role of bcl2 expression in lung cancer progression we 
examined the clinieo-pathological features of bcl2 positive tumours to see if 
pathologically they represented a less aggressive group. Among our 134 patients we 
could discern no significant association between bcl2 expression and disease stage or 
lymph node metastasis (Section 5.4.6). There was a non-significant trend for poorly 
differentiated tumours to have higher bc12 indices (Section 5.4.7). The majority of other 
investigators in lung cancer have reported similar results i.e. they could find no 
correlation between bcl2 expression and tumour size (T), nodal status (N) or histological 
grade (Fontanini et al., 1995; Kargi et al., 1997; pezzella et 01., 1993; Tormanen et aI., 
1995; Van et al., 1996). Two groups reported more bcl2 positive cases in stages I and II 
than in the higher stages (Higashiyama et al., 1997; Ohsaki et al., 1996). 
We also investigated some of the non-traditional markers of disease progression against 
bcl2 expression (Section 5.4.7). In many tumours at other sites (see below) bc12 
overexpression has been found to be closely associated with a slower proliferation rate. 
In our series there was no association between bcl2 and proliferation rate as assessed by 
AgNOR. Other investigators who have used PCNA, Ki-67 and mitotic indices to assess 
proliferation rate in lung cancer, have also reported a lack of correlation (Fontanini et 01., 
1995; Kaiser et al., 1996; Oneill et al., 1996). One group found a significantly higher 
proliferation rate (assessed by Thymidine labelling) in the bcl2 positive lung tumours 
(Kennedy et al., 1997). 
There was a non-significant trend for higher bcl2 counts in aneuploid tumours in our 
series (p = 0.160, see Section 5.4.7». We could find no other study in lung cancer which 
had investigated these two parameters together. Joensuu et al., investigating breast 
cancer, found bcl2 to be strongly correlated with DNA diploidy (Joensuu et al., 1994). 
In the recent past, there has been considerable interest in the role of neoangiogenesis in 
tumour progression and metastasis. Two recent studies which have investigated this 
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parameter in NSCLCs found bcl2 not to influence the rate of new vessel formation in 
lung tumours (Apolinario et al., 1997; Pastorino et al., 1997). 
The association of bel2 with other oncogenes in lung cancer is another area of very 
active interest. Our findings about the correlation between bcl2 and CD40 are detailed in 
Section 5.4.3. Most other investigators, both in lung cancer and in cancers elsewhere 
have concentrated on the association between bcl2 and p53. Normally, p53 
downregulates the expression ofbcl2 and upregulates its antagonist bax. It thus alters the 
bcl2/bax ratio in the cell in favour of apoptosis (see Section 1.2.3.5 b). If this regulatory 
mechanism is maintained in cancerous tissues, one would expect to see an inverse 
correlation between the two oncogenes. 
This however is manifestly not the case in lung cancers as shown by the investigations 
of several groups who found no correlation between the two (Eerola et al., 12997; 
Kennedy et 01., 1997; Ohsaki et 01., 1996; Reeve et 01., 1996; Tonnanen et 01., 1995; 
Yan et al., 1996). As mentioned before even in pre-malignant lung lesions, bcl2 and p53 
are found not to be correlated. Thus in lung cancer cells the bcl2 gene seems to be 
independent of its normal regulatory control. In breast cancer, however, this is certainly 
not the case and investigators have invariably found an inverse correlation between bcl2 
and p53 (Barbareschi et 01., 1996; Gasparini et al., 1995; Hurlimann et al., 1995; 
Joensuu et 01., 1994; Olopade et 01., 1997; Silvestrini et al., 1994). In colonic carcinoma 
(Watson et 01., 1996; Kaklamanis et 01., 1996) and gastric cancer (Saegusa et al., 1995b) 
too the inverse correlation is maintained. 
In lung cancer the association between bc12 and chemoresistance is complex. Small cell 
lung cancers, although they are bcl2 positive, usually show a good response to 
chemotherapy whereas in NSCLCs the opposite is usually the case. Volm and Mattern 
found bc12 positive lung SCCs to be invariably resistant to doxorubicin in an in vitro test. 
In their series of 8S patients bc12 overexpression was strongly related to the resistance 
related proteins P-gly~protein and glutathione S-transferase (Volm and Mattern, 1995). 
Wu and EI-diery found no such correlation between bcl2 and chemoresistance in four 
lung cancer derived cell lines. However they found that induction of apoptosis correlated 
very strongly with chemosensitivity irrespective ofbcl2 and p53 status (WU and El-diery, 
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1996). Transfection of bc12 into the SCLC derived cell line SBC-3 increased its 
resistance to some chemotherapeutic agents but not to others (Ohmori et aI., 1993) 
indicating that there are bc12 independent pathways of apoptosis in lung cancer cells. 
Overall, bc12 status does not promise to be a good guide for predicting response to neo-
adjuvant chemotherapy in lung cancer. 
In breast cancer bc12 expression has been consistently demonstrated to be associated 
with favourable clinico-pathological factors. The majority of investigators have found 
bc12 to be associated with smaller tumour size (T) and lower stage (Barbareschi et aI., 
1996; Kobayashi et al., 1997; Sundblad et al., 1996; Olopade et al., 1997; Silvestrini et 
al., 1994 the sole exception being Joensuu et al who found no such correlation. In 
general bc12 does not seem to affect the lymph node status (N) (Kobayashi et al., 1997; 
Joensuu et al., 1994; Yamaguchi et al., 1997) although in one study bc12 positive breast 
tumours seemed to have a higher chance of lymph node disease (Sierra et al., 1996). 
Without exception bc12 has been found to be associated with better differentiated 
tumours, and with oestrogen receptor positivity prompting some authors to comment 
that bc12 may be a differentiation inducing factor in breast cancer cells. Because of all 
these favourable associations of bc12 in breast cancer it comes as no surprise that bcl2 
positive breast cancers should fare so much better than their bc12 negative counterparts 
(see Section 6.8). 
Contrariwise, in prostate cancer bc12 expression is associated with unfavourable clinico-
pathological parameters e.g. large tumour size (Bubendorf et al., 1996), poor 
differentiation (Stattin et al., 1996) and androgen independent phenotype (McDonnell et 
al., 1992). Bc12 positive prostatic cancers have been found to respond poorly to 
hormone therapy (Apakama et al., 1996; Taniguchi et al., 1996) which is understandable 
since hormone ablation supposedly acts by causing apoptosis, something which is less 
likely to happen if there is plenty of bcl2 protein within the cell. Strangely, however, in 
breast cancer radiotherapy, chemotherapy and anti-hormone therapy (Tamoxifen) all 
three of which are known to act by causing apoptosis, are invariably more effective in 
bc12 positive tumours (Elledge etal., 1997; Gee el al., 1994; Willsher el al., 1996). 
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In summary , it can be said that for the three cancers we have examined here - lung, 
breast and prostate - bc12 expression is not correlated with clinico-pathological features 
(lung)~ correlated with favourable features (breast)~ and with adverse features (prostate). 
In the next section the correlation ofbcl2 with survival will be reviewed in the light of its 
associations (positive or negative) with apoptosis and clinico-pathological features. 
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6.8 Bel2 and survival 
Bcl2 overexpression, by preventing apoptotic cell death, is expected to lead to a rapid 
increase in tumour size and therefore a worse prognosis. In practice the opposite is often 
found to take place in lung cancers. In our study patients were followed up for 10 years 
following resection of their lung tumours. Those who were bcl2 positive lived longer 
than those who were bc12 negative (p = 0.013, see Section 5.4.5). Similar results have 
been reported in a number of other cancers, and this apparent paradox needs explanation. 
Pezzella et 01. were the first to report the beneficial effect of bcl2 expression in lung 
cancers (pezzella et 01., 1993). In their 122 cases ofNSCLC taken together, they found 
no correlation between bc12 and survival. But when the 80 SCCs were considered 
separately, the bcl2 positive tumours were found to gave a better chance of survival over 
a five year period (p < 0.05). In this group bc12 proved a better predictor of prognosis 
than the N-status of a tumOUT. 
Better prognosis for bc12 positive SCCs has also been reported by two other groups 
(Ritter et 01., 1995; Volm and Mattern, 1995). Other investigators have found bcl2 
expression to have a beneficial effect in all NSCLCs irrespective of the histological 
subtype (Apolinario et al., 1997; Fontanini et al., 1995; Ohsaki et aI., 1996; Pastorino et 
aI., 1997). In SCLCs as well, Kaiser and coworkers have reported a trend towards 
longer survival in bc12 positive tumours (Kaiser et 01., 1996). Two groups have reported 
a lack of correlation in lung cancer (Oneill et al., 1996; Tormanen et al., 1995). 
The effect ofbc12 expression has been studied in many other cancers. In breast cancer 
the advantage of bc12 expression was first demonstrated by Silvestrini et al. and 
subsequently corroborated by several others (Silvestrini et 01., 1994; Elledge et al., 1997; 
Hurlimann et 01., 1995; Joensuu et al., 1994; Kobayashi et 01., 1997; Lipponen et al., 
1995; Yamaguchi et 01., 1997). Other tumours which show a similar positive correlation 
include ovarian cancer (Diebold et 01., 1996; Herod et al., 1996; Marx et 01., 1997) and 
colonic cancer (Baretton et 01., 1996; Other et ai, 1995). However in colonic cancer 
some investigators have found no correlation between bcl2 and survival (Pereira et al., 
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1997; Schneider et aI., 1997; Scott et al., 1996). Squamous cell carcinomas of the 
oesophagus seem to progress independently of bcl2 expression (Koide et aI., 1997; 
Puglisi et aI., 1996) but SCCs of the head and neck fare worse if they are bcl2 positive 
(Friedman et al., 1997). 
In prostate cancer bc12 positive tumours have been found to have a worse prognosis 
(Bauer et al., 1996; Bubendorf et al., 1996). Similarly in leukaemias and lymphomas bc12 
positive cases usually have a shorter survival. 
If we integrate the observations in this section with that in the previous two (Sections 
6.6 and 6.7) it will be clear that the effect of bc12 expression on apoptosis and clinico-
pathological status is highly variable among tumours. As an example the observations in 
three common tumours are summarised in Table 6.1. 
Table 6.1 
Cancer 
Breast 
Prostate 
Lung 
Correlation of bcll expression with apoptosis and clinico-
pathological parameten in three common tumours. 
Increased bd2 expression is associated with 
Apoptosis Differentiation Size (T) Survival 
decreased better smaller better 
decreased worse larger worse 
no association no association no association better 
In bc12 positive breast cancer, survival is prolonged and this could be because these 
tumours are better differentiated and of smaller size. A lower rate of apoptosis in these 
tumours does not seem to off-set the advantage conferred by the other two factors. Bc12 
positive prostate cancers on the other hand are larger, less well differentiated and show 
less apoptosis and not surprisingly they die earlier. In the great majority of cases of non-
small cell lung cancer, bc12 expression is associated with prolonged survival. Why this 
should happen is not clear but some possible reasons will be discussed below. 
When Pezzella et al. first reported in 1993 that bel2 positive lung cancers survive 
longer, they ascribed the beneficial effects to the ability of bcl2 to prevent apoptosis. 
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Because bcl2 positive tumours were expected to have a slower apoptotic rate, they 
would be able to survive and grow even if the rate of cell division were low. A low 
mitotic rate would lead to a slower rate of acquisition of additional genetic defects as 
suggested by McDonnnell et al. from observations in transgenic mice (McDonnell et al., 
1989). Less genetic defects would make for a more indolent phenotype and therefore 
longer survival. To prove their point Pezzella et al cited the example of follicular 
lymphomas where bc12 expression is a frequent primary aberration. These tumours have 
a slow apoptotic rate, a low mitotic rate and an excellent prognosis presumably because 
they acquire fewer additional mutations (Vaux et ai, 1988). 
For a time this seemed a very plausible explanation until two of the basic assumptions 
made by Pezzella were proved to be wrong by subsequent investigations. Bcl2 positive 
lung tumours neither have a slow apoptotic rate, nor do they have a lower rate of cell 
proliferation. Although in other tumours bc12 expression does reduce the rate of 
apoptosis, in lung cancer this is not found to happen. The reasons for this are explained 
in Section 6.6. Also, be12 positive tumours proliferate just as rapidly as their bel2 
negative counterparts and therefore they should have just the same risk of acquiring 
additional genetic defects. In practice the vast majority of bc12 positive tumours do not 
show any pathological indication (i.e. T and N stage) of being more indolent yet they 
survive longer. 
Soon afterwards, in 1994, Pietenpol et al. reported some unexpected experimental 
observations which could explain the prognostic effects ofbcl2. They demonstrated that 
in vitro bc12 overexpression could suppress the growth of several solid tumour cell lines 
including a lung adenocarcinoma cell line HI299. This was surprising because bc12 had 
been shown previously to stimulate the growth of other cell types under circumstances 
otherwise leading to apoptosis. Pietenpolt s observation seemed to indicate that in certain 
tissues bc12 may act as a tumour suppressor gene (pietenpol et al., 1994). It is not 
unusual for oncogenes and growth factors to have widely disparate effects on different 
cell types depending on lineage and stage of differentiation. For instance introduction of 
ras genes or proteins into certain cell lines induces differentiation rather than 
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proliferation and in some cases this is accompanied by growth arrest (Nakagawa et al., 
1987). Expression of fos has been shown to induce growth arrest in tumour derived cell 
lines (Garrido et al., 1993). 
However, effects observed in vitro are not always paralleled by in vivo observations. 
Breast cancers overexpressing bel2 are usually smaller in size which is what one would 
expect following Pietenpol's experiments. In lung cancer, though, most groups have 
found no correlation between tumour size (T) andbcl2 status. 
For an explanation it may be necessary to look beyond bcl2' s role in tumour growth 
rate and focus on some other putative aspect of its biology. As noted in Section 6.7, bel2 
is associated in some cancers with differentiation status of the tumour, and in 1995 
Hockenberry had postulated that the bcl2 gene may also have a role in cell differentiation 
(Hockenberry, 1995). During their life span immature cells pass through sequential 
transitions to a differentiated state and eventually undergo cell death and in parallel with 
this, bel2 expression usually decreases as cells become more differentiated. In in vitro 
experiments, when cell lines derived from myeloid precursors are induced to differentiate 
with a variety of agents (retinoic acid, phorbol ester, interleukin-6) the expression ofbel2 
is observed to be concomitantly down regulated (Benito et al., 1995; Nagy et al., 1996). 
The question arises - is this down regulation a cause or a consequence of cell 
differentiation? In HL-6O cells, Blagosklonny et al., have shown that the actual loss of 
Bcl2 protein is not required for the accomplishment of the differentiation programme and 
the terminal loss of be12 expression is just one of the many changes that take place in 
differentiating cells (Blagosklonny et al., 1996). In epithelial cells however the situation 
may be slightly different. Transfection of bel2 into primary human keratinocyte derived 
cell lines not only prevents apoptosis but also blocks further differentiation leading one 
to conclude that bcI2 influences epidermal differentiation in addition to blocking 
apoptosis (Nataraj et al., 1994; Martbinuss et al., 1995). In neural differentiation be12 
expression increases as cells become more differentiated (mature nerve cells are 
irreplaceable and cannot be allowed to die). If the over-expression of bel2 in immature 
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cells is blocked by anti-sense oligonucleotides no further differentiation occurs (Zhang et 
aI., 1996). 
In breast cancer bcl2 positive tumours are invariably well differentiated and oestrogen 
receptor positive, suggesting that bc12 may indeed be related to tumour differentiation at 
this site (although in a manner opposite to that in keratinocytes and more akin to neural 
cells). However in non-small cell lung cancer there is no correlation between bcl2 and 
histological differentiation (see Section 5.4.7). 
It may be that in lung cancer the bc12 gene induces cells to differentiate along particular 
histological lines. The possibility of NE tumours and basaloid lung cancer has already 
been discussed (see Section 6.5). Initial small studies have shown a strong correlation 
between bcl2 overexpression and NE differentiation of lung cancers. The NSCLC-NEs 
represent a relatively benign group of tumours which are more likely to respond to 
chemotherapy (Linnoila et aI., 1989). However long term studies have shown that 
despite a better initial response the patients did not live a longer period of time 
(Sunderesan et al., 1991). Similarly the basaloid hypothesis even if proved to be true 
may not explain the prognostic advantage of bc12. Basaloid lung cancers, unlike their 
skin counterpart, run an aggressive course leading to a poor prognosis. The median 
survival rate is only 22 months for Stage I and II disease (Brambilla et aI., 1992). 
For an explanation many have turned to bc12's inverse correlation with p53. Mutation 
of this tumour suppressor gene leads to loss of function and also to overexpression of 
the protein product due to an increase in its half life. Mutation of pS3 occurs in about 
60010 of human malignancies and very commonly leads to poor prognosis. The mutant 
pS3 protein is still able to downregulate bc12 expression and therefore maintains some 
aspects of its normal physiology. (Haldar et al., 1994) An inverse correlation between 
bcl2 and p53 is therefore a very common observation in many malignancies. 
It has been argued that the sole reason that bcl2 positive tumours fare better is because 
they are associated with normal p53 function. Again this may be true in some cases but 
not in the case of NSCLC where the normal physiological control mechanisms between 
bc12 andp53 seems to be disrupted from a very early stage in tumourigenesis. Walker et 
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al found bel2 expression in dysplastic lung lesions to be independent of p53 expression 
(Walker et aI., 1995). In lung cancer cell lines Reeve et al could find no correlation 
between the two proteins (Reeve et aI., 1996). In keeping with these observations, the 
vast majority of studies involving lung cancer sections have found no correlation 
between bc12 and p53. 
Having thus exhausted the more likely explanations it may now be necessary to look for 
possible associations of bc12 against a wider array of pathological markers e.g. new 
vessel formation, matrix metalloproteinase synthesis etc. Several oncogenes have been 
shown to have initially unexpected biological effects in tissues. Such investigations might 
prove valuable for two reasons. Firstly, by placing it on a firm theoretical footing it 
would strengthen the case for routinely using bc12 status as a prognostic indicator in 
NSCLC. Secondly, the results of such investigations might provide new insight into the 
pathological and molecular mechanisms of lung cancer and thus indicate new ways of 
tackling it. 
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6.9 CD40 expression in squamous cell cancer of the lung 
A major part of our investigations involved a systematic analysis of the pathological and 
biological associations of CD40 expression in squamous cell carcinoma of lung (see 
Section 1.4). In our series 22% of the SCCs were CD40 positive (i.e. more than 50% of 
the tumour cells stained positively). 41 % of the SCCs expressed CD40 in at least some 
of their cells (Section 5.4.2). 3 of the 6 adenocarcinomas in our series of fresh lung 
tumours were CD40 positive (see Section 5.5.2.6). 
On a ten year follow up, there was no difference in survival between the CD40 positive 
and CD40 negative groups, even when differences in stage, grade, proliferative rate and 
ploidy were corrected for. 
On analysis of the pathological markers, CD40 expression did not correlate with 
tumour stage, lymph node metastasis, histological grade or proliferative index as 
assessed by AgNOR There was a significant correlation between tumour ploidy and 
CD40 status. Diploid tumours had bigher CD40 indices compared to aneuploid tumours 
(p = 0.029). 
In an extensive survey of literature we could find only one other study attempting to 
correlate CD40 expression with clinico-pathological features of cancer. Vandenoord et 
al analysed the role of CD40 as a prognostic marker in 71 cases of malignant melanoma 
(MM). They found CD40 to be a bad prognostic factor in this skin neoplasm 
(Vandenoord et al., 1996). Like many other cancers, MMs are known to progress step-
wise through various pathological stages i.e. melanocytic naews, dysplastic naews, 
radial growth phase (RGP), vertical growth phase (VGP) and finally metastatic 
melanoma. 
In their series Vandenoord et al. found CD40 to be expressed in a larger fraction of the 
VGP melanomas than in the RGP melanomas. Patients expressing CD40 in the vertical 
growth phase of their melanomas did not differ significantly from CD40 negative patients 
with respect to any of the known prognostic parameters but showed a significantly 
shorter tumour free survival. In about a third of the VGP tumours, CD40-L was seen in 
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the same tumour areas that expressed CD40. Patients with CD40(+)/CD40-L(+) 
malignant melanomas tended to have a shorter tumour free survival than those lacking 
CD40-L. These findings suggest that the CD40/CD40-L autocrine growth loop is an 
important disease modifying factor in the vertical growth phase of MM. 
A significant shortcoming of our investigations was the lack of information about 
CD40-L expression among the lymphocytes that were frequently seen to infiltrate the 
tumour areas. This limitation makes it difficult to interpret the results of some of the 
analyses that we undertook i.e the effect of CD40 on apoptosis and the inter-relation of 
CD40 and bcl2 expression. 
In our series there was no correlation between CD40 expression and the apoptotic 
index of a tumour (Section 5.4.8) but this result must be interpreted with caution. One 
cannot be certain if the C040 that is seen to be expressed on the cell surface is likely to 
have been activated by the presence of CD40-L bearing cells in the vicinity. Ideally one 
would have to stain for both CD40 and CD4O-L and compare the apoptotic indices of 
CD40(+)/CD40-L(+) tumours with that ofCD40(-)/CD40-L(-) and CD40(+)/CD40-L(-) 
tumours. Even on theoretical grounds it is difficult to predict the outcome of such an 
analysis as the in vitro evidence is scarce and conflicting. CD40 activation has been seen 
to variously promote and prevent apoptosis in normal and transformed epithelial cells 
(see Section 1.4.4.3). The situation is uncertain and it may be that C040 has different 
effects on different types of epithelium. Such uncertainty makes it all the more imperative 
to conduct detailed analyses. 
Uncertainty also surrounds the relationship between CD40 and the bcl2 family of genes. 
In situations where it prevents apoptosis (e.g. in B cells) activation of C040 has been 
seen to upregulate the expression of either Bc12 or Bel-XL depending on the cell line that 
is being investigated (see Section 1.4.5.3). Regarding epithelial cell lines, we could find 
no information in the literature about the relation between CD40 and the bc12 family. 
Our investigations indicate a trend towards inverse correlation between CD40 and bcl2 
expression in squamous cell carcinoma of lung (see Section 5.4.3). The implications of 
this inverse correlation are not immediately clear. Lack of information about CD40-L 
expression is a major handicap to meaningful interpretation of the results. The mean 
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apoptotic index of the CD40( + )lBc12( -) group was lower than the mean AI of the 
CD40(+)lBcl2(+) group but this difference was not statistically significant. Neither was 
there any significant difference between the AIs of the other groups created according to 
their Bc12 and CD40 status (see Section 5.4.12). The immediate impression is that the 
co-expression of these two oncogenes does not seem to significantly alter the course of 
apoptosis in squamous cell carcinoma of lung. Neither does it influence any other 
pathological marker e.g. stage, grade, lymph node status, ploidy or differentiation. When 
survival time was investigated Bc12( + )/CD40( -) patients survived the longest (66.9 
months) compared to BC12(-) ICD40(-) patients (29.7months). There was no difference 
between CD4O( + )/Bcl2( -) and CD4O( + )lBcI2( +) as regards survival. 
From these initial observations it does not seem likely that CD40 will emerge as an 
important prognostic indicator in SCC even when it is considered in conjunction with 
Bcl2 expression. Concomitant examination of the expression of CD40-L may reveal 
significant pathological and clinical associations. Further investigations are necessary. 
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6.10 Measurement of apoptosis in cultured tumour cells 
There have always been doubts about the rationality of measuring a dynamic process 
like apoptosis in a static system like a histological section. No matter how refined the 
staining technique employed, from a section one can never properly estimate the duration 
of apoptosis which is one of the key determinants of tissue turnover kinetics. This is an 
important lapse as, both the speed of formation of apoptotic bodies and the speed of 
phagocytosis are known to vary widely from tissue to tissue, and small variations can 
result in large overall differences in apoptotic index. 
Tormanen et al. in their investigations attempted to estimate the duration of apoptosis 
in tumour tissues on the basis of the relative occurrence of various types of apoptotic 
bodies thought to represent the various stages of apoptosis (Tormanen et al., 1995). In 
their study, the ratio between apoptotic cells and bodies in lung carcinoma was roughly 
1 :2, whereas in control lung tissue it was 1: 1. This was taken to indicate a higher 
turnover rate of apoptosis in tumours when compared to non-neoplastic tissues. 
However, the correction they suggested in the calculations can at best result in a crude 
estimate of the rate of apoptosis. 
By definition apoptotic rate is the rate of change of apoptosis with time. To calculate 
such a rate one would need two estimations of apoptosis separated by a measured 
interval of time. Obviously a histological section would be singularly inadequate for this 
purpose. A suspension of live cells obtained from fresh disaggregated tumour tissue 
would be needed from which samples could be drawn at intervals. The rate of rise of the 
fraction of apoptotic cells from one sample to the next would theoretically give the exact 
rate of apoptosis. This is the principle on which we based a series of experiments 
conducted on pleural effusions and fresh lung tumours (see Section 4.2). The aim of our 
experiments was to investigate if the apoptotic rate of a tumour calculated in this fashion 
correlated with the apoptotic index obtained from the corresponding histological section. 
Before considering this question, let us first examine the validity of the results obtained 
from the cell suspensions. There are several sources of error which we have not been 
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able to eliminate completely from our calculations. One main worry IS that 
mechanical/enzymatic disaggregation to which the tumours were subjected could 
probably cause apoptosis or morphological changes resembling apoptosis and thus 
potentially distort the results to a significant degree. To avoid this source of distortion 
we initially conducted our experiments on pleural effusions. Here the malignant cells are 
already in suspension and there would be no need for disaggregation of any kind. 
Previously, in our laboratory, similar experiments have been done on leukaemia cells 
(Chant et al., 1996). The pleural effusions would serve as an intennediate step between 
leukaemia and solid cancers (i.e. lung cancer). Unfortunately the experiments on pleural 
effusions proved to be unsuccessful for other reasons (see Section 5.5.1). 
To eliminate this source of error from the results obtained from fresh lung tumours we 
adopted a subtractive approach as outlined in Section 5.5.2.1. The rationale behind this 
approach is that disaggregation might distort Ao(DayO) but would leave Ao(Dayt) 
unaffected. Subtracting DayO from Dayt would eliminate this error and give a true 
picture of the amount of apoptosis taking place in vitro in 24 hours. But a small source 
of error would probably still remain. Before estimating apoptosis on Day 1 adherent cells 
were removed from the culture flasks by treating with Trypsin for 5 minutes. This is as 
likely to cause artefactual apoptosis as treatment with other enzymes (e.g. hyaluronidase, 
collagenase) which were used for disaggregation. Thus, Ao(Dayt) is probably prone to 
the same distortions as Ao(DayO) but to a lesser degree. 
Ideally one would want to separate the viable cells from the apoptotic cells immediately 
after disaggregation so that the starting cultures had no apoptotic cells at all. This way 
one would ensure that the apoptosis observed at 24 hours was genuinely the result of 
apoptosis in vitro. The technicalities of implementing such a cell separation are still being 
worked out in our laboratory. 
Bearing in mind such reservations, if one were to embark on a comparison between the 
apoptotic rate and the apoptotic index obtained from histological sections, the first 
striking feature is that apoptosis in cultured cells is much higher than apoptosis in 
histological sections however measured. This is not totally unexpected because the 
cultured cells are deprived of several survival signals which are normally present in vivo. 
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Close contact with neighbouring cells and the extracellular matrix (ECM) is known to 
send strong anti-apoptotic signals via surface integrin receptors (Section 1.2.3.2). 
Paracrine and endocrine growth factors are also known to play an important role. The 
cells in culture are deprived of such survival signals and therefore undergo apoptosis at a 
much faster rate. Freed of many of the usual outside influences, this could be thought to 
represent an "intrinsic" apoptotic rate which is at least useful in comparing between 
tumours. One may argue that the circumstances under which this "intrinsic" rate is being 
obtained are so far removed from reality as to be of no practical relevance whatsoever. It 
is certainly true that the situation in the tumour nodules in vivo does not resemble that in 
the culture flasks and hence the total lack of correlation between the AIs obtained from 
histological sections and those obtained from cell culture. However, even in vivo, there 
are situations when the tumour cells are free of the influence of close contact with other 
cells or ECM e.g. metastatic cells in the blood circulation. Such cells are likely to have 
high apoptotic rates comparable to that seen in culture flasks. 
Thus the cultured cells might tell us of the state of affairs prevailing during a very 
important phase of the tumours natural history (i.e. metastasis) which often determines 
clinical outcome. It is possible, therefore, that the apoptotic rate obtained from the 
cultured cells might give a somewhat better indication of prognosis than AI obtained 
from sections. The latter as we have seen is of very limited prognostic value in most 
cancers and is of almost no value in lung cancer. Thus, it would be extremely useful to 
calculate the apoptotic rates from fresh specimens of a larger number of patients of lung 
cancer who should be followed up prospectively to monitor disease outcome. 
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6.11 Concluding remarks 
Several facts emerge from our investigations. Apoptotic index obtained from 
histological sections is of very little prognostic value in most cancers including lung 
cancer. And yet one intuitively feels that apoptosis - which does seem to vary widely 
from tumour to tumour - must have some influence on the outcome of cancer. Are we 
measuring apoptosis properly? In our cell culture experiments (discussed in Section 
6.10) we have tried to formulate an alternative way of measuring apoptotic rate which 
we believe is more realistic and therefore more likely to correlate with clinical outcome. 
Of course the method we employed is cumbersome and requires fresh tissue as its raw 
material which is a distinct disadvantage. Also, some procedural refinements are 
necessary. For instance it might be a better idea to measure apoptosis at intervals of 8 
hours or 16 hours rather than 24 hours, to prevent secondary necrosis of apoptotic cells. 
Whether apoptosis measured in this fashion correlates with clinical outcome remains to 
be seen from prospective studies which would logically be the next step in the 
investigations. It is possible that it might still not emerge as a relevant factor - and 
thereby confirm the suspicion that apoptosis is not of very great import in an established 
tumour although it is almost certainly important during carcinogenesis. 
A great deal more needs to be learnt about the genes controlling apoptosis. For 
instance, bc12 probably regulates epithelial cell differentiation in addition to blocking 
apoptosis (see Section 6.8). It may influence other physiological processes as well 
depending on cell lineage. The effect on one process (e.g. differentiation) may confound 
the effect on another (e.g. apoptosis) and hence the unexpected (in our present state of 
knowledge) observation that bc12 prolongs survival in lung cancer. 
Knowledge about CD40 in lung cancer is truly very, very limited. Our investigations 
have shown that a substantial fraction of lung cancers express this surface molecule but 
this does not seem to influence matters (apoptosis, clinico-patbological parameters or 
survival) to any appreciable degree. The question of co-operation between bcl2 and 
CD40 still remains unresolved. 
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Thus, at the end of our investigations, we have answered some questions but many 
more new ones have emerged. This confirms the old adage that the more we know, the 
more we discover that we don't know. 
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APPENDICES 
APPENDIX A 
WHO II Lung Cancer Classification of 1982 
I. Epithelial Tumours 
A. Benign 
I. Papillomas 
2. Adenomas 
B. Dysplasia! carcinoma in situ 
C. Malignant 
1. SqumnousceUcMcino~ 
a. Spindl&-eell variant 
2. Small cell carcinoma 
b. Oat cell carcinoma 
c. Intermediate cell type 
d. Combined oat cell cMcinoma 
3. AdenOCMcinoma 
c. AcinM 
d. Papillary 
e. BronchioloalveolM 
f. Solid carcinoma with mucin formation 
4. Large cell carcinoma 
d. Giant cell carcino~ 
e. Clear cell carcinoma 
2. Adenosquamous carcinoma 
3. Carcinoid tumour 
4. Bronchial gland carcinoma 
5. Others 
II. Soft Tissue Tumours 
III. Mesothelial Tumours 
A. Benign 
B. Malignant 
I. Miscellaneous Tumours 
D. Benign 
E. Malignant 
I. Secondary Tumours 
II. Unclassified Tumours 
III. Tumour-like lesions. 
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APPENDIXB 
TNM classification of lung cancer 
PRIMARY TUMOUR (T) 
TO No evidence of primary tumour 
TX Tumour proven by the presence of malignant cells in bronchopulmonary secretions 
but not visualised roentgenographically or bronchoscopically, or any tumour that 
cannot be assessed as in a retreatment staging. 
TIS Carcinoma in situ 
TI A tumour that is 3.0 cm or less in greatest dimension surrounded by lung or 
visceral pleura, and without evidence of invasion proximal to a lobar bronchus at 
bronchoscopy. 
T2 A tumour more than 3.0 cm in greatest dimension, or a tumour of any size that 
either invades the visceral pleura or has associated atelectasis or obstructive 
pneumonitis extending to the hilar region. At bronchoscopy the proximal extent 
of demonstrable tumour must be within a lobar bronchus or at least 2.0 em distal 
to the carina. Any associated atelectasis or obstructive pneumonitis must involve 
less than an entire lung. 
T3 A tumour of any size with direct extension into the chest wall (including superior 
sulcus tumours), diaphragm, or the mediastinal pleura or pericardium without 
involving the heart, great vessels, trachea, oesophagus or vertebral body, or a 
tumour in the main bronchus within 2.0 cm of the carina without involving the 
carina. 
T 4 A tumour of any size with invasion of the mediastinum or involving heart, great 
vessels, trachea, oesophagus, vertebral body or carina or presence of malignant 
pleural effusion 
NODAL INVOLVEMENT (N) 
NO no demonstrable metastasis to regionallympb nodes. 
NI Metastasis to lymph nodes in the peribronchial or the ipsilateral hUar region, or 
both, including direct extension. 
N2 Metastasis to ipsilateral mediastinal lymph nodes and subcarinal lymph nodes 
N3 Metastasis to contralateral mediastinal lymph nodes, contralateral hilar lymph 
nodes, ipsilateral or contralateral scalene or supraclavicular lymph nodes 
DISTANT METASTASIS (M) 
MO No (known) distant metastasis 
Ml Distant metastasis present-specify site(s) 
SUMMARY OF STAGING 
Stage 0 
Stage I 
Stage IT 
Stageilla 
Stage illb 
Stage IV 
TIS 
Tl 
T2 
Tl 
T2 
T3 
T3 
Tl-3 
anyT 
T4 
anyT 
NO 
NO 
Nl 
Nl 
NO 
Nl 
N2 
N3 
anyN 
anyN 
MO 
MO 
MO 
MO 
MO 
MO 
MO 
MO 
MO 
Ml 
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APPENDIXC 
Table describing the apoptotic index, Bel2 index, CD40 index and other clinico-
pathological parameten of the archival series of squamous lung cancen that were 
investigated in this project. 
c-No Aft Sell A.L Bd2 CD40 8Cue G .... e A_NOR PIoWy SantY .. 
110 69 M 33.1 0 0 D · · · 7· 
239 so M 37.4 1&.7 0 I P 14.9 A 21 
631 56 M 39.7 100 0 D M 9.3 A 93· 
6&1 49 F 65.7 100 0 I P 7.9 A 6 
733 70 M 39.1 0 0 I M 13.4 A 1641 
833 
" 
M '-1 0 0 111 M 13.9 
· 
7 
1026 52 M 73 0 65.5 Wa P 24.0 · Id 
1314 5& M 29.7 65.7 0 I M 10.7 0 33 
1422 60 M 108.7 89.6 100 m. M 15.1 A 3 
1602 6& M 12.1 0 0 n p 12.1 0 19 
1603 58 M 23.4 3.6 0 UIb P 14.9 A 16 
16" 65 F 5.1 0 0 D M 9.7 0 12 
1708 72 M 34.2 66.9 0 nib · · · 7 
178& 57 F 65.3 12.2 9.5 U · · · 5 
1811 54 M 107.2 16.3 100 n M 12.6 0 IS 
180& 67 M 87.7 100 100 I · · · 77 
1869 63 M 4&.9 0 1.2 I M 10.9 A 17 
1967 60 M 14!1.7 0 0 UIb · · · 17 
2004 62 M 24.7 20.1 0 U P 22.2 A 29 
2016 63 M 20.8 0 26.S I W 11.6 0 29 
21" 53 M 14.4 0 &S.l Ulb M · 0 9 
2164 52 M 56.8 0 8S.1 I M 7.S A 120 
2208 57 M 30.& 0 0 IIlb W 9.7 0 135 
2272 68 M 77 0 8.8 1 M 9.9 0 7 
2362 66 F 16.5 16.2 7.6 I P 7.9 A 16 
236& 65 M 11.8 94.0 100 D M 10.4 0 10 
2396 62 M 21.& 0 100 1 W 13.3 0 IS 
2434 63 M 17.3 90.1 0 I M 11.1 · 118-
2578 5& M 11.7 0 0 I M 9.7 A 32 
2911 57 M 18.5 as.8 0 n M 9.7 A 25 
3065 66 M 11.6 0 13.3 U M · 0 32 
309& 71 M 4&.5 0 0 1 M 14.6 A 29· 
3127 53 M 90.& 0 0 n p 10.3 A 4d 
3160 72 M 10.5 2.0 4.1 I M 6.8 · 5 
3176 57 M 19.0 0 ~ n w 7.1 0 133 
3434 57 M 19.3 74.6 0 IDa . · · 72 
347& 62 M 8&.4 100 0 IDa M · 0 2 
3517 40 M 27.4 &&.3 0 I P 13.4 0 4 
3686 64 M 16.6 100 75.3 n p 19.4 · 12& 
3688 69 M 13.7 0 0 I P 13.7 A Id 
3709 66 M 14.4 0 0 IDa M 11.0 A 1 .. 
3737 63 M 49.9 0 2.1 Illb M 13.1 A 8 
3744 50 F 46.5 0 100 I M 5.9 0 10 
3896 65 M 49.2 0 100 I11b W 9.9 A 5 
3884 48 M 4&.7 100 12.1 IDa M 11.0 0 15 
3932 66 M . . . U M 4.6 0 17 
3996 50 M 49 72.7 0 I P 16.6 0 132 
4141 
" 
M 22.4 75.2 6.2 n p 11.4 A 125 
4152 61 F 9.2 100 69.2 I M 7.3 A 72 
4158 70 M 12.0 0 0 U M 12.2 A 23 
4196 56 M 52.9 100 88.7 n p 20.9 A 5 
4317 64 M 27.6 10.7 79.1 II P · 0 43 
4359 67 M &4 0 16.4 nla p 20.5 1511 
4428 69 M 36.7.0 1.4 88.1 IDa P 11.9 A td 
239 
Cae No Aae Sex A.L Bd2 CD40 SCue Gnde AIINOR PIoIdv hniv .. 
4599 64 M 22.4 96.7 0 I P 13.1 A ~ 
4420 54 M 6.4 8U 8.5 II M - D 7 
4728 66 M 48.9 100 0 II M 6.3 A 46 
4784 61 M n.8 85.8 0 lila v.' 10.3 A 65 
4790 71 M 12 29.2 0 II P 17.2 D 14 
48S1 57 M 52.4 0 0 lila W 5.9 D 10 
4852 53 F 10.1 0 0 I - - A 131 
5048 59 M 16.9 0 100 n M 11.2 A 29 
5057 66 M 31.7 85.2 18.6 I M 15.9 A 122 
5126 64 M 34.1 20.3 0 I - - - 25· 
5174 62 M 14.9 0 0 11 M IB A 15* 
5265 62 M 6.5 100 0 I W 15.0 D 129 
5327 54 M 14.7 0 0 D M 9.0 A 10 
5461 69 M 10.6 0 0 Ill. W 13.7 A 24 
5521 65 F 8.6 0 100 U P 8.4 A 22 
5672 69 M - - - 1 M 13.0 D 110 
5607 71 M 20.8 19.2 33.3 I M 6.4 A 52· 
5620 67 M 22 0 0 II P 10.5 A 9 
5665 65 M 24 52.9 0 I M 5.9 A 129 
5984 65 M 18.3 25.8 59 n M IB.4 D 6 
5986 66 M 60.2 16.8 0 I - · · 33 
6057 51 M 31 92.6 0 1 M 9.8 A 54 
6180 65 M 52.6 0 0 I · · - 79* 
6279 55 M 4.9 0 94.6 I · · · 129 
6309 60 M 3.1 3.4 36.8 lila M 10.8 D 17 
6318 59 M 4.2 10.5 0 U P 9.2 D 13* 
6372 68 M 7.5 5.2 0 D · · · 13 
6486 60 M 47.5 98 0 I P 11.6 A 23 
6517 62 F 31.4 57.5 19 ma M 1.6 A 13 
6526 52 M 7.9 0 18.7 I · · D 42· 
6572 52 M 31.6 0 0 II · · - 138 
6590 73 M 21.3 I 0 I M 12.2 A 5 
6672 61 M 14.1 0 10.3 n M 11.1 A 10 
6676 60 M 16.9 0 93.7 I · · · 42-
6679 58 M 3.6 0 100 nib M 9.2 D ., 
6732 65 M 22.4 0 5.1 U M 5.9 A 7 
6792 68 M 23.6 16.3 14.1 D P 9.8 D 5 
6880 54 M 35.7 6.9 0 I M 13.6 A 14 
6879 SS M 10.6 0 7.4 D · · · lid 
6903 60 F 19.8 0 39 II M 13.6 A n. 
7044 72 M 22.7 100 0 RIa P 6.7 · 134 
7092 SS M 19.7 0 31.3 1 M 17.2 D 19 
7131 57 M 9.9 2.5 0 n w 8.8 D 3S· 
7171 66 M 27.7 0 80 n p 9.1 D 16 
7172 68 M 25.6 100 20.4 1 P 14.1 A 133 
7259 57 M 4.7 0 0 IV P · D 15 
7266 52 M 20.8 7.9 100 n p · D 128 
7273 65 M 11.3 100 0 IV P 10.9 A IOd 
7365 56 M 18.6 100 0 II M 8.1 A 129 
7480 64 M 8.3 42 0 lila P 6.6 A 6 
7484 68 M 16.0 67 0 U P 10.1 A 11 
7560 62 M 42.1 4.2 3.3 Ula P 12.4 A II 
7604 53 F 22 12 0 ilia M 10.S 0 35 
7700 60 M 10.0 0 0 lila W 13.4 A lid 
7887 67 F 2.6 100 0 IDb P 8.1 A 94 
7963 64 M 21.7 0 0 ilia M 8.4 0 132 
8000 43 M 22.7 0 90.3 UIa M 9.3 D 4 
8157 49 M 29.6 3.3 0 IV P 1.4 A I. 
7923 63 M 11.4 4.8 0 n p · D 120 
1360 62 M 3.9 11.6 0 n p 10.0 A 21 
8395 68 M 24.6 100 0 I W 8.4 A 2§1 
8405 57 M 51.1 0 100 lila M 9.8 D 9 
8SS5 64 F 15.7 0 0 III. P 12.9 D 7. 
8626 44 M 24.4 77.9 0 I M 12.9 D 24 
Cae No Al!e Su A.I. Bd2 CD40 State Grade AINOR PloIdy Survl"aI 
8711 53 M 23.6 80.4 0 [ - - - 132 
8741 58 M 16.2 0 0 lila - - - 12 
8763 60 M 41.2 76.5 0 [ - - - 133 
8779 58 M 8.1 3.3 78.4 II M I\.9 A 4 
881~ ~7 M 3.8 0 0 II M 111.9 A 16 
8919 53 M 10.8 0 SS.7 II P - D 12 
8897 70 M 46.9 80.3 0 II M 11.0 A 126 
8931 62 M 66.2 S7.S 8.7 II P 14.8 0 131 
8941 63 M 28.1 0 0 I M 9.0 A 23 
8987 51 M 050.2 0 0 11 P - A II 
9073 057 M 13.11 7.S 0 nIa M II.S 0 7. 
9074 68 M 69.7 S7.9 0 IV P '-' - 6d 
9269 65 M 10.9 0 100 [ P 7.4 - 3d 
9309 
" 
M 30.9 88.S 0 lIla M 10.1 A 14 
9332 S7 F 29.2 0 0 I P 23.6 0 126 
9335 57 M 3.9 9.7 9.1 lIla M ~.O A I' 
9336 54 M 59.2 19.1 0 IIIb - - - 17 
9419 66 M 1.5.11 10 0 nIa M 14.' A 6 
9470 59 M - - - I W 9.2 0 49 
Key to tbe table 
Case No 
Age 
A. I. 
Bc12 
CD40 
Stage 
Grade 
AgNOR 
Ploidy 
Survival 
" " 
Serial number of histological slide (year = 1977) from the Pathology 
Department, East Birmingham Hospital. 
In years 
Apoptotic index: = apoptotic cellsllO,OOO malignant cells. 
Bc12 index = percentage ofBcl2 positive tumour cells. 
CD40 index = percentage of CD40 positive tumour cells. 
See Appendix 2 for staging system employed 
Histological differentiation 
W = well differentiated 
M = moderately differentiated 
P = poorly differentiated 
Mean AgNOR count per cell nucleus per specimen 
A = aneuploid 
D = diploid 
In months except where followed by 'd' = survival in days 
bold = death in immediate post-operative period 
• = death from causes other than lung cancer 
No data available 
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